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1. ZUSAMMENFASSUNG 
Natürliche Killer (NK)-Zellen bilden als Teil des angeborenen Immunsystems die erste 
Abwehr gegen Virusinfektionen und maligne Transformationen und stellen daher einen 
vielversprechenden Anwendungsbereich für die Immuntherapie gegen Krebs dar. Die 
vollständige Aktivierung der NK-Zellen wird jedoch durch inhibitorische Signale 
eingeschränkt, die durch die Interaktion von inhibitorischen Killer-Immunglobulin-
ähnlichen Rezeptoren (KIRs) auf den NK-Zellen mit körpereigenem HLA-I auf autologen 
Tumor Zellen vermittelt werden. Es ist daher überaus wichtig für die Immuntherapie gegen 
Krebs, die KIR-vermittelte Hemmung der NK-Zellen zu umgehen, um das volle Potenzial 
von autologen NK-Zellen ausschöpfen zu können. Obwohl die molekularen Mechanismen 
der de novo Genexpression von KIR-Rezeptoren während der Entwicklungsphase von NK-
Zellen ausreichend ergründet sind, ist wenig über eine mögliche Regulation auf reifen NK-
Zellen bekannt.  
In dieser Studie präsentieren wir eine neue Strategie, wie NK-Zellen vorübergehend von 
KIR-vermittelter Hemmung befreit werden können, um den autologen NK-Zell–Transfer in 
der Therapie von HLA-I positiven Tumoren zu verbessern. Stimulation von reifen NK-
Zellen, isoliert aus dem menschlichen Blut, mit einer Kombination der Zytokine Interleukin 
(IL)-12, IL-15 und IL-18 führte zu einer verminderten Oberflächenexpression der 
bedeutenden inhibitorischen KIR2DL2/L3, KIR2DL1 und KIR3DL1 Moleküle. Im Gegensatz 
dazu zeigten andere Rezeptoren keine Veränderung oder erfuhren sogar eine 
Hochregulierung wie z.B. die alpha-Kette des IL-2 Rezeptors (CD25). Die ausgeprägteste 
Herabregulation der KIR-Rezeptoren war zwei Tage nach Zytokinstimulation sichtbar und 
konnte auf erniedrigte KIR-mRNA-Spiegel zurückgeführt werden. Die Verringerung der 
KIR Expression war transient und sowohl die mRNA als auch die Oberflächenexpression 
der KIR-Rezeptoren konnte durch Kultivierung in IL-2 oder IL-15 erneut induziert und 
wiederhergestellt werden. 
Die verringerte Expression der KIR2DL2/L3 Rezeptoren auf IL-12/15/18–aktivierten NK-
Zellen war mit einer geringeren KIR-vermittelten Hemmung und mit einer erhöhten CD16-
abhängigen Zytotoxizität verbunden. Vor allem aber ermöglichte die erniedrigte 
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Expression der KIR2DL2/L3 Rezeptoren eine deutlich verbesserte Zytotoxizität der 
IL-12/15/18–aktivierten NK-Zellen gegenüber Tumorzellen, die den passenden HLA-I 
Liganden trugen. Zusätzlich konnten wir eine Herabregulierung von inhibitorischen KIR-
Molekülen auf NK-Zellen in einem Infektionsmodell des humanen Zytomegalie Virus 
(HCMV) beobachten, welches ein physiologisches System mit hohen Konzentrationen an 
pro-inflammatorischen Zytokinen (wie z.B. IL-12) darstellt.  
Zusammenfassend beschreibt unsere Studie einen neuen Mechanismus der 
Herunterregulation von inhibitorischen KIR-Rezeptoren durch pro-inflammatorische 
Zytokine auf reifen NK-Zellen. Die herabgesenkte Expression der KIR-Rezeptoren auf 
IL-12/15/18–aktivierten NK-Zellen führte zu einer verminderten Hemmung durch 
entsprechende HLA-I Liganden, wodurch potente Effektorzellen für die Behandlung HLA-I 
positiver Tumore generiert werden konnten. Diese Ergebnisse implizieren, dass die hier 
aufgezeigte vorübergehende Resistenz gegen KIR-vermittelte Inhibition die 
Behandlungsmöglichkeiten der Immuntherapie deutlich verbessern könnte, insbesondere 
bezüglich der Infusion von autologen NK-Zellen.  
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2. SUMMARY 
Natural killer (NK) cells form the first line of defense against viral infections and malignant 
transformation and therefore represent promising targets for cancer immunotherapy. 
However, NK cell anti-tumor efficacy in the patient is often impaired through inhibitory 
signals mediated by the interaction of inhibitory killer immunoglobulin-like receptors 
(KIRs) with self–HLA-I expressed on autologous tumor cells. Therefore, it is crucial to 
circumvent KIR-mediated self-inhibition in immunotherapy to unleash autologous NK cell 
potency. Although the molecular mechanisms of de novo KIR expression during NK 
development are well established, little is known about regulation of their expression on 
mature NK cells.  
We here present a new strategy of transiently and safely releasing NK cells from KIR-
mediated inhibition to improve autologous NK cells transfer against HLA-I–expressing 
tumors. Stimulation of mature peripheral blood NK cells with a combination of the 
cytokines interleukin (IL)-12, IL-15 and IL-18 resulted in decreased surface expression of 
the major inhibitory KIR2DL2/L3, KIR2DL1 and KIR3DL1 molecules. In contrast, other NK 
receptors remained unchanged or even got upregulated such as the IL-2 receptor alpha-
chain (CD25). Most pronounced KIR downregulation was observed two days after cytokine 
exposure and was attributed to decreased KIR mRNA levels. Downregulation of KIR 
expression was transient and KIR mRNA and surface expression could be re-induced upon 
culture in IL-2 or IL-15. Reduced KIR2DL2/L3 expression on IL-12/15/18–activated NK 
cells was associated with less KIR-mediated inhibition and increased CD16-dependent 
cytotoxicity in redirected lysis assays. Importantly, downregulation of KIR2DL2/L3 
expression enabled improved cytotoxicity of IL-12/15/18–stimulated NK cells against 
cognate HLA-I–expressing tumor targets. Additionally, we observed downregulation of 
inhibitory KIR molecules on NK cells after 3 days in a human cytomegalovirus (HCMV) 
infection model, representing a physiological setting with high concentrations of pro-
inflammatory cytokines such as IL-12.  
Taken together, our study reports a novel mechanism of KIR downregulation on mature 
peripheral blood NK cells by pro-inflammatory cytokines. Decreased KIR expression of 
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IL-12/15/18–activated NK cells translated into reduced inhibition by self–HLA-I, 
generating potent effectors cells for the treatment of HLA-I–expressing tumors. These 
results imply that the transient resistance to self-inhibition might greatly improve 
immunotherapy protocols especially for autologous NK cell infusions. 
 
 
 
 
IL-12/15/18–induced downregulation of inhibitory killer immunoglobulin-like receptors (KIRs) on 
NK cells translated into reduced KIR-mediated inhibition and enhanced cytotoxicity against cognate 
HLA-I–expressing tumor cells, indicating high potency in autologous infusions. Adapted from the 
graphical abstract from Ewen et al. 2018 Eur. J. Immunol. 710. 
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3. INTRODUCTION 
3.1. The immune system 
Every species is constantly exposed to diverse pathogens such as bacteria, viruses, 
parasites or fungi and has developed strategies to protect the organism from pathogenic 
threat. Vertebrates have developed a complex system consisting of specialized organs, 
tissues, effector cells and soluble molecules to fight foreign pathogen and to protect against 
malignant transformation of the own body. Therefore, the immune system can detect and 
discriminate healthy from non-self or altered-self cells but is also carefully regulated to not 
attack healthy tissue. The importance of a functional immune system is illustrated through 
the link of immune dysfunctions or immunodeficiencies to severe disorders such as 
autoimmune diseases and an increased risk of lethal infections and of developing cancer 1. 
Two major branches of the immune system are distinguished in vertebrates according to 
their mechanism and specificity of antigen recognition, kinetics of the immune response 
and the capability of memory formation: The evolutionary conserved innate immunity and 
the adaptive immunity, which has evolved in vertebrates including rodents and humans 2.  
 
3.1.1. The innate immune system 
The innate immune system is characterized by its rapid immune response and based on a 
germline encoded receptor repertoire recognizing a variety of different pathogens. It is 
conserved among plants, invertebrates and vertebrates and virtually every species has 
developed basic defense mechanisms against pathogens. The first defenses of the body are 
anatomical as well as chemical barriers such as the skin or the acidic milieu in the stomach. 
An intact epithelial barrier can prevent pathogens to enter the body and mucosal surfaces 
additionally produce antimicrobial peptides such as β-defensins. Innate immunity is 
further mediated by humoral (e.g. the complement system) as well as cellular components 
which include phagocytic cells (macrophages, monocytes, dendritic cells and neutrophils), 
granulocytes (eosinophils and basophils), mast cells and innate lymphoid cells (ILCs and 
NK cells) 2. 
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Cells of the innate immune system express germline-encoded receptors that recognize 
molecules expressed on stressed and malignantly transformed cells, or molecular 
microbial structures such as pathogen-associated molecular patterns (PAMPs). These 
PAMPs are evolutionary conserved structures common to many pathogens and include 
complex carbohydrates found on bacterial cell walls (peptidoglycans, lipopolysaccharides) 
and nucleic acids typical for viruses or bacteria (unmethylated CpG DNA, double-stranded 
RNA). Similar to PAMPs, innate receptors can also detect endogenous ligands associated 
with cellular stress, so called damage-associated molecular patterns (DAMPs), such as the 
chromatin-associated protein high-mobility group box 1 (HMGB1), heat shock proteins or 
chromatin DNA 3.The best characterized pathogen recognition receptors (PRRs) are the 
Toll-like receptors (TLRs) expressed on phagocytic cells like monocytes, macrophages, 
dendritic cells or neutrophils 3. These sensory cells can directly induce effector functions 
via phagocytosis and degradation of the pathogen, but also orchestrate both innate and 
adaptive immunity through recruiting and activation of other immune cells. The 
production of cytokines helps to shape and amplify a specific immune response while 
chemokines act as chemo-attractants attracting cells from the blood circulation into 
lymphoid organs or tissues. Phagocytic uptake of pathogens by dendritic cells (DCs), also 
named professional antigen-presenting cells (APCs), leads to their maturation and 
migration to the lymph node where they present antigens to adaptive immune cells. 
Presentation of processed antigens by APCs on their major histocompatibility complexes 
(MHC) class II is a major mechanism to activate antigen-specific immune cells. In general, 
many mechanisms of the innate immune system not only eliminate pathogens, but also 
function to prime and enhance the adaptive immune response 2,4–6.  
Another important part of the cellular innate immunity comprises the family of innate 
lymphoid cells (ILCs), including natural killer (NK) cells, which will be described in detail 
in section 3.2.  
 
3.1.2. The adaptive immune system 
The hallmarks of the adaptive immune system are the delayed, but yet strong and antigen-
specific immune response and the capability to generate immunological memory, 
providing long-lasting immunity. Adaptive lymphocytes develop in the bone marrow from 
a common lymphoid progenitor (CLP) and comprise B cells, that mature in the bone 
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marrow, and T cells that further differentiate in the thymus. Each B and T lymphocytes 
express a unique surface receptor with a single antigen-specificity. The high diversity of the 
antigen-specific receptors is formed by somatic recombination of various gene segments 
encoding the B cell (BCR) and T cell receptor (TCR). The random rearrangement of V(D)J 
gene segments requires the recombinases RAG-1/2 and can result in 1014 - 1018 receptors 
with different specificities enabling the adaptive immune system to respond against a vast 
variety of antigens 7,8. To ensure tolerance, T cell clones with self-reactive or non-functional 
TCRs are subsequently deleted or inactivated in the thymus through positive and negative 
selection 2. 
Upon encounter of their cognate antigen, activation of antigen-specific naïve T and B cells 
leads to clonal expansion in secondary lymphoid organs and differentiation into effector 
lymphocytes highly efficient against the specific pathogen. The clearance of the infection is 
followed by a contraction phase and formation of a small pool of long-lived memory cells, 
which are capable of mounting a faster and stronger recall response after secondary 
challenge with the same antigen. Long-lasting immunity through the formation of 
immunological memory marks the basis of successful vaccination. Immunological memory 
has mostly been accounted to be a feature of adaptive immune cells. However, a growing 
body of experimental evidence suggests that also innate immune cells can possess adaptive 
features such as longevity and superior recall responses, blurring the lines of innate and 
adaptive immunity 9–11. This aspect will be discussed in more detail in section 3.6.  
The B cell receptor (BCR) is a membrane-bound immunoglobulin (Ig) and directly binds 
native antigens without the need of presentation and can therefore detect extracellular 
pathogens. In addition, B cells can also function as APCs and present processed antigens on 
MHC class II. Upon activation and maturation into plasma cells, B cells secrete a soluble 
form of the BCR, termed antibodies, which constitute the humoral arm of the adaptive 
immunity and possess the same antigen specificity as the BCR. Antibodies are Y-shaped 
molecules composed of two identical heavy and two light chains. Depending on the heavy 
chain, five different antibody or Ig isoforms exist (IgA, IgD, IgE, IgG and IgM) with different 
functions and localizations in the body. Antibodies further consist of a constant Fc region 
and two highly variable regions created through somatic recombination, enabling 
recognition of a vast variety of antigens. Antibodies can either directly neutralize antigens 
or exert different functional outcome via their Fc part such as opsonization of pathogens 
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for phagocytes, antibody-dependent cytotoxicity (ADCC) or activation of the complement 
system 2,12. 
The T cell receptor (TCR, CD3) is composed of two chains, the α- and β-chain, that undergo 
somatic rearrangement and determine the highly variable antigen specificity. The TCR can 
only recognize antigens that are processed and presented on MHC molecules. CD4+ T helper 
cells recognize peptides in the context of MHC class II molecules on APCs, while CD8+ T cells 
interact with MHC class I that is expressed on any nucleated cell. Upon activation, naïve 
CD8+ T cells differentiate into cytotoxic lymphocyte effector cells (CTLs), which are potent 
producers of interferon-gamma (IFN-γ) and mediate their cytotoxicity via secretion of 
perforin and granzymes 2.  
In addition to the antigen-specific TCR engagement, T cells require co-stimulatory signals 
provided by APCs in order to become fully activated. This includes interaction of the B7 
family ligands with co-stimulatory CD28 on T cells or with inhibitory CTLA-4, which 
functions as checkpoint to inhibit excessive T cell activation. In addition, cytokines 
produced by adjacent immune cells can polarize T cell differentiation into effector cells 
with different properties and functions. After activation, CD4+ T cells can differentiate into 
different subtypes of cytokine producing helper cells, depending on the co-stimulatory 
cytokine milieu. The main lineages comprise regulatory T cells (Tregs) and TH1, TH2 and TH17 
helper cells, which are defined by their characteristic cytokine expression profile and 
function 13. TH1 cells characteristically produce IFN-γ to activate macrophages, DCs and B 
cells and to fight intracellular pathogens. TH1 subsets are differentiated in the presence of 
interleukin (IL-) 12 and IL-18, whereas IL-4 triggers the polarization of TH2 cells. Key 
cytokines of TH2 cells are IL-4, IL-5 and IL-13 to assist B cells, mast cell and basophils in the 
control of extracellular parasite infections such as helminths. TH17 cells produce IL-17 and 
IL-22 and play a major role in clearance of extracellular bacteria and fungi at mucosal 
surfaces. Transforming growth factor beta (TGF-β) can induce regulatory T cells (Tregs) 
expressing the transcription factor FoxP3 (forkhead box protein P3) and the IL-2 receptor 
α-chain (CD25). Regulatory T cells can inhibit other effector cells through secretion of 
immunosuppressive cytokines e.g. TGF-β and IL-10, limiting an ongoing immune response 
but also preventing autoimmunity 2. 
In addition to T cells with a TCR composed of α- and β-chains, also γδ-T cells exist, which 
have a limited TCR diversity but can recognize antigens in a non-MHC restricted manner 14. 
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γδ-T cells exhibit features of both innate and adaptive immunity and are enriched at 
epithelial surfaces. Another cell type bridging innate and adaptive immunity are natural 
killer T (NKT) cells, which co-express an αβ-TCR (CD3) and surface markers typically 
associated with natural killer cells e.g. NK1.1. NKT cells recognize lipids or glycolipids 
presented by CD1d, are activated by DC-derived IL-12 and subsequently stimulate activate 
TH1 cells and CTL mediated immunity 15.  
 
3.2. Natural killer cells 
Natural killer (NK) cells are large granular immune cells that constitute about 5 – 10 % of 
lymphocytes in the peripheral blood. They have been first described in 1975 as a subset of 
lymphocytes distinct to T or B cells and have been named according to their function of 
spontaneous or ‘natural’ cytotoxicity without the need of prior sensitization 16–18. 
Observations that these natural killers are specifically cytotoxic against malignant cells 
lacking expression of self-MHC class I proposed the ‘missing self’ hypothesis (see section 
3.3) of NK specificity 19. NK cells have traditionally been classified as classical innate 
immune cells because, unlike B and T cells of the adaptive immune system, they express 
germline encoded receptors that do not require RAG recombinase-mediated 
rearrangement 20,21. However, a recent study has reported a role for the RAG recombinase 
in NK cell development and cellular fitness 22 and accumulating evidence suggests adaptive 
features of NK cells, blurring the borders between innate and adaptive immunity 10,23–25. 
Natural killer cells act as first line of defense against various pathogens, viral infections and 
malignant cells 26,27. Besides their ability to directly eliminate and kill infected and 
transformed cells, NK cells function through production of cytokines and chemokines that 
shape the innate and adaptive immune response 28,29. They provide protection against viral 
infection and metastatic dissemination and play a central role in pregnancy and graft 
rejection 30–34.  
 
3.2.1. Definition 
NK cells represent a unique subset of lymphocytes, distinct from T and B cells, which 
recognize their targets in an inherent and MHC–unrestricted manner based on a germline-
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encoded receptor repertoire 20. NK cells belong to a larger family of innate lymphoid cells 
(ILCs), which are involved for instance in tissue homeostasis and immunity in mucosal 
tissues 35,36. Three subsets of ILCs have been described to date based on their functionality 
and transcription factors, with NK cells classified as part of the subgroup of ILC1 37–39.  
In flow cytometry, human NK cells are usually phenotypically defined as CD3–CD56+ 
lymphocytes. The T cell marker CD3 needs to be excluded, since CD56 is also expressed on 
CD3+ NKT cells 15,40. In addition to CD56, NKp46 has been proposed as general NK marker 
due to its expression on mouse NK cells 41–43. Both markers have their disadvantages since 
CD56 negative NK cells have been detected in certain diseases 44. At the same time, 
expression of NKp46 is not restricted exclusively to NK cells and might be a subject of 
regulation in certain conditions such as infections or in NK cells with adaptive 
features 38,43,45. In order to discriminate NK cells from other ILC1, the transcription factor 
Eomes, the presence of cytolytic granules and expression of NKp80 are currently suggested 
as NK cell specific markers 39,46,47. 
 
3.2.2. NK cell development: 
Compared to murine NK cell development, most conclusions about NK precursors in 
humans are derived from in vitro differentiation data or from monitoring NK cell 
reconstitution after hematopoietic stem cell transplantation (HSCT). However, it is wildly 
accepted in the field that NK cell and ILC development takes place in the bone marrow from 
CD34+ hematopoietic stem cells (HSC) into a common lymphoid progenitor (CLP) that can 
also give rise to other lymphocytes as B and T cells 28,48,49. But the bone marrow might not 
be the only site of NK cell development, as precursors have been found in several other 
tissues as the thymus, lymph nodes, liver, gut and uterus 50–54. Extramedullary 
compartments might represent important sites of NK development and terminal 
differentiation, shaping NK diversification and functional heterogeneity by the unique 
milieus of different tissues. De novo acquisition of CD122, the IL-15Rβ chain, marks the 
commitment to the NK cell precursor (NKP) 48–50,55 and IL-15 has been shown to be 
essential for further differentiation, maturation and the survival of NK cells in the 
periphery 56–58. In addition, a complex interplay of multiple transcription factors drives 
commitment to the NK cell lineage such as ID2, PU.1, Ets-1, TOX, NFIL3 as well as Tbet and 
Eomes at later stages of NK cell development 59–63. Immature NK cells (iNK) differentiate 
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further into mature NK cells (mNK) in the periphery where they gain their effector 
functions, i.e. the capability of IFN-γ production and cytotoxicity, and sequentially acquire 
functional receptors such as CD56, CD94, NKG2A, NKp46, NKG2D and eventually CD16 and 
killer immunoglobulin-like receptors (KIRs) 52,53,64–67.  
 
3.2.3. NK cell subsets 
In humans, CD56+CD3– NK cells can be further divided into two subsets on the basis of their 
CD56 expression levels, into CD56bright and CD56dim NK cells 26,68–70. The CD56bright subset 
comprises approximately 10 % of NK cells in peripheral blood but is enriched in secondary 
lymphoid organs 54,66,70,71. They are attributed to have a predominantly immunomodulatory 
role due to their high potential of cytokine production upon monokine (IL-12 or IL-18) 
activation but contain rather low levels of perforin and granzyme 71–74. CD56dim NK cells 
constitute the prevalent subset of human peripheral (pb)NK cells and display a high 
capacity of target cell-induced cytotoxicity and cytokine production 68,70,73–75. In addition, 
CD56dim NK cells express the FcγRIII (CD16), allowing them to exert antibody-dependent 
cytotoxicity (ADCC) 12. CD56dim NK cells are less efficient effectors upon cytokine activation 
in comparison to the CD56bright subset, but are potently stimulated upon activating receptor 
engagement 71–74. Increasing evidence suggests that CD56bright cells are precursors of 
CD56dim NK cells, as the latter possesses lower proliferative capacity associated with 
shorter telomers 64,66,76. CD56bright NK cells predominate neonatal tissues and umbilical cord 
blood and are the first population to be detected after engraftment following HSCT in 
humanized mouse models and patients 64,77–80. Several reports suggest linear maturation 
from CD56bright to terminally differentiated CD56dim NK cells characterized by coordinated 
changes of surface receptors associated with maturation, activation and homing 64,65,77. In 
contrast to CD56dim NK cells, the CD56bright subset is uniformly high for CD94/NKG2A but 
lacks the expression of CD16 and KIRs 68. The continuous differentiation from CD56bright 
(CD94/NKG2AhiCD16–KIR–CD57–) to CD56dim (CD94/NKG2A–CD16+KIR+CD57+) NK cells is 
marked by a progressive decrease in NKG2A expression and an inverse correlation of 
sequential KIR and CD57 acquisition via phenotypical and functional intermediates 
(CD56dimCD94/NKG2A+CD16+KIR+/–CD57–) 64,65,77,81,82.  
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3.2.4. NK cell effector functions 
Natural killer cells serve as the first line of defense in the elimination of transformed or 
virally infected cells. Their effector function is mainly characterized by granzyme/perforin-
mediated cytotoxicity and by the production of cytokines, but can also involve immune-
modulatory functions 27. The integration of all signals delivered by activating and inhibitory 
receptors decides whether or not the NK cell becomes effectively activated and determines 
the kind of effector function 83–85. The final response is further influenced by cytokines, 
chemokines and additional immune cells in the local microenvironment of the NK cell. 
Cytotoxicity  
NK cells have several modes of inducing death of a target cells, either via the secretion of 
perforins and granzymes or via membrane-bound death receptor-related pathways. 
Death receptors include the ligand-receptor pairs FasL-Fas (CD95L-CD95), TNF-TNFR and 
TRAIL-TRAILR of the TNF superfamily 86–88. The interaction between NK cells expressing 
death ligands and death receptors on target cells induces the recruitment of various 
intracellular adaptors leading to the formation of the death-inducing signaling complex 
(DISC) 89. The DISC recruits and proteolytically activates the pro-caspases 8 and 10 and 
thereby initiates the enzymatic caspase cascade, resulting in apoptosis of the target 
cell 86,90. 
The second mechanism of NK cell-mediated target cell killing involves the release of lytic 
granules containing pre-formed perforin and granzyme 91. Upon recognition of a target cell, 
an immunological synapse is formed between both cells, inducing the exocytosis of 
cytotoxic granules in close proximity to the target cells 92,93. Perforin molecules form pore-
like structures in the membrane of the target cell, thereby disrupting the membrane 
integrity and allowing the entry of granzyme molecules in the cytoplasm 94. The serine 
proteases granzyme A and B induce apoptosis through initiation of the caspase cascade or 
via mitochondrial depolarization and DNA fragmentation mediated by proteolytic 
cleavage 95.  
Antibody-dependent cellular cytotoxicity (ADCC) also functions via the perforin/granzyme 
pathway 96,97. Antibody-coated target cells can be cross-linked by FcγRIII (CD16), the low-
affinity receptor for IgG, triggering a strong NK cell cytotoxic response that does not require 
additional co-activation 12,98,99. The capacity of strong NK cell effector and anti-cancer 
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functionality upon ADCC is currently exploited in the clinical application of therapeutic 
antibodies 100,101. 
Cytokine production 
NK cells present an important source of various cytokines and chemokines such as IFN-γ, 
TNF-α, GM-CSF and IL-6 75. IFN-γ is considered to be the signature cytokine of NK cells and 
has been demonstrated to have anti-proliferative and pro-apoptotic effects on cancer cells 
via upregulation of caspases, FasL and TRAIL 102. The combined secretion of TNF-α and 
IFN-γ has been shown to induce senescence in cancer cells 103. In addition, IFN-γ stimulates 
antigen presentation on MHC class I and II molecules and promotes macrophage 
functionality 27,104. Cytokine secretion and the release of cytotoxic granules are regulated 
differentially, enabling specific NK cell responses through combinatory mechanisms or by 
either mechanism independently 105,106. Furthermore, cytokine production by NK cells not 
only contributes to target cell death but also influences and shapes the adaptive immune 
response of T and B cells 5,6,107,108. In addition, activation of NK cells by cytokines such as 
IL-15, IL-12 or IL-18 can further augment NK cell effector functions 109.  
 
3.3. NK cell receptors and their ligands 
NK cells express a variety of adhesion molecules and receptors for cellular ligands as well 
as for cytokines and chemokines. The following chapter will outline a small selection of the 
most important receptors relevant for the context of this thesis. Activation of NK cells is 
tightly regulated by a delicate balance of signals delivered via activating and inhibitory 
receptors 75,83,106,110. Activating receptors primarily recognize stress-induced ligands on 
virally infected or transformed cells thereby enabling NK cells to detect and eliminate 
potentially harmful cells. Inhibitory receptors mostly bind conventional or non-
conventional self–MHC class I molecules and can thereby distinguish between self and non-
self thus protecting healthy cells and sensing cells that lack self-MHC-I 32,111–114. The 
integration of all signals delivered by activating and inhibitory receptors decides whether 
or not the NK cell becomes effectively activated and determines the kind of effector 
function 83–85,115. The final response is further influenced by cytokines, chemokines and 
additional immune cells in the local microenvironment of the NK cell. In steady state 
conditions, inhibitory signals dominate through the interaction of inhibitory receptors 
3  INTRODUCTION  
14 
recognizing self–MHC class I on healthy cells. A seminal study by Klas Kärre and colleagues 
revealed that NK cell cytotoxicity is triggered by tumor cells that have lost self–MHC-I 
expression on their surface 19. MHC class I molecules are expressed on all healthy nucleated 
cells thereby preventing NK cells from being activated during normal conditions. In 
contrast, MHC-I is often downregulated on virus-infected or transformed cells to evade 
detection by CD8+ T cells 116, thus becoming susceptible to NK cell mediated killing 
(‘missing-self’ recognition) 19,117–119. Deficiency of MHC-I is not sufficient to trigger full NK 
cell activation but in addition requires co-expression of ligands for activating 
receptors 84,112,120,121. These ligands can be pathogen-derived or induced by cellular stress 
upon viral infection or malignant transformation 32,113,122–124. This ‘induced-self’ model 
explains how NK cells can overcome the inhibitory signals if MHC-I expression is preserved, 
as well as their inability to attack healthy cells with no or low MHC-I levels (e.g. 
 
Figure 3.1: NK cell activation by 
missing self or induced self. NK cell 
tolerance (a) to healthy cells 
expressing cognate self–MHC class I 
molecules is mediated by dominant 
inhibitory receptors counteracting 
activating signals. (b) Down-
regulation of MHC-I molecules on 
tumor cells results in loss of NK cell 
self-inhibition (‘missing self’) 
shifting the balance towards NK cell 
activation. (c) Stress-induced 
upregulation of activating ligands on 
tumor cells can overcome inhibitory 
signals of self–MHC-I leading to 
‘stress-induced self’ triggered 
activation of NK cells. Adapted from 
Vivier et al. Nat Rev Immunol 
2012 610.  
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erythrocytes or neurons). Downregulation of activating NK ligands or expression of decoy 
MHC-I molecules hence display one strategy of immune escape of viruses and cancer 125–
127. 
 
3.3.1. Activating NK receptors 
In contrast to B or T cells, NK cells express a wide array of germline encoded activating 
receptors, which can act in synergy to potently stimulate NK cell effector functions 84,98,111. 
Most activating receptors signal via immunoreceptor tyrosine-based activation motifs 
(ITAMs) leading to recruitment and activation of the tyrosine kinases Syk and Zap70 106,115. 
ITAM signaling leads to NK activation by inducing signaling pathways of phosphatidyl-
inositol-3-OH kinase (PI3K), phospholipase C and Vav 83,128. Activating NK receptors can be 
classified according to their function and structure or their association with adapter 
molecules such as DAP10 or DAP12.  
Natural Cytotoxicity Receptors 
One major family of activating NK receptors is composed of the natural cytotoxicity 
receptors (NCRs) which include NKp30, NKp44, NKp46 and NKp80 41,47,129–131. They belong 
to the immunoglobulin superfamily and associate with different intracellular adaptor 
molecules bearing ITAMs such as CD3ζ, FcεRIγ or DAP12 132–135. NKp30, NK46 and NKp80 
are constitutively expressed on mature human NK cells and NKp46 is also a marker for 
mouse NK cells 41,47,130,132. Expression of NKp44 is not detected on resting NK cells but is 
induced by IL-2 or IL-15 activation 129,133.  
A variety of pathogen-encoded ligands have been characterized for the NCRs, such as viral 
hemagglutinins or PfEMP1 of Plasmodium falciparum for binding and activation of NKp46 
and NKp30 131,136,137. Human cytomegalovirus (HCMV) protein pp65 has been described as 
a viral ligand of NKp30 138 and binding of heparan sulfate proteoglycans to NKp30, NKp44 
and NKp46 has been reported 139–141. Recently, interaction of NKp30 with the fungal cell 
wall component β-1,3-glucan has been demonstrated 142 and complement factor P has been 
identified as a new ligand for NKp46 143. Although cellular or tumor-derived ligands for 
some NCRs remain elusive, they have been shown to play a major role in NK-mediated 
tumor immunosurveillance 131,144–146. For instance, a recent publication could reveal a new 
function of NKp46-mediated IFN-γ release in controlling tumor architecture and metastatic 
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dissemination 147. For NKp30 two bona fide cellular ligands have been identified: B7-H6 148, 
expressed on the surface of tumor cells ,and BAT-3 (BAG-6) 149, which is released in 
exosomes. Shedding or down-regulation of B7-H6 has been elucidated as an immune-
escape mechanism of tumor cells 150,151. A recent publication has described the platelet-
derived growth factor DD (PDGF-DD) as a ligand for NKp44, involved in cell cycle arrest 
and tumor control in vivo 152. Furthermore, NKp44 has been shown to bind the mixed-
lineage leukemia-5 protein (MLL-5) 153 and the proliferating cell nuclear antigen (PCNA), 
an inhibitory cellular ligand assisting in tumor immune-evasion via blocking the 
receptor 154. NKp80 is expressed on all NK cells in human peripheral blood and has been 
recently suggested as a marker for discrimination of conventional NK cells and other 
members of the ILC family 46,47. NKp80 has been shown to recognize the activation-induced 
C-type lectin (AICL) 155, which is upregulated on myeloid cells after TLR stimulation and 
also on NK cells after activation with IL-12/15/18 156. 
Natural Killer Group 2 Receptors  
The class of natural killer group 2 (NKG2) receptors belong to the C-type lectin-like family 
and comprises activating as well as inhibitory receptors 157–159. NKG2C and NKG2D are 
activating members, whereas NKG2A represents an inhibitory receptor and will be 
discussed in more detail in section 3.3.3. 
Figure 3.2: NK cell 
receptors and their ligands 
determine the balance of 
activation and inhibition. A 
selection of important 
activating and inhibitory 
receptors and their cognate 
ligands are depicted. Adapted 
from Chan et al. Cell Death 
Differ 2014 751 
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The NKG2C receptor is expressed as a disulfide-linked heterodimer with CD94 on human 
and mouse NK cells and on subsets of human memory T cells 134,160. NKG2C/CD94 couples 
to the ITAM-bearing adaptor molecule DAP12, thereby transmitting activating signals 161. 
CD94/NKG2C recognizes the non-classical MHC class I molecule HLA-E as a ligand in 
humans and Qa-1b in mice 162,163. Furthermore, the expansion of a NKG2C expressing subset 
upon HCMV infection has been linked to the generation of memory-like NK cells with 
adaptive features (see section 3.6.2) 164–166. 
NKG2D is a homodimeric receptor and does not associate with CD94. It is expressed on the 
surface of all human and mouse NK cells and a fraction of CD8+ and γδ-T cells 167,168. Upon 
receptor ligation, NKG2D signals via the adaptor molecule DAP10 in humans and DAP10 
and DAP12 in mice resulting in Vav-1 phosphorylation and activation of 
phosphatidylinositol-3 kinase (PI3K) 169–172. NKG2D detects stress-induced MHC class I 
homologue ligands, which are upregulated upon viral or malignant transformation and 
genotoxic stress 113,173,174. They include MHC class I chain-related gene (MIC)-A, MIC-B and 
the UL16 binding proteins (ULBP) 1 - 6 167,175,176. In mice, the respective NKG2D ligands are 
the retinoic acid early transcript-1 molecules (Rae-1), murine UL16-binding-like 
transcript-1 (MULT-1) and histocompatibility antigen 60 (H-60) 122,123,177,178. These ligands 
are expressed below threshold on healthy tissues but have been shown to be induced upon 
viral or malignant transformation and genotoxic stress e.g. due to DNA damage and heat 
shock response pathways 173,174,179–182. NKG2D is often targeted in immune evasion 
strategies for instance via shedding of ligands from tumor cells or TGF-β mediated receptor 
downregulation 183–186. A recent publication emphasizes the impact of NKG2D-mediated 
anti-cancer immunity by blocking the shedding of NKG2D ligands from the surface of tumor 
cells 187. The importance of NKG2D in tumor immunosurveillance has been demonstrated 
for several cancer entities in vivo 173,188–190. 
CD16 (FcγRIIIA) 
Complete activation of resting human NK cells requires combined signals of stimulation via 
two or more receptors 98. A potent exception is CD16, the low affinity FcγRIIIA, which is 
expressed on most mouse NK cells and on the human CD56dim subset. It associates with the 
ITAM-containing FcεRIγ chain and CD3ζ 191,192. CD16 binds the Fc part of IgG class 
antibodies and therefore enables NK cells to exert antibody-dependent cell-mediated 
cytotoxicity (ADCC) against antibody coated targets 12,193,194. Recently, our group has 
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demonstrated the importance of CD16-mediated ADCC in anti-cancer immunity and innate 
memory formation 99. 
 
3.3.2. Co-stimulatory receptors 
DNAX accessory molecule-1 (DNAM-I, CD226) 
The co-stimulatory receptor DNAX accessory molecule-1 (DNAM-I, CD226) is a member of 
the immunoglobulin superfamily and signals via ITAM motifs and PKC recruitment 195,196. 
It is constitutively expressed on most human NK cells, on approximately 50% of murine NK 
cells and on subsets of T cells and myeloid cells 197–199. CD112 (Nectin-2) and CD155 (polio 
virus receptor, PVR), two members of the nectin family, have been identified as ligands for 
DNAM-I and are broadly distributed on hematopoietic, endothelial and epithelial cells 200–
203. These ligands are upregulated on cancer cells upon genotoxic stress, indicating a role 
for DNAM-I in NK cell-mediated anti-tumor immunity in vivo 144,204,205. Of note, the DNAM-I 
ligands CD112 and CD155 can also interact with the two inhibitory NK receptors CD96 
(TACTILE) and TIGIT, which can oppose DNAM-I activation 199,203. DNAM-I has been further 
implicated in adhesion and migration of monocytes and shown to interact with the 
β-2-integrin LFA-1 195,206. 
Tumor necrosis factor receptor superfamily (TNFRSF) 
The members of the tumor necrosis factor receptor superfamily (TNFRSF) are widely 
expressed among lymphoid and non-lymphoid tissues in mice and humans, and are critical 
for modulating the immune response against pathogens by regulating cell death and 
survival 207,208. The TNFR superfamily is subdivided into two groups, the death domain 
(DD)-containing receptors and TRAF (TNF receptor-associated factor) binding receptors. 
The DD-containing ‘death receptors’, such as Fas (CD95), TRAIL-R1, TRAIL-R2, and TNFR1, 
associate with the adapters Fas-associated DD protein (FADD) and TNFR-associated DD 
protein (TRADD) leading to caspase activation and apoptosis 207,209,210. 
The second subgroup of TRAF binding receptors include OX40 (CD134), 4-1BB (CD137), 
HVEM, CD27, CD30, CD40, and GITR (CD357). Most receptors of the TNFRS family are not 
constitutively expressed on NK cells but can be induced upon activation 211–215. They 
generally operate as co-stimulatory receptors and their function in T cell activation is well 
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defined. On T cells, TNFRSF members are upregulated after sequential TCR and CD28 or 
CD40 stimulation. They signal via recruitment of TRAF adaptor proteins resulting in 
activation of the NF-κB pathway and enhanced proliferation and cell survival 213,216,217. 
Ligands for TNFRSF members (TNFSF) are primarily expressed on APCs but also by non-
immune cells as smooth muscle and endothelial cells. Additional immune cells such as NK 
cells, conventional activated T cells, lymphoid tissue inducer (LTi) and other ILCs can 
express ligands depending on the stimulatory environment 212,213,217–219. Thus, under 
defined conditions, NK cells can express either the receptors and/or the ligands of the 
TNFRSF, which enables an extensive cross-talk with other immune cells during an ongoing 
immune response. 
4-1BB (CD137) and Ox40 (CD134), the two TNFRSF members examined in this study, are 
absent on resting NK cells but can be induced upon cytokine activation and are binding to 
4-1BBL and Ox40L, respectively 214,216,217,220,221. A co-stimulatory role has been described 
for T cells, but their function in NK cells might be ambiguous and depending on the cytokine 
milieu, the environment and nature of the ligand 214. Agonistic antibodies for both receptors 
are currently tested in clinical trials to enhance T cell anti-cancer immunity 222–226. 
 
 
3.3.3. Inhibitory receptors  
The best characterized inhibitory receptors are the MHC-I binding Ly49 receptors in mice 
and the killer cell immunoglobulin-like (KIR) family in humans (see section 3.4), and the 
lectin-like heterodimer CD94/NKG2A in both species 110,111,227,228. The downregulation of 
HLA-I expression on virally-infected or transformed cells impairs inhibitory signals and 
therefore confers enhanced NK cell activation (‘missing self’ recognition, see section  
3.3) 19,118. Both families of KIR and CD94/NKG2 have inhibitory as well as activating 
members. Under steady state conditions, the ligand binding affinity of the inhibitory 
receptors is higher compared to their activating receptor counterparts, allowing the 
inhibitory signal to dominate 229–232. Although they are quite divers in their extracellular 
domains, all inhibitory NK receptors transmit signals via cytoplasmic immunoreceptor 
tyrosine-based inhibitory motifs (ITIMs) 83,128,233. The inhibition is based on the 
recruitment of phosphatases such as SHIP, SHP-1 and SHP-2, which dephosphorylate and 
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inactivate the signaling molecules downstream of activating receptors. Thereby ITIM 
signaling interferes with ITAM signaling and blocks effective NK cell activation 234–238. 
CD94/NKG2A 
The inhibitory C-type lectin like receptor NKG2A is expressed as a disulfide-linked 
heterodimer with CD94 on human and mouse NK cells and on subsets of memory CD8+ and 
γδ-T cells 157,160,239,240. NKG2A contains two ITIMs and thus can transmit inhibitory signals 
by recruiting the phosphatases SHP-1 and SHP-2 241–243. Like its family member NKG2C, 
NKG2A/CD94 binds to the non-classical MHC-I ligand HLA-E in humans and to the 
homologous mouse Qa-1b, albeit with a significantly higher affinity than 
NKG2C/CD94 162,163,229,244. HLA-E and Qa-1b present peptides derived from the leader 
segments of other MHC class I proteins, directly reflecting the overall MHC-I expression of 
the cell 239,244–246. Since the surface expression of HLA-E and Qa-1b is dependent on the 
availability of classical MHC-I molecules, this provides a mechanism to monitor the total 
expression of MHC-I on tissues which is often impaired upon viral infection or malignant 
transformation. 
TIGIT  
In addition to inhibitory receptors recognizing self-MHC class I, other inhibitory receptors 
can negatively regulate NK responsiveness such as the T cell immunoreceptor with Ig and 
ITIM domains (TIGIT). It is a co-inhibitory immunoglobulin superfamily receptor of the 
CD28 family and was discovered by bioinformatic approaches of different 
laboratories 200,247–249. TIGIT is present on effector and memory T cells, regulatory T cells 
(Tregs), follicular helper T cells and NKT cells 200,247,248,250–252. It is constitutively expressed 
on human naïve NK cells, but not on mouse NK cells where it is inducible upon 
activation 249,253. TIGIT proteins form homodimers on the cell surface and contain an ITIM 
motif and an additional immunoglobulin tail tyrosine (ITT)-like motif in their cytoplasmic 
tail 247–249,253. The importance or redundancy of both motifs for the inhibitory function of 
TIGIT is not well understood and might differ between species and cell types 249,253–255. The 
ITT-like motif recruits SHIP-1 through the cytoplasmic adaptor Grb-2 (growth factor 
receptor-bound protein 2) leading to dephosphorylation and abrogation of PI3K and MAPK 
signaling pathways 254,255. Additionally, the ITT-like motif can impair NF-κB signaling and 
combined effects result in strong inhibition of NK cell cytotoxicity and cytokine 
production 254. TIGIT binds to the nectin family members CD112 (Nectin-2) and CD155 
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(polio virus receptor, PVR) which are broadly distributed on T cells, APCs and a variety of 
non-hematopoietic tissues 200–203,247–249. Their expression is upregulated upon DC 
maturation and can be induced on cancer cells upon genotoxic stress 203,204,256–258. TIGIT 
shares its cellular ligands with another inhibitory receptor, CD96 (TACTILE), and with the 
co-activating receptor DNAM-I (CD226), but TIGIT was shown to possess a higher affinity 
and to compete with DNAM-I in a dose dependent manner 203,247–249,253. The interactions of 
TIGIT/CD96 and DNAM-I closely resemble the CD28/CTLA-4 pathway, where the co-
stimulatory receptor DNAM-I shares ligands with the high-affinity co-inhibitory receptors 
TIGIT and CD96 199,247,259. TIGIT can not only counterbalance DNAM-I–mediated activation 
of NK cells through competition for its ligand, but also by directly interacting with DNAM-I 
in cis, thereby disrupting its homodimerization and functionality 249,251,260,261. In addition, 
TIGIT can also indirectly suppress the immune response through interaction with CD155-
expressing DCs. CD155 itself contains an ITIM motif which induces a transformation to a 
tolerogenic DC phenotype 248. In the tumor microenvironment, TIGIT is expressed on 
murine and human tumor-infiltrating lymphocytes (TILs) which exhibit a dysfunctional 
phenotype and co-express other inhibitory checkpoint molecules such as PD-1, Tim-3, and 
Lag-3 257,260,262. Although its inhibitory role in anti-tumor functionality of CD8+ T cells and 
Tregs is well defined, the influence of TIGIT on NK cell-mediated tumor control is less 
clear 258,263,264. However, the importance of DNAM-I, its competing co-stimulatory receptor, 
in NK cell-mediated immunity has been demonstrated in vivo 199,205,265,266. Moreover, 
suppression of NK cell functionality by MDSCs (myeloid-derived suppressor cells) was 
shown to depend on TIGIT-CD155 interactions, supporting the development of therapeutic 
strategies targeting TIGIT for cancer immunotherapy 267. 
 
3.3.4. Cytokines and their receptors  
Cytokines and chemokines are soluble mediators of the immune system and are involved 
in the activation, regulation and communication between different cell types of innate and 
adaptive immunity. The cytokine milieu determines the nature of the NK cell effector 
function and also modulates the extent of the general immune response. Cytokine signaling 
is essential for efficient NK cells activation in inflammation but also in their development, 
differentiation, homeostasis and migration or homing at steady state 268. Especially pro-
inflammatory cytokines such as interleukin-2 (IL-2), IL-15, IL-12, IL-18, IL-21 and type-I 
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interferons (IFNs) have been demonstrated to play pivotal roles in NK cell biology 109,269 
The combination of different cytokines together with cellular ligands can have synergistic 
effects on NK cell reactivity as e.g. when cytokine concentrations are limited in vivo 270,271. 
Due to the importance of IL-2, IL-15, IL-12 and IL-18 in this thesis, these cytokines, their 
receptors and their impact on NK cell function are described in more detail below.  
Common gamma-chain cytokines 
Cytokines sharing the common cytokine receptor gamma-chain (γc or CD132) are crucial 
for development and homeostasis of lymphoid cells as γc-deficient mice have defective B, 
T and NK cell compartments 272–275. The γc family consists of several members with a 
similar protein structure and comprises IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. The high 
affinity heterodimeric receptors are formed by a cytokine specific α-chain and the 
γc-chain 276,277. The only exceptions are IL-2 and IL-15 binding to a heterotrimeric receptor 
complex. The γc is the essential signaling component for these cytokines. It associates with 
Janus tyrosine-kinase (JAK)-3 which phosphorylates and activates different STAT 
molecules (signal transducer and activator of transcription) 278. Phosphorylated STAT 
dimers translocate to the nucleus where they serve as transcription factors. IL-4 
preferentially activates STAT-6, whereas IL-2, IL-7, IL-9 and IL-15 mostly act through 
STAT-5, and IL-21 signals via STAT-1 and STAT-3 272,273,279.  
The impact of IL-2 and IL-15 on NK cell function and survival is well studied. Both cytokines 
share the same IL-2/15Rβ (CD122) and the and γc (CD132) and thus have overlapping 
signaling pathways and functions 56,280,281. Both cytokines only interact with intermediate 
affinity to the heterodimeric βγ-receptor complex, requiring nanomolar concentrations. 
IL-2 and IL-15 have distinct high affinity α-chains, which accounts for the different 
biological functions of IL-2 and IL-15 282,283. The high affinity IL-2Rα chain (CD25) is 
incorporated into a heterotrimeric IL-2Rαβγ receptor complex, highly increasing the 
affinity to picomolar concentration of IL-2 284,285. CD25 is constitutively expressed on CD4+ 
Tregs and on CD56bright NK cells, which is associated with their high proliferative capacity in 
response to picomolar IL-2 concentrations 286,287. CD25 can be induced on NK and T cells 
upon various stimulations and is therefore often used as activation marker 288–291. Soluble 
IL-15 can directly bind with low affinity to the IL-15Rβγ, but high affinity binding requires 
its trans-presentation via the IL-15Rα. The high affinity IL-15Rα is primarily expressed on 
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macrophages and dendritic cells and trans-presents membrane-bound IL-15 to the 
IL-15Rβγ complex on the surface of NK or T cells 292–295. 
Signal transduction downstream of the shared IL-2/15Rβγ involves activation of different 
signaling cascades such as the MAPK/ERK pathway or STAT-3/5 phosphorylation by 
JAK1/3 296. Furthermore, signaling via the PI3K-AKT-mTOR pathway leads to the induction 
of anti-apoptotic Bcl-2 promoting cell survival 297–300.  
Both cytokines enhance NK cell proliferation and effector functions such as cytokine 
production and cytotoxicity and can improve NK-mediated anti-tumor 
responses 74,272,283,298,301. However, in vivo administration of IL-2 has been shown to 
simultaneously expand CD25+ regulatory T cells competing for the availability of IL-2 302–
305. Although both cytokines enhance NK cell effector functions and proliferation, the 
different phenotypes of IL-2 or IL-15 knockout mice have suggested unique roles for both 
cytokines in immune cell homeostasis 56,306–309. This is also reflected in the different sources 
of both cytokines as IL-2 is mainly produced by activated T cells, illustrating its importance 
for crosstalk during an activated immune response 71. In contrast, IL-15 is provided at 
steady state by a variety of APCs and non-immune cells 295,310. IL-15 signaling is 
indispensable for NK cell development, as mice deficient for STAT-5, IL-15 or IL-15R have 
impaired NK cell compartments 294,307,311. IL-15 has been shown to promote NK cell 
development from hematopoietic precursors in vivo and was capable of differentiating 
CD34+ hematopoietic progenitor cells into NK cells in vitro 55,77,268,297,312. Furthermore, IL-15 
is essential for NK cell homeostasis and survival in the periphery 58,275,294. 
 
IL-12 and its receptor 
IL-12 is a heterodimeric molecule with two subunits (p35 and p40) and belongs to the 
monokine family 313–315. It is produced by activated DCs and phagocytotic cells in response 
to pathogen encounter 316–319. The cognate receptor is composed of IL-12Rβ1 and IL-12Rβ2 
chains and is primarily expressed on activated NK and T cells as well as on resting NK cells, 
facilitating rapid immune responses without prior activation 320–324. Ligand binding and 
dimerization of the IL-12R results in JAK2 and TYK2 activation and phosphorylation of 
downstream STAT-3, STAT-4 and STAT-5 324–326. IL-12 was shown to be a strong inducer of 
IFN-γ and TNF-α and to improve NK cell cytotoxicity by upregulating granzyme and 
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perforin levels 313. The effects of IL-12 on NK cell mediated IFN-γ production and enhanced 
cytotoxicity have been mainly attributed to STAT-4 signaling 321,325,327.  
IL-12 synergizes with other activating stimuli such as cytokines or activating receptors, 
resulting in robust NK cell effector responses 328–332. IL-2 and IL-15 can augment IL-12 
signaling by regulation of the IL-12R and STAT-4 329,332 and combinatorial stimulation of 
IL-2/IL-15, IL-12 or IL-18 leads to a dose-dependent and synergistic effect on IFN-γ 
secretion 74,271,288,333,334. An essential mechanism of the synergy between IL-12 and IL-18 is 
based on the STAT-4 dependent upregulation of the IL-18 receptors and vice versa 335–338. 
In T cells, IL-12 acts synergistically with IL-2 signaling and TCR or CD28 stimulation for 
induction of IFN-γ production 328,331. In this way, NK and T cells can tune their 
responsiveness to the extent of inflammation. Furthermore, IL-12 has been shown to favor 
a TH1 response and to be instrumental in resistance against bacterial infections and 
intracellular parasites 316,317,339–342.  
IL-18 and its receptor 
IL-18 belongs to the IL-1 family and is synthesized as a biological inactive precursor protein 
(Pro-IL-18) which has to be processed and activated by caspase-1 or proteinase-3 343–346. 
As a monokine, IL-18 is produced by activated monocytes, macrophages and dendritic cells 
upon TLR stimulation but also by non-immune cells such as keratinocytes or osteoblastic 
stromal cells 347–350. The IL-18R is composed of a ligand binding chain (IL-18Rα) and an 
accessory signaling protein (IL-18Rβ) 351,352. The IL-18R complex primarily signals via 
recruitment of MyD88 (Myeloid differentiation primary response gene 88) and IRAK 
(interleukin-1 receptor-associated kinase) / TRAF6 (TNF receptor associated factors) 
leading to NF-κB activation 353. In addition, induction of STAT-3 and MAPK transduction 
pathways has been reported in NK cells and neutrophils 354–356. IL-18Rα is constitutively 
expressed on resting NK cells, naïve T and mature TH1 cells as well as on other immune 
cells 338,357–360. Free IL-18 can also be bound by the IL-18–binding protein (IL-18BP) in the 
circulation, preventing its receptor binding and its biological function 361. IL-18 stimulation 
alone only induces minor effects due to the low constitutive expression levels of the IL-18R. 
However, IL-18 can function synergistically with type-I IFNs, IL-12 and IL-15, particularly 
because IL-12 signaling upregulates the expression of the IL-18R 337,338. In synergy, IL-18 
can stimulate potent proliferation and IFN-γ production in NK cells and upregulation of 
perforin and FasL dependent cytotoxicity in NK cell and CD8+ T cells 74,270,271,288,333,362–365. 
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IL-18 has further been implicated in the priming of NK cells during their maturation in the 
periphery since NK cells deficient for IL-18 have impaired IFN-γ production and 
cytotoxicity 365,366. For T cells, IL-18 together with IL-12 plays an important role in TH1 
differentiation, providing another link between innate and adaptive immune 
responses 343,365,367. In contrast, IL-18 alone or in combination with IL-2 rather stimulates a 
TH2 response 368–370, whereas synergy with IL-23 induces TH17 differentiation 371. 
 
3.4. The killer immunoglobulin-like receptor system 
Activation of NK cells is counterbalanced by inhibitory receptors like the KIR family and 
the lectin-like NKG2A receptors, both binding to MHC class I molecules expressed on all 
nucleated cells 110,227. Therefore, both receptor families largely contribute to NK self-
tolerance towards autologous healthy cells preventing uncontrolled activation and 
immunopathology. Upon perturbation of MHC-I expression during viral infection or 
malignant transformation, inhibition through these receptors is attenuated, rendering the 
target cell susceptible to NK cell mediated killing (‘missing-self’) 19,118. In the human system, 
the killer cell immunoglobulin-like receptor (KIR) family comprise the biggest and best 
studied group of inhibitory receptors and recognizes HLA-A, -B, and -C alleles. KIR 
receptors were first described and cloned in the 1990s by several groups and were 
subsequently shown to function as inhibitory receptors for different HLA class I 
molecules 372–383. 
KIRs are not detectable in mice, where the structurally different Ly49 receptors recognize 
MHC class I and perform analogous functions 384,385. Ly49 and KIR molecules have evolved 
independently and KIR genes have diversified rapidly in primates and humans 386,387. 
Similar as their polymorphic MHC-I ligands, the human KIR and mouse Ly49 loci are both 
highly polymorphic in gene content and allelic polymorphism 388,389. The complexes for 
KIR/Ly49 and MHC genes are located on different chromosomes and independent 
segregation results in variable receptor-ligand combinations. Interaction between KIR 
receptors and HLA-I variants have been shown to influence the potency of an immune 
response and certain KIR-HLA combinations have been associated with autoimmunity, 
reproductive complications as well as resistance or susceptibility to viral infections and 
cancer 390,391. 
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In addition to NK cells, KIRs are expressed on divers T cell subsets including NKT cells, γδ-T 
cells and on memory/effector αβ-T cells 392–397. KIR expression on T cells occurs after TCR 
rearrangement and is considered to protect from activation-induced cell death as the KIR+ 
subset increases with age 393,398–400. 
 
3.4.1. Structure and nomenclature of KIR molecules 
KIR proteins are type-I transmembrane glycoproteins belonging to the immunoglobulin-
like superfamily and are composed of a different number of extracellular Ig-like domains 
(“D”), indicated in their nomenclature as KIR2D or KIR3D 111,401,402. They express either a 
long or a short cytoplasmic tail involved in signal transduction 83,128. Inhibitory KIRs with a 
long cytoplasmic tail (“L”) contain ITIM motifs (immunoreceptor tyrosine-based inhibitory 
motifs) thus transferring inhibitory signals 83,128. Binding of inhibitory KIRs to their cognate 
ligands results in inhibitory signaling and in suppression of NK effector functions. ITIM 
signaling involves recruitment of SHP-1/2, leading to dephosphorylation and inhibition of 
Vav-1 234–237. ITIM-mediated inhibition dominates over activating signals by blocking 
signaling at a proximal step and thus preventing downstream stimulatory signals 83,236. In 
contrast, activating KIRs harbor a short cytoplasmic tail (“S”) that signals via recruitment 
of the ITAM-bearing adapter DAP12, leading to activation of NK cells 83,134,135.  
The last digit of KIR nomenclature indicates the number of the gene encoding the molecule 
in the leukocyte receptor complex (LRC). The denotation “P” refers to non-expressed 
pseudogenes 111,401,402. Exemplarily, KIR2DL1 encodes an inhibitory receptor containing a 
long cytoplasmic tail and two Ig domains, whereas KIR3DS1 represents an activating KIR 
with three Ig domains and a short cytoplasmic tail.  
KIR2DL4 represents an interesting exception, harboring a long cytoplasmic tail with only a 
single ITIM and weak inhibitory potential 403. In contrast, KIR2DL4 contains a charged 
arginine residue allowing the receptor to couple with FcεRIγ resulting in high IFN-γ 
production but low cytotoxicity 404,405. In addition, KIR2DL4 transcripts are ubiquitously 
detected in all NK cells but do not always correlate with protein surface expression 406.  
 
3.4.2. Ligand binding specificity of KIR receptors 
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KIR bind HLA-A, -B and -C alleles and the ligand-receptor interactions for most inhibitory 
KIRs have been clearly defined (Figure 3.3) 407,408. Most KIR receptors recognize specific 
motifs located at the α1 and α2 helices of HLA-I molecules and certain amino acids within 
the HLA binding groove define KIR binding specificity 228,407,409,410. KIR2DL1 recognizes 
HLA-C C2 epitopes defined by expression of lysine at position 80 of the HLA-C heavy chain 
(HLA-C Lys80) 374,376,411,412. KIR2DL2 and KIR2DL3 bind to HLA-C C1 epitopes carrying an 
Asparagine at position 80 (HLA-C Asn80) 376,411,413. In addition, KR2DL2 can also detect 
some C2 allotypes 414. Of note, the interaction of KIR2DL1 with its C2 ligands results in 
relatively stronger inhibitory signals compared to KIR2DL2/L3 and C1 interactions 414,415. 
Some HLA-A and approximately 40% of all HLA-B alleles possess the HLA-Bw4 serological 
motif (located at amino acids 77-83), which functions as ligand for KIR3DL1 375,413,416,417. 
Recent studies indicate a peptide dependency of peptides loaded on HLA-I on the KIR 
binding affinity, which is much broader compared to TCR specificity and is rather mediated 
by motifs than sequences 418,419. In particular, the strength of the binding of KIR3DL2 to 
HLA-A3 and A11 allotypes 420,421 and of KIR3DL1 to the Bw4 motif is highly sensitive to the 
bound peptide 422–424. Chrystal structures of KIR–HLA-I interactions could define these 
binding parameters in molecular detail, demonstrating importance of amino acids at 
position 7 and 8 in the peptide 228,407,409,410. The strength of inhibitory and activating signals 
induced upon KIR–HLA-I interaction is dependent on the presented peptide and thus can 
be manipulated by viral infection or malignant transformation 418,422,425.  
The ligands for activating KIRs have been harder to identify, probably due to high peptide 
selectivity and lower binding affinity as their inhibitory counterparts 418,425. Exemplarily, 
KIR2DS1 binds to the same C2 epitope as the structurally similar inhibitory KIR2DL1 
receptor, although with reduced affinity and higher peptide selectivity 415,426,427. Peptide 
specific binding to HLA-A*11:01 and only weak binding to HLA-C1 was detected for the 
activating KIR2DS2 receptor in contrast to the structurally related KIR2DL2 
molecule 230,428. Additionally, KIR2DS2 was shown to directly recognize conserved flaviviral 
peptides in context of HLA-C1 and to bind cancer cell lines in a β2-microglobulin (β2m)-
independent manner 429,430. The most prevalent KIR2DS4 receptor exhibits a unique 
binding specificity for HLA-A11 and selective HLA-C1 and C2 alleles 431. Interaction of 
KIR3DS1 with HLA-Bw4 alleles has been implicated by epidemiological studies to 
contribute to HIV resistance and slow AIDS progression 432,433. Recently, KIR3DS1 has been 
described to additionally recognize HLA-F open conformers (a non-classical HLA-Ib 
3  INTRODUCTION  
28 
without association of β2m), which might be expressed on HIV-infected lymphocytes 434,435. 
Therefore, activating KIRs might also recognize viral-induced or altered ligands and non-
classical HLA-I molecules. Furthermore, the interaction of KIRs to their HLA-I ligands is 
constantly subjected to viral escape strategies. Up- and downregulation of HLA-I 
expression could both influence binding to inhibitory and activating KIRs and viral 
manipulation of selected peptide presentation can further impact KIR binding specificity 
and affinity 418,422,425,436.  
The rather activating KIR2DL4 (see section 3.4.1) binds to HLA-G molecules expressed on 
trophoblasts mediating tolerance of the fetus and indirectly promoting vascularization of 
the maternal decidua via IFN-γ production 30,437–439. Ligands for KIR2DL5, 3DL3, 2DS3 and 
2DS5 remain elusive and are currently under intensive investigation. 
 
3.4.3. KIR expression on NK cells 
KIRs are encoded within the leukocyte receptor complex (LRC) on chromosome 19q13.4. 
containing 15 genes and 2 pseudogenes 440,441. The variable gene content of the LRC locus 
and allelic nucleotide sequence polymorphism of each KIR gene contribute to the 
substantial KIR diversity in the human population 388,442–444. In an individual, KIRs are 
expressed in a stochastic and variegated manner and therefore each NK cell clone 
Figure 3.3: HLA class I ligands for activating and inhibitory KIRs. Inhibitory killer 
immunoglobulin-like receptors (KIRs) harbor a long cytoplasmic tail (‘L’) with ITIM domains 
transmitting inhibitory signals. Activating KIRs with short cytoplasmic tails (‘S’) couple to ITAM 
containing adapters such as DAP12 for activating signaling. KIRs bind specifically to HLA-A, -B, -C, -F 
or -G allotypes. The binding motifs for HLA-C are referred to as HLA-C1/C2 and HLA-Bw4 for HLA-
A and -B, which comprise specific epitopes characterized by defined amino acid sequences. The 
interaction between certain KIRs and their ligands are peptide dependent and some ligands still 
remain elusive. (Adapted from Béziat et al. Immunology 2017) 408 
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expresses a different combination of the encoded KIRs, leading to a diverse KIR receptor 
repertoire on individual NK cell clones 373,406,442,444,445. The frequency of an NK cell 
expressing a certain KIR as well as the levels of its surface expression can vary between 
individuals depending on e.g. the copy number of the KIR gene (‘gene-dose’ effect) or the 
allelic variation at the locus (KIR alleles with high or low protein surface densities) 446–449. 
These factors contribute to the broad range of functionally distinct NK populations enabled 
to detect expression changes of highly polymorphic MHC class I molecules on target cells. 
Co-expression of different KIR genes within one NK cell clone is mainly predicted by the 
product rule, meaning that the probability of co-expression is predicted by the product of 
the individual expression frequencies of each KIR, which are independent events 442,445,450. 
Reports in mice indicate a negative correlation of the expression frequency of MHC-I 
ligands and their inhibitory receptors Ly49 and CD94/NKG2A, suggesting a role for MHC-I 
in shaping individual KIR repertoires 451–453. The interaction of MHC-I with its cognate 
inhibitory receptor would suppress the co-expression of a second cognate receptor, 
limiting the number of self-specific inhibitory receptors. Thus, the expression of KIR/Ly49 
during development would be dependent on a MHC-I–based selection 454–457. In humans, 
however, this influence is still under debate and might be reflected as an imprint from 
previous infectious challenges 443,445,458,459. 
Two KIR haplotypes can be distinguished by the composition of their KIR genes. Group A 
haplotypes mostly comprise inhibitory KIRs, whereas group B haplotypes harbor 
additional genes encoding activating KIRs 443,444,460. Combination of these haplotypes 
 Figure 3.4: Human haplotypes A and B at the KIR locus. Two examples for each haplotype are 
shown. The gene content of each haplotype can vary giving rise to a high diversity of KIR haplotypes 
that are either AA, AB or BB. Activating KIR genes are indicated as green and inhibitory KIR genes as 
red boxes. Conserved genes present in both haplotypes are depicted in purple and pseudogenes in 
grey. (Thielens et al. Curr Opin Immunol 2012) 693 
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results in KIR genotypes with ‚AA‘, ‚AB‘ or ‘BB’ content. Studies indicate a correlation 
between group A haplotypes and improved immunity against pathogens whereas group B 
haplotypes are associated with productive fitness 388,390,391. 
NK cells acquire KIR expression late during maturation and terminal differentiation. KIR 
expression is weak or absent in CD56brightNKG2A+CD94hiCD16– cells and increases 
gradually during maturation with highest expression in terminally differentiated 
CD56dimNKG2A–CD94loCD16+ NK cells 64–66,81.  
 
3.4.4. Regulation of KIR gene expression 
KIRs are expressed in a stochastic manner on individual NK cell clones during development, 
but the molecular mechanism defining which KIR gene is expressed and which is silenced 
remain poorly defined. Although the regulatory regions of most KIR genes are highly 
conserved, the individual KIR alleles are regulated independently resulting in variegated 
and clonally restricted expression patterns 440. The regulatory regions of KIR2DL4 and 
KIR3DL3 mark exceptions consistent with their distinct expression characteristics 
(ubiquitously and non-expressed, respectively) and are driven by a different type of 
promoter 461,462. Acquisition of KIR expression during development has been shown to be a 
complex process involving epigenetic DNA modifications, multiple promoter elements, 
intergenic fragments, bidirectional transcription and anti-sense RNA 463,464. 
Epigenetic mechanisms controlling KIR expression 
In hematopoietic stem cells, the KIR locus is epigenetically silenced by DNA methylation 
and histone condensation accompanied with a closed chromatin state. In order for KIR gene 
transcription to take place, transcription factors need to gain access to the promoter 
regions. As hematopoietic progenitor cells commit to the NK cell linage, initiation of KIR 
gene transcription thus first requires chromatin opening via histone acetylation. In a two-
step model, euchromatic histones represent a prerequisite for subsequent DNA 
demethylation and gene transcription, since active as well as untranscribed KIR genes 
exhibit a high degree of histone acetylation associated with an open chromatin 
signature 465,466. 
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It has been shown by several groups that the clonally restricted expression of highly 
homologous KIR genes is stably maintained by epigenetic mechanisms 465,467,468 and 
expression frequency and intensity are passed on during cell division 442,455,458. De novo KIR 
expression and generation of the clonal KIR repertoire are established by DNA 
demethylation during development 465,467,468. The methylation status of CpG island 
clustered in an upstream region of the KIR transcriptional start site was found to correlate 
with transcriptional activity of the KIR gene. Highly methylated CpG islands corresponded 
to non-expressed and silenced KIR genes and vice versa 467. Chan and colleagues 
demonstrated that DNA methylation ensured a predominant mono-allelic expression of 
highly homologous KIR genes indicating an individual control of the regulatory 
regions 465,468. Exposure of mature NK cells to 5-aza-2'-deoxycytidine (5Aza-dC, a DNA 
methyltransferase inhibitor causing demethylation) was shown to induce de novo 
expression of previously silenced KIR genes and conversely, in vitro methylation of CpG 
islands resulted in repression of reporter gene transcription 465,467. 
KIR promoter elements 
To date, several promoter elements are described that are shared by most KIR genes, such 
as a distal promoter Pro-D), a bidirectional proximal promoter switch (Pro-S), an intron 2 
promoter and an intermediate promoter element (Pro-1) 463,464. A model illustrates how 
these different promoters orchestrate KIR expression during development (see Figure 
3.5) 464,469. 
Anti-sense transcripts originating from an intron 2 promoter are restricted to early 
progenitor and hematopoietic stem cells but have not been detected in mature NK cells as 
the intron 2 promoter activity declines during NK cell linage commitment 466,470. These 
lncRNAs (long non-coding RNAs) may play a role in establishing epigenetic marks such as 
DNA methylation or histone modifications. 
The distal promoter element (Pro-D) exerts a low transcriptional activity early during NK 
cell development due to non-methylated transcription factor binding sites. During lineage 
specific transition from the pro- to the immature NK cell stage, basal Pro-D activity 
contributes to the ‘priming’ of KIR gene expression through recruitment of chromatin 
modifying enzymes that increase DNA accessibility 471,472. As developing NK cells acquire 
IL-15 responsiveness via CD122 (IL-15Rβ) expression at the CD56bright stage 28,48, IL-15 
drives full transcriptional activity of the KIR distal promoter element 464,472. Transcripts 
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from the distal promoter span the downstream proximal promoter region, which leads to 
initial opening of the chromatin structure allowing access of transcription factors that 
promote demethylation such as Runx/AML 464,473. 
The proximal promoter has a probabilistic, bidirectional activity and is active in both the 
forward and reverse direction and is therefore often referred to as probabilistic promoter 
switch (Pro-S) 473,474. Probabilistic transcription from the bidirectional proximal promoter 
in CD56dim NK cells defines whether a certain KIR gene is expressed and accounts for the 
stochastic and clonal KIR distribution 449,473. It harbors a multitude of transcription factor 
binding sites and their relative affinity of inducing sense vs antisense promoter activity 
determines the probability of sense vs antisense transcription 449,461,473. The anti-sense 
Figure 3.5: Model of successive regulation of KIR acquisition during development by different 
promoter elements. The scheme depicts the 5′ control region and the first three exons encoding 
KIR genes with ‘ATG’ labeling the initiation of protein translation. Promoter elements are indicated 
by filled rectangles. Three main promoter elements mark the three phases of KIR gene transcription 
with green rectangles highlighting the promoters that define the proposed phase of expression. 
Black arrows represent sense transcripts and red arrows show antisense transcription with dsRNA 
displayed as red box. (Adapted from Anderson, Mol Ther Nucleic Acids 2014) 474. 
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transcripts spread the upstream distal promoter generating a double-stranded (ds)RNA, 
which is processed into a 28bp piwiRNA involved in epigenetic re-silencing of the locus 475. 
A higher ratio of sense to anti-sense transcripts thus allows a higher chance of stable gene 
transcription and expression of the particular KIR allele. Polymorphisms in KIR promotor 
sequences that alter transcription factor binding sites can impact KIR expression and can 
account for expression differences in different alleles as shown for KIR3DL1 449,473. A mouse 
study investigating the highly homologous Ly49 bidirectional promoter further suggests a 
role of activating receptor signaling during NK cell development in induction of proximal 
promoter sense-activity, thus increasing the probability of KIR expression 476. 
Once the clonal KIR gene expression is established, the regulation of the surface expression 
frequency or intensity of an expressed KIR are poorly defined. A recently identified 
intermediate promoter element (Pro-1) upstream of the proximal promoter has been 
reported to be involved in regulating the expression of actively transcribed KIR genes in 
mature CD56dimKIR+ NK cells 477,478. Sense transcription from the proximal promoter was 
shown to be not sufficient but additional activity of the intermediate promoter was 
required to drive KIR protein expression in mature NK cells. 
Figure 3.5 illustrates a successive model of KIR expression during different developmental 
stages 474,477: KIR gene expression is epigenetically silenced in early progenitor cells by DNA 
methylation and condensed histone signatures but is transformed into euchromatin as NK 
cells progress during development. Upon transition to the CD56bright stage, transcription 
from the distal promoter (Pro-D) opens the downstream proximal promoter region (Pro-S). 
The sense to anti-sense ratio of transcripts from the bidirectional switch (Pro-S) 
determines the stochastic clonal expression patterns of KIR alleles, while the intermediate 
promoter (Pro-1) controls expression in mature KIR+ NK cells. 
 
3.5. NK cell education 
The complexes for KIR/Ly49 and MHC genes are located on different chromosomes and 
independent segregation results in variable receptor-ligand combinations. KIR expression 
of NK cells is a stochastic event and genetically unlinked to the HLA haplotype of the 
individuum, resulting in NK cells expressing multiple or no KIRs on the surface 442,443. In 
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line with this, some NK cells lack expression of a receptor for binding of self MHC-I 
molecules. 
Ligand specificity of KIR/Ly49 receptors for self-MHC class I is essential for NK cells in 
order to recognize and eliminate ‘missing-self’ target cells with downregulated or altered 
self–MHC-I expression 19,117–119. To prevent autoimmunity, self-tolerance of NK cells lacking 
any inhibitory receptors for self-HLA-I is generated in a process termed ‘education’ or 
‘licensing’ 479,480. NK cells are educated by the interaction of self–MHC-I and their cognate 
inhibitory receptors resulting in acquisition of full responsiveness 481–483. Thereby, 
educated NK cells are functional competent but remain tolerant towards self–MHC-I 
positive cells because they express at least one inhibitory receptor. Conversely, NK cells 
that fail to bind self–MHC-I are hyporesponsive to ligation of activating receptors and thus 
preserve tolerance towards self. NK cells developing in the absence of interactions with 
self-MHC class I molecules, as shown in MHC deficient mice, are hyporesponsive and 
defective in killing of MHC-I negative target cells 481–485. In addition to KIRs, also other 
inhibitory receptors are involved in licensing of NK cells. Among others, these include the 
CD94/NKG2A heterodimer, which recognizes the non-classical MHC-I molecule HLA-E, and 
the signaling leukocyte activating molecule (SLAM) family receptors 2B4 and SLAMF6 486–
489. Furthermore, not only interactions of inhibitory self-receptors with their ligands on 
adjacent cells (in trans) contribute to NK cell tolerance but several studies have 
demonstrated a role for cis interactions (on the same cell) in the education process 490–494. 
Currently, several models exist that describe the molecular mechanism leading to NK 
education upon engagement of a self–MHC-I specific receptor with its cognate ligand 480,495–
497. In the arming model, NK cells only acquire functional competence after encountering 
self–HLA-I and are actively endowed with effector potential 481,495. The disarming model 
postulates that initially functional NK cells are disarmed through constant activation-
induced anergy to preserve tolerance if the activation is not balanced by inhibitory 
signals 483,497. In general, both licensing mechanisms seem to require functional ITIM 
signaling upon inhibitory receptor engagement, which might act through an additional 
signaling pathway than dephosphorylation of Vav-1 235,481. The rheostat model proposes 
that NK effector potential is calibrated by the quantitative and qualitative interactions 
between inhibitory receptor and their ligands 487,498–502. The density of inhibitory self-
receptors correlates with the strength of responsiveness of individual NK cells tuning the 
magnitude of education to environmental MHC. The different models could be rather 
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complementary than mutually exclusive and experimental evidence supports the concept 
that NK cell education could be adaptable to changes in the MHC-I environment of the 
host 503. Chronic exposure of mature or developing cells to activating ligands could tolerize 
NK cells, rendering them hyporesponsive even towards unrelated stimuli. The reversibility 
of the anergic state indicates an ongoing calibration of NK cell education to maintain 
tolerance to constantly changing environments 504–507. Adoptive studies in mice have 
further demonstrated plasticity in the education status of mature NK cells. Uneducated and 
hyporesponsive NK cells regain their functional competence when transferred into a MHC-I 
sufficient host and vice versa 508,509. However, studies in humanized mice and HSCT in 
patients have indicated that transferred NK cells remain educated in the different HLA-I 
environment of the recipient 492.  
However, uneducated NK cells are not completely dysfunctional but rather exhibit a higher 
threshold for excitability by activating receptors and inefficient target cell recognition. 
They are still capable of robust effector function when stimulated with pro-inflammatory 
cytokines or with pharmacological stimuli such as PMA/Ionomycin 481,510. Furthermore, in 
vitro studies using human NK cell and in vivo tumor models in mice revealed that anergy of 
unlicensed NK cells was reversible and responsiveness could be restored in the presence 
of inflammatory cytokines such as IL-2, IL-12 or IL-18 510–512. Marçais et al. recently 
demonstrated that the level of education and responsiveness correlated with mTOR 
activity which was restored in hyporesponsive NK cells upon cytokine treatment resulting 
in re-educated NK cells 513. Thus, mTOR operates as a molecular rheostat of NK cell 
responsiveness and education. Unlicensed NK cells may thus be functional during 
inflammatory conditions, suggesting that the cytokine milieu may overcome strict MHC-
dependent licensing requirements which primarily affects contact-dependent NK cell 
activation. Moreover, it was shown that infection with Listeria monocytogenes as well as 
virus-induced inflammation was capable of breaking self-tolerance in mice 483,514. Recent 
studies suggested distinct roles for licensed and unlicensed NK cells in viral infection, anti-
tumor immunity and engraftment of allogeneic transplantations 515–517. Unlicensed cells 
dominate the protection against MCMV infection and are superior effectors compared to 
licensed NK cells, probably because they become functional in the pro-inflammatory milieu 
and are enabled to expand preferentially in absence of restraining inhibitory self-
receptors 518. Furthermore, hyporesponsiveness of uneducated NK cells could be overcome 
by robust CD16 signaling resulting in a beneficial role of these uneducated NK cells in 
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mediating ADCC in therapeutic settings of MHC-I–expressing neuroblastoma or 
lymphoma 519–521. Taken together, NK cell licensing provides an individual activation 
threshold that is adjusted to perturbations in the peripheral environment such as 
transplantation or inflammation with specialized functions of educated NK cells in 
providing immunity against MHC-deficient tumors and uneducated NK cells protecting 
against viral infections or MHC-I sufficient tumors. 
 
3.6. Memory in NK cells 
Immunological memory is defined as the generation of a faster and more potent recall 
response upon subsequent challenge with the same antigen as during the initial encounter. 
The formation of immunological memory was classically attributed to the adaptive immune 
system. T and B cells encountering their cognate antigen undergo clonal expansion and 
differentiation into potent effector cells, expanding the pool of cells specific for a particular 
antigen. After clearance of the infection, cell numbers decrease in the contraction phase, 
leaving some cells to differentiate into long-lived memory cells that are capable of fast and 
enhanced effector responses upon re-challenge with the same antigen 522. Antigen 
specificity is one of the main characteristics of adaptive immunity and a crucial hallmark of 
immunological memory.  
Since NK cell activation is facilitated by germline encoded receptors without somatic gene 
re-arrangement, NK cells were considered to lack antigen specificity and immunological 
memory. However, a growing body of experimental evidence suggests that NK cells as well 
as other innate immune cells can possess adaptive features such as clonal expansion, long-
term persistence and superior recall responses 10,11,24,25.  
Several ways have been described that can induce the formation of NK cell memory 523. 
Memory-like NK populations with robust recall responses have been reported during viral 
infection 23,524 and contact hypersensitivity reactions 525, indicating an antigen-specific 
immunologic memory of NK cells (Figure 3.6). Stimulated NK cells can undergo a robust 
clonally expansion followed by a contraction phase and creation of a long-lived memory 
pool persisting for several month. Upon re-challenge cells are capable of a more robust 
recall response, mediating greater effector functions than conventional NK cells. Besides 
antigen-specific memory, short pre-activation with the pro-inflammatory cytokines 
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IL-12/15/18 has been shown to induce an antigen-unspecific memory-like phenotype with 
sustained effector function persisting for several weeks in vitro and even for up to 3 month 
in vivo 288,289,333,334,526. 
 
3.6.1. Liver-restricted memory NK cells 
The first observations of NK cells exerting antigen-specific recall responses have been 
described in a model of hapten-specific contact hypersensitivity (CHS). In 2006 O'Leary et 
al. reported NK cell dependent specific memory in response to haptens in T and B cell 
deficient RAG-/- mice 525. The mice exhibited pronounced recall responses to a secondary 
challenge with the same hapten, but not to a related molecule with similar chemical 
Figure 3.6: Memory and memory like cells in mice and human. A variety of factors contribute to 
the generation of memory or memory-like cells. Antigen-specific memory is created in mice against 
haptens and the MCMV m157 protein. The human NK subset expressing the activating CD94/NKG2C 
receptor expands in HCMV, Hantavirus, Chikungunya Virus, HIV, and HBV infection. Memory-like NK 
cells in both mice and human can be generated by short pre-activation with IL-12/15/18. (Adapted 
from Rölle et al. PLOS pathogens 2013) 524. 
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structure. Hapten-specific contact hypersensitivity responses persisted for 4 weeks and 
could be transferred from hapten-sensitized mice into naïve mice. Antigen-specific 
responses were shown to be mediated by CXCR6+CD90+ liver NK cells and to be induced 
additionally by various viral components 527.  
 
3.6.2. NK memory in viral infections 
MCMV-induced memory 
NK cells with adaptive features have also been detected in murine and human 
cytomegalovirus (MCMV and HCMV) infections 524,528. MCMV infection in mice were 
reported to drive the expansion of NK cells expressing the Ly49H receptor recognizing the 
viral glycoprotein m157. Expansion of Ly49H+ NK cells was followed by a contraction phase 
and generation of a pool of long-lived memory cells 529,530. Upon re-challenge with MCMV, 
the persisting Ly49H+ NK cells were capable of conferring protection against the infection 
and exhibit robust recall response such as secondary expansion and superior effector 
functions 529,530. In addition to m157 antigen-specificity and Ly49H-DAP10 signaling, 
signaling via the pro-inflammatory type-I IFNs, IL-18R–myD88, IL-12R and STAT-4 was 
indispensable for the NK cell anti-viral response 531–533. Moreover, critical roles for 
microRNA-155, DNAM-I and the transcription factor Hopx have been reported 534–536. The 
contraction phase was shown to be driven by Bim-mediated apoptosis after Ly49H+ subset 
expansion 537 and to involve mitophagy to generate MCMV-specific memory 538. Moreover, 
the transcription factors IRF8 and Zbtb32 were demonstrated to be induced upon IL-12 
and STAT-4 signaling and to maintain a high proliferative potential of MCMV-specific NK 
cells in part by antagonizing pro-apoptotic Blimp-1 539,540.  
HCMV-induced memory 
In line with observations in the murine CMV infection model, memory-like properties of NK 
cells were detected in human CMV infections. Increased frequencies of NK cells expressing 
the activating receptor CD94/NKG2C correlated with a positive serostatus for HCMV of 
healthy individuals 541. Preferentially expansion of the NKG2C+ NK cell subset was detected 
during acute HCMV re-infection and in an in vitro co-culture system of peripheral blood 
leukocytes (PBLs) with HCMV-infected fibroblasts 164,542. A study of HCMV re-activation 
after hematopoietic stem cell transplantation (HSCT) reported enhanced recall responses 
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NKG2C+ NK cells in HCMV-seropositive recipients in contrast to HCMV-seronegative 
patients 543,544. High numbers of NKG2C+ NK cells were still detectable one year after 
transplantation, presenting evidence for adaptive features of an antigen-specific NK cell 
subset resembling the observations in murine CMV infection. Moreover, clinical studies 
suggest a beneficial role for HCMV re-activation after HSCT in protection against leukemia 
relapse indicating anti-leukemia properties of adaptive NKG2C+ NK cells 545–548. Recently, 
ex vivo expansion of adaptive NKG2C+ NK cells using HLA-E–expressing feeder cells has 
been reported, resulting in effector cells with high anti-tumor potential against ALL (acute 
lymphoblastic leukemia) blasts 549. 
In addition to HCMV infection, expansion of NKG2C+ NK cells has been observed in other 
viral infections such as Hantavirus and Chikungunya virus infection and also in chronic 
HIV-1 and HBV infections 550–554. Of note, NKG2C+ subset expansion has only been detected 
in HCMV co-infection or in HCMV seropositive patients, supporting the hypothesis that 
HCMV primes NK cells for memory formation. Interestingly, antigen-specific NK cell 
memory responses were detected in simian immunodeficiency virus (SIV) infected rhesus 
macaques, depending onNKG2C and NKG2A and persisting for up to five years 555. 
Rölle and colleagues from our laboratory recently demonstrated that HLA-E expression on 
infected fibroblasts is responsible for driving the expansion of the NKG2C+ subset in HCMV 
infection 556. Using an in vitro co-culture system of PBMCs and HCMV-infected fibroblasts, 
our laboratory further reported a crucial role for IL-12 produced by inflammatory 
monocytes in expansion of NKG2C+ NK cells and for the CD2-CD58 axis in functionality of 
adaptive NKG2C+ cells 556,557. Expanded NKG2C+ NK subsets have been described to co-
express self-specific KIRs and the maturation marker CD57 552,558,559. A recent study 
indicated a role for activating KIRs, for instance KIR2DS2 and KIR2DS4, in HCMV specific 
memory formation in the absence of NKG2C expression in NKG2C deficient patients 560,561.  
reported HCMV-specific NK cell expansion in the absence of NKG2C expression in patients 
carrying a homozygous deletion in the NKG2C gene 561. Importantly, these NK cells were 
shown to express activating KIRs, including KIR2DS2 and KIR2DS4 involved in 
activation 560.  
The elevated functionality of adapted NKG2C+ NK cells has been attributed to epigenetic 
imprinting driven by HCMV infection such as high demethylation of the IFN-γ locus 562. 
Furthermore, adaptive NKG2C+ NK cells in HCMV-seropositive individuals were found to 
3  INTRODUCTION  
40 
be negative for the CD16 adaptor molecule FcεRIγ 563,564. FcεRIγ-deficient NK cells 
possessed enhanced antibody-dependent responses compared to conventional NK cells 
against HCMV-infected antibody-coated target cells 564. Furthermore, FcεRIγ-deficient NK 
cells were shown to harbor several deficiencies of proteins classically attributed to innate 
immunity, including signaling molecules and transcription factors such as SYK or EAT-2, 
leading to altered cytokine responsiveness 565,566. FcεRIγ-deficient NK cells in HCMV-
seropositive individuals were associated with distinct genome-wide DNA methylation 
patterns, resembling rather adaptive than innate immune cells 566.  
 
3.6.3. Cytokine-induced memory-like NK cells 
The importance of pro-inflammatory cytokines, especially of IL-12, for driving NK cell 
memory has been demonstrated in viral MCMV and HCMV infection 531,556, suggesting a 
mechanistic link between pro-inflammatory cytokines and adaptive NK cells. Indeed, short 
overnight pre-activation of mouse and human NK cells with a combination of the pro-
inflammatory cytokines IL-12, IL-15 and IL-18 were demonstrated to generate NK cells 
with sustained effector functions termed cytokine-induced memory-like NK cells 333,567. 
IL-12/15/18–pre-activated NK cells showed high longevity and persistence for up to 
3 month after adoptive transfer and were able to reject established tumors in mice 288,333. 
Moreover, cytokine-induced memory-like NK cells exhibited high proliferative capacity and 
pronounced anti-tumor responsiveness after an in vitro resting phase in IL-2 or IL-15 as 
well as after adoptive transfer into tumor-bearing mice 288,289,334,526,568,569. The strong 
proliferative capacity of IL-12/15/18–stimulated NK cells has been assigned to enhanced 
expression the high affinity IL-2R α-chain (CD25), facilitating strong expansion and 
persistence in response to low-dose IL-2 288,289. Furthermore, pre-activation with 
IL-12/15/18 has been shown to induce epigenetic remodeling of the IFN-γ locus upon 
adoptive transfer in mice, contributing to their superior IFN-γ production upon re-
activation 569.  
Recently, the safety and feasibility of adoptive transfer of IL-12/15/18–pre-activated NK 
cells has recently been reported in a phase-I clinical trial against AML 526. In this first-in-
human trial, the adoptively transferred cytokine–pre-activated NK cells exhibited 
substantial proliferation and long persistence in the recipient. Importantly, upon ex vivo re-
stimulation 7 days post-infusion, IL-12/15/18–pre-activated NK cells showed potent anti-
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leukemia responses correlating with improved patient survival. Of note, cytokine-induced 
memory-like NK cells lack antigen specificity and respond to a variety of stimuli. Until now, 
no specific marker could be identified to discriminate these cells from activated or 
conventional NK cells. 
 
3.7. Tumor immunology 
Cancer is a life-threatening disease with high mortality and growing incidence worldwide. 
Cancer development is a complex process involving multiple steps of malignant 
transformation and de-regulation of previously healthy cells. Malignant transformation can 
be induced through irradiation, chemicals, viruses or chronic inflammation. Through 
accumulation of genetic mutations, normal body cells lose regulatory circuits controlling 
proliferation, DNA repair, apoptosis and cellular motility. During cancer progression, 
uncontrolled proliferation of de-regulated cells results in formation of a solid tumor mass. 
Dissemination of single cancer cells can lead to metastasis at distant sites in the body, which 
are often fatal for the cancer patient. Although cancer is a complex, heterogeneous and 
multi-factorial disease, most cancer types share several common properties that can be 
summarized as the hallmarks of cancer (Figure 3.7) 570,571. 
 
3.7.1. Hallmarks of cancer 
In 2000 Hanahan and Weinberg proposed the six hallmarks of cancer, describing shared 
capabilities enabling cancer formation, which were extended by 4 additional features in 
2011 570,571. 
Sustained proliferative signaling. During cancer progression, tumor cells receive 
sustained proliferative signaling, enabling uncontrolled proliferation and growth. In 
healthy tissue, proliferation is carefully controlled through growth-promoting signals and 
several checkpoints in the cell division cycle. Tumor cells acquire the competence of 
producing their own growth factors or induce growth-factor production in the tumor 
microenvironment and the tumor-associated stroma. In addition, mutations in growth 
factor receptors or downstream signaling pathway components can render tumor cells 
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independent of growth signals. Tumor growth promoting oncogenes include for instance 
MYC, RAS, BRAF and components of the MAPK pathway 570,572. 
Evading growth suppressors. Tumor cells avoid negative regulatory mechanisms 
controlling cell division and growth. This often involves mutations in tumor suppressor 
genes such as retinoblastoma protein (Rb) and tumor protein 53 (p53), which act as central 
checkpoints of the cell cycle regulating the induction of proliferation, senescence or 
apoptosis. In addition, the ‘contact-inhibition’ through neighboring cells, usually 
controlling aberrant growth in tissues, is de-regulated in tumorigenesis 570.  
Resisting cell death. Cancer cells acquire resistance to apoptosis-mediated cell death, 
which usually controls the removal of malignantly transformed cells and is induced in 
response to DNA damage or cellular stress. Resistance to apoptosis is often accompanied 
with loss of function of the DNA damage-sensing protein p53, by downregulation of pro-
Figure 3.7: The hallmarks of cancer and their therapeutic targeting. The hallmarks of cancer 
describe ten common characteristics inherent to all tumors. For each hallmark, potential 
strategies for tumor therapy are indicated. (Hanahan and Weinberg, Cell 2011) 570. 
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apoptotic factors such as Bim or Bax and overexpression of anti-apoptotic proteins such as 
Bcl2 570.  
Enabling replicative immortality. During tumorigenesis, cancer cells gain an unlimited 
replication potential through overexpression of telomerase and by preventing the 
induction of senescence 570. 
Induction of angiogenesis. Tumor cells are able to induce an ‘angiogenic switch’ through 
the formation of new vessels and a tumor-associated vasculature. Thereby, an increased 
supply of nutrients and oxygen reaches the neoplasia via the blood stream to cover the 
increased demand of the constantly growing tumor mass. In this process, cancer cells or 
cells in the tumor microenvironment induce angiogenesis through production of pro-
angiogenic factors like vascular endothelial growth factor-A (VEGF-A) 570. 
Invasion and metastasis. Malignant cells can disseminate and invade into distant tissues, 
forming often fatal metastasis in vital organs. Invasion into tissues involves alternations in 
matrix proteases and adhesion molecules. Furthermore, cytokines and chemokines, which 
are expressed by the tumor or the tumor microenvironment, can influence metastatic 
dissemination, 570,571. 
Genome instability and mutation. Additional hallmarks of cancer include characteristics 
enabling the acquisition of the previous hallmarks. Mutations are considered to be the main 
driver of tumorigenesis and accumulation of mutations results in destabilization of the 
gene copy numbers 573,574. Commonly, inactivation of tumor suppressor genes promotes 
tumorigenesis, especially of proteins involved in DNA damage recognition and repair 575. 
Tumor-promoting inflammation. Tumor-infiltrating immune cells can cause chronic 
inflammation resulting in the induction of angiogenesis and invasion. In addition, chemicals 
like reactive oxygen species (ROS) secreted by inflammatory cells can further promote 
mutagenesis 570,576.  
Reprogrammed energy metabolism. Modification and reprogramming of the glucose 
metabolism from aerobic oxidative phosphorylation towards the faster anaerobic 
glycolysis, indicated as ‘glycolytic switch’ and ‘aerobic glycolysis’, facilitates unrestricted 
expansion of cancer cells 570. Due to their uncontrolled growth, tumors often contain 
hypoxic areas with high levels of the hypoxia-inducible (HIF)-1/2α transcription factors, 
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which can induce the expression of glucose transporters and glycolytic enzymes and 
thereby upregulate glycolysis 570,577.  
Evasion from immune destruction. The immune system is constantly monitoring tissues, 
recognizing and killing virus-infected, stressed and transformed cells, a process called 
tumor immunosurveillance 578. Therefore, tumor cells evade immune-mediated 
destruction for instance by reducing the expression of immune recognition structures on 
their surface and by creating an immunosuppressive tumor microenvironment 570,578. 
 
3.7.2. The immune system and cancer 
The immune system has a two-sided role in tumorigenesis and possesses both tumor-
suppressive and tumor-promoting functions. In a process called immunosurveillance, the 
immune system identifies and eliminates malignantly transformed and stressed cells 
before a tumor mass can establish and become clinically apparent. On the other hand, under 
certain conditions immune cells can promote tumor progression through chronic 
inflammation or the creation of an immunosuppressive milieu. Thus, the immune system 
can shape the tumor during cancer progression by influencing its growth and 
immunogenicity characterized in three distinct stages of immunoediting: elimination, 
equilibrium and escape 578–580.  
In the elimination phase, immune cells recognize and eliminate emerging tumor cells via 
the release of perforins/granzymes, type-I IFNs, pro-inflammatory cytokines or damage-
associated molecules (DAMPs). Tumor cells express tumor-specific antigens detected by T 
and NKT cells and stress-induced ligands for activating NK cells receptors such as 
NKG2D 15,581. If complete elimination by the immune system fails, the system reaches a 
balance of tumor cell destruction and tumor growth, the equilibrium phase. Killing of 
immunogenic tumor cells can facilitate the outgrowth of tumor cell clones with low 
immunogenicity, defined by low or no expression of tumor-specific antigens, 
downregulation of MHC-I and of activating NK cell ligands. These clones are hardly detected 
by the immune system and are thus able to escape the immunosurveillance. In this escape 
phase, the immune system is no longer capable of controlling the tumor. Moreover, tumor 
cells that leave their functional state of dormancy become clinically apparent as primary 
tumor or as metastasis 582.  
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In addition, the anti-tumor potential of immune cells is hampered by the 
immunosuppressive microenvironment containing high levels of immunosuppressive 
mediators, such as TGF-β, IL-10, arginase-1, PGE-2 (prostaglandin-2) or IDO (indolamin-
2,3-dioxygenase involved in tryptophan metabolism) 125. The inhibitory character of the 
tumor microenvironment is shaped through the recruitment of suppressive immune 
compartments such as regulatory T cells (Tregs), myeloid derived suppressor cells (MDSCs) 
and tumor-associated M2 macrophages (TAMs). Tregs are the main source of the 
immunosuppressive cytokines TGF-β and IL-10 and additionally express inhibitory 
molecules such as CTLA-4 or PD-1 583,584. Additionally, they compete with T and NK cells for 
the availability of IL-2 due to their constant expression of the high affinity IL-2Rα-chain 
(CD25) 302,303. Their accumulation in the tumor site is often correlated with poor prognosis 
in the clinics 585. MDSCs are a heterogeneous population of immature myeloid cells with 
immunosuppressive activity via the depletion of arginine and the secretion of IL-10, TGF-β 
and ROS 586,587. Moreover, suppression of NK cell functionality by MDSCs has been shown 
to depend on TIGIT-CD155 interactions, supporting the development of strategies that 
target TIGIT for cancer immunotherapy 267. Furthermore, they have been shown to directly 
support tumor growth and to be associated with resistance to immunotherapy 588–590. To 
boost anti-tumor immunity in cancer patients, many of these escape strategies are targeted 
in tumor immunotherapy 578,580,590. 
 
3.8. NK cell-based immunotherapy 
Multiple components of the immune system have been implicated to play important roles 
in cancer immunosurveillance and immunotherapy of cancer has been recently honored as 
the breakthrough of the year 591. Based on the ‘missing-self’ hypothesis of target 
recognition, NK cells are especially promising options for therapy of HLA-I negative 
tumors 592. Partial or complete loss of MHC-I expression, to avoid T cell–mediated 
recognition, occurs in a wide spectrum of tumor types. In these clinical settings, T cell 
therapy is compromised through lack of recognition, but NK cells are potently activated.  
NK cells deficiencies and defective functionality have been associated with higher 
incidences of cancer and recurring viral infections in patients and in mouse models 1,593–597. 
Conversely, high NK cell infiltration into tumor tissue has been correlated with better 
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disease outcome in different solid tumor entities 598–601. In vivo, NK cells have been shown 
to control tumor growth and metastasis of many transplanted, induced or spontaneous 
tumors in various mouse models 122,123,578,602–605. Evidence for NK cell cancer 
immunosurveillance in patients has been derived from several clinical studies supporting 
their therapeutic potential in the clinic to participate in tumor eradication 34,100,606–608.  
Their capacity to distinguish healthy cells from stressed, altered and malignant cells 
(missing self/induced self, see section 3.3) can be exploited as a promising tool in cancer 
therapy 592,609,610. Furthermore, cytokines and chemokines secreted by NK cells were shown 
to contribute to the anti-tumor immune response of tumor infiltrating T cells and myeloid 
cells 5,6,104,611,612. 
NK cells are particularly effective against metastasis, minimal residual disease and 
hematological cancers such as acute myeloid leukemia (AML) or multiple myeloma 
(MM) 605,613–615. However, the effectiveness of NK cell therapies depends on the type of 
malignancy as solid tumors (e.g. colorectal cancer or breast cancer) are poorly infiltrated 
by NK cells 598,599,616. Several strategies have been designed for the therapeutic use of NK 
cells in the clinics  100,609,617.  
 
3.8.1. Adoptive transfer of NK cells 
Clinical data from adoptive transfer of NK cells and from hematopoietic stem cell transfer 
(HSCT) have indicated safety and clinical effectiveness of NK cell-based 
immunotherapy 618,619. Various approaches can be applied for adaptive cellular transfer of 
NK cells, differing in the source, degree of maturity, number and activation status of the 
transferred NK cells 620. Cells can be obtained from a healthy donor (allogeneic) or directly 
from the patient (autologous). NK cells for adoptive transfer can be derived from different 
sources such as peripheral blood (PB), umbilical cord blood (UCB), bone marrow (BM), 
human embryonic stem cells (hESC) or induced pluripotent stem cells (iPSC) 585,621–623. 
Other sources include NK cell lines (e.g. NK-92), which exhibit high cellular cytotoxicity, 
lack inhibitory KIRs and can be easily genetically modified under GMP conditions 624–627.  
NK cells can be infused as part of HSCT, transferred alone as purified and expanded mature 
NK cells or as additional treatment shortly after HSCT. For a successful therapeutic 
approach, high numbers of transferred NK cells but also high purity and functionality are 
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required. Standard GMP protocols include enrichment of NK ells and CD3+ T cell depletion, 
which is important to prevent the induction of GvHD 628,629. Numerous methods have been 
developed for long-term ex vivo expansion of NK cells using different kinds of cytokines 
such as IL-15 or IL-21 or feeder cells expressing membrane bound cytokines and co-
stimulatory molecules (e.g. 4-1BB) 630–633. Automated long-term expansion protocols can 
generate high numbers of clinical grade NK cells under standardized conditions 634–636. 
Major approaches for adoptive NK cell therapy include infusion of autologous or allogeneic 
NK cells or as part of HSCT treatment. 
Adoptive transfer of autologous NK cells 
The first clinical application of NK cells involved infusion of autologous PBMCs that were 
ex vivo activated with IL-2 (lymphokine activated killer cells, LAK cells) and mainly 
contained NK cells and CD8+ T cells 637–639. Although the IL-2 stimulated cells were highly 
activated and functional at the time of transfer, only limited clinical efficacy of LAK cells 
was observed. Transferred cells persisted in the recipient, but anti-tumor activity could 
only observed upon re-stimulation with IL-2 640. To sustain expansion and activity of the 
transferred cells, daily administration of IL-2 was applied but clinical efficacy was limited 
by the toxicity of high dose IL-2 641. In addition, administration of low-dose IL-2 has been 
shown to induce expansion of IL-2Rα–expressing (CD25) Treg cells that hamper NK cell 
activity 642–646.  
To maintain NK cell expansion in vivo and to prevent Treg cell induction, application of IL-15 
is currently explored in clinical trials, which preferentially stimulates NK cells and CD8+ T 
cells in the absence of Treg activation 647–649. For high biological activity, IL-15 has to be 
trans-presented by IL-15Rα in the body 292. Therefore, superagonists combining IL-15 and 
IL-15Rα in heterodimeric fusion proteins such as hetIL-15 (IL-15/sIL-15Rα) or the IL-15–
IL-15Rα–Sushi-Fc fusion complex (ALT-803) hold promise as potent activator of NK cell 
proliferation in vivo 650–652. 
However, the functionality of transferred NK cells is limited in autologous settings by the 
inhibitory signals transmitted through KIR receptors interacting with self–HLA-I on cancer 
cells. Hence, novel approaches are needed to preserve NK cells activation and to improve 
their anti-cancer efficacy.  
Adoptive transfer of allogeneic NK cells 
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A well-established example of allogenic NK cell transfer is hematopoietic stem cell 
transplantation (HSCT) in patients with hematological malignancies such as leukemia, 
resulting in disease free survival and reduced relapse rates 607,653. In allogeneic settings, 
hematopoietic stem cells or bone marrow grafts can be obtained from unrelated 
(mismatched) or related, haploidentical (partially matched) donors. T cells should be 
carefully removed to prevent graft-vs-host disease (GvHD), because donor-derived T cells 
can recognize the healthy tissue of the recipient as foreign cells and induce tissue damage 
of life threatening extent 654. To avoid rejection and to allow engraftment of the 
transplanted donor cells, pre-conditioning of the recipient’s immune system is required by 
preparative regiments such as total body irradiation or chemotherapy 607. Blood NK cells 
have been shown to recover early after transplantation and to exert a strong graft-vs-
leukemia (GvL) effect without induction of GvHD 655–657. A seminal study by Velardi and 
colleagues provided evidence for the importance of haploidentical donor-derived NK cells 
in successful HSCT, observing significant lower relapse rates of AML patients that received 
allogeneic bone marrow transplants 606. A prerequisite for the successful treatment was the 
KIR/ligand mismatch of donor and host cells. In these settings, the recipient’s tumor cells 
should lack one or more cognate HLA-I ligands for donor inhibitory KIRs. Tus, the 
alloreactivity of donor NK cells is based on KIR/ligand-mismatched graft NK cells not 
inhibited by host HLA-I, resulting in high cytotoxicity against leukemic blasts in spite of 
HLA-I expression 658,659. Genetic studies further showed that the presence of KIR B 
haplotypes in HSCT grafts, possessing high gene content of activating KIRs, correlated with 
lower relapse rates and improved survival 660–663. 
Moreover, purified and expanded allogeneic NK cells with high GvL potential can be 
adoptively transferred in addition to HSCT or as individual therapy 664–666. This approach, 
also called donor lymphocyte infusion (DLI), represents an effective treatment option upon 
relapse after HSCT or in combination for high-risk leukemias 667,668. In several studies, 
infusion of expanded and IL-2–activated NK cells resulted in favorable responses in 
patients with various hematological malignancies 646,669–671. It is based on the infusion of T 
cell depleted and highly purified haploidentical NK cells, which can be pre-activated ex vivo 
with IL-2 and are potent effector cells.  
To potentiate their anti-tumor activity, NK cells can be stimulated with various cytokines 
ex vivo before adoptive transfer 288,511,526,669. Ex vivo manipulations presents the possibility 
to use cytokines or drugs that might be otherwise harmful for in vivo application 109,672. The 
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combination of IL-12, IL-15 and IL-18 for ex vivo activation is of particular interest as it is 
involved in the generation of long-lived memory-like NK cells with high proliferative 
capacity and sustained effector functions (see section 3.6.3) 673. Short pre-activation of NK 
cells with IL-12/15/18 has been shown to induce expression of the high affinity IL-2R α-
chain (CD25) 288,289, facilitating strong expansion and persistence in response to low-dose 
IL-2 after adoptive transfer in mice 288. Furthermore, cytokine-induced memory-like NK 
cells exhibit pronounced anti-cancer responsiveness in vivo and in vitro 288,334,526,568. Safety 
and feasibility of adoptive transfer of cytokine-induced memory-like NK cells has recently 
been demonstrated in a clinical trial with AML patients 526. 
However, the adoptive transfer of allogenic NK cells alone or as HSCT requires the 
availability of a matching donor and might be hampered by short persistence of the 
transferred NK cells in the patient 645. Moreover, it might bear the risk of promoting GvHD, 
as recent studies reported severe GvHD upon adoptive allogeneic NK cell transfer in 
combination with HSCT, which was probably exerted by contaminating alloreactive T 
cells 666,674–678.  
 
3.8.2. Strategies to improve NK cell anti-tumor potential  
NK cell anti-tumor efficacy in clinical trials has been limited by various mechanisms such 
as inhibitory KIRs, low persistence of transferred cells, weak tumor infiltration and 
attenuation of their activation status through the immunosuppressive tumor 
microenvironment 34,582,679. Current approaches aim to improve effectiveness of NK cell-
based therapies through increasing NK cell numbers by novel expansion protocols, 
improving their activation state and trafficking to the tumor site and by transfer of selected 
subpopulations with desired functional capacities 680–682 
The application of therapeutic antibodies or antibody-related constructs to bolster anti-
tumor efficacy of NK cells experiences currently intensive investigations in cancer 
immunotherapy 101. Therapeutic antibodies can specifically redirect immune cells to 
tumor-restricted antigens expressed on cancer cells and have been shown to greatly 
improve the outcome of cancer patients 100,101. Antibodies with different specificities for 
various cancer entities are widely used in the clinics targeting for instance CD19, CD20 
(rituximab), Her2/neu (trastuzumab), GD2 or EGFR (cetuximab). Their clinical efficacy has 
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been mainly contributed to the exertion of ADCC mediated via engagement of CD16 
(FcγRIIIA) through the Fc part of the antibody. CD16 triggering can elicit strong activation 
of NK cells without the need of additional co-activation, resulting in potent effector 
cells 12,98. 
Bispecific antibodies and bispecific killer engagers (BiKEs) are bivalent molecules 
containing two antigen binding specificities, designed to bind a tumor-specific antigen with 
one arm while engaging an activating NK receptor (e.g. CD16) with its second specificity 683. 
Simultaneous binding of both antigens cross-links NK cells with the tumor target cell and 
can elicit potent NK cell activation and effector function. TriKEs (trispecific killer engagers) 
can simultaneously bind either two antigens, two receptors or can incorporate e.g. IL-15 to 
additionally stimulate NK cells 684. The anti-tumor efficacy of therapeutic antibodies or 
bispecific constructs can be enhanced by combination with cytokines that stimulate and 
expand NK cells in vivo 109,673,684. 
Activating chimeric antigen receptors (CARs) contain an antibody-related receptor for a 
tumor-specific antigen on the surface, coupled to potent intracellular signaling modules 
such as CD3ζ, CD28 or 4-1BB. Antigen-specific binding thus results in strong activation of 
the effector cell 685. CAR-expressing T cells yielded promising results in the clinics but also 
raised severe safety issues 686. The generation of CAR-expressing lymphocytes has been 
previously focused on T cells, but also protocols for genetically engineering NK cell lines 
and primary NK cells are currently exploited 687–690.  
Similar to checkpoint blockade of exhausted T cells, blocking antibodies against inhibitory 
checkpoint molecules are currently explored for NK cell immunotherapy 691,692. The anti-
tumor effector function of autologous NK cells is substantially diminished by inhibitory 
signals delivered through the interaction of inhibitory KIR molecules with cognate HLA-I 
ligands on tumor cells. Checkpoint blockade of inhibitory receptors such as KIR or NKG2A 
therefore represents a promising strategy to reduce the threshold for NK cell activation and 
to increase their responsiveness towards self–HLA-I positive tumors 693,694. Blocking of 
pan-KIR2D receptors with the blocking anti-KIR2D antibody Lirilumab 
(1-7F9/IPH2101/IPH2102) has been shown to enhance NK cell activity in vitro and in 
transgenic mouse models against HLA-I–expressing tumor cells 695–698. In addition, an anti-
KIR3DL2 blocking antibody is currently under clinical development 699. The safety and 
efficacy of KIR blockade has been reported for the treatment of patients with AML or 
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multiple myeloma 700–705. Recently, clinical investigations of KIR checkpoint blockade have 
been additionally extended for various other hematological malignancies and for solid 
tumors 706. However, a recent study indicated contraction and functional detuning of KIR2D 
positive NK cells upon single therapy with Lirilumab in smoldering multiple myeloma 
patients 707. Therefore, combination of anti-KIR therapy with other approaches are 
currently considered, for instance together with anti–CTLA-4 or anti–PD-1 blockade 682,708 
or with ADCC inducing therapeutic antibodies 697,698,709.
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4. AIM OF THE STUDY 
Cancer immunotherapy based on NK cells is a promising field in the treatment of 
hematological malignancies. However, one major obstacle represents the attenuated 
activation of NK cells in the patient by the interaction of inhibitory killer immunoglobulin-
like receptors (KIRs) with self–HLA-I on autologous tumor cells. Several approaches are 
currently applied for circumventing KIR-mediated inhibition to fully unleash NK cell anti-
tumor efficacy in immunotherapy. For instance, adoptive transfer of haploidentical 
KIR/ligand-mismatched NK cells has been shown to greatly improve the clinical outcome 
of leukemia patients compared to matched NK cells that are inhibited by KIR/self–HLA-I 
interaction. Moreover, Lirilumab, a therapeutic antibody blocking inhibitory KIR2D 
molecules on NK cells, is currently tested in clinical trials. However, in contrast to 
autologous infusions, adoptive transfer of allogeneic cells is limited by the selection of a 
matching donor, low persistence of transferred NK cells in the adoptive host and the risk of 
graft-vs-host disease (GvHD). Therefore, it is of great importance in the field to develop 
new strategies to further improve the anti-cancer potency of NK cells against HLA-I–
expressing tumors in autologous transfer.  
Short pre-activation of NK cells with the pro-inflammatory cytokines IL-12/15/18 has been 
implicated in the generation of NK cells with sustained effector functions, high longevity 
and memory-like features. Recently, a clinical trial in AML patients employed adoptive 
transfer of IL-12/15/18 pre-activated allogeneic NK cells, which showed superior memory-
like anti-tumor activity one week after transfer and mediated remission in a subset of 
patients. However, no characterization of the cytokine-stimulated NK cells was performed 
at the time of infusion into the patient, evaluating their immediate anti-cancer potential. 
In the present study, we wanted to uncover the mechanisms underlying the potent effector 
functions of IL-12/15/18–activated NK cells to further improve treatment options for 
autologous cell transfer. We therefore performed a comprehensive phenotypical and 
functional analysis of NK cells at different time points after IL-12/15/18 stimulation, 
focusing on the balance of activating and inhibitory NK cell receptors. We aimed to gain 
mechanistic insights into the superior competence of IL-12/15/18–activated NK cells 
against transformed cells that express self–HLA-I. To study the implication of the 
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modulated KIR/HLA-I axis on NK cell functionality, we performed redirected lysis assays 
with specific antibody-mediated stimulation of single activating and inhibitory receptors. 
Furthermore, we assessed the impact of IL-12/15/18 stimulation on NK cell cytotoxicity 
against tumor targets bearing cognate HLA-I molecules. Finally, we employed an in vitro 
HCMV infection model to evaluate our phenotypical observations in a physiological setting 
of pro-inflammatory cytokines.  
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5. MATERIALS AND METHODS 
5.1. Materials 
5.1.1. Cells and cell lines 
Table 5.1: Cells and cell lines 
Cells or cell line Cell type Medium 
Primary PBMCs 
Human peripheral blood 
mononuclear cells 
RPMI, 10% FCS, 1% P/S 
Primary NK cells Human natural killer cells 
SCGM, 10-20% human 
serum, 1% P/S 
K562 
Human myelogenous 
leukemia cell line 
RPMI, 10% FCS, 1% P/S 
P815 
Mouse mastocytoma cell 
line 
RPMI, 10% FCS, 1% P/S 
MRC-5 
Human fetal lung 
fibroblasts 
DMEM, 10% FCS, 1% P/S 
721.221 
Human EBV transfected B 
lymphoblastoid cell line 
RPMI, 10% FCS, 1% P/S, 
Gln 2mM 
721.221_HLA-Cw03 
Human EBV transfected B 
lymphoblastoid cell line 
RPMI, 10% FCS, 1% P/S, 
Gln 2mM 
 
5.1.2. Cell culture products 
Table 5.2: Cell culture products 
Product Company 
Biocoll separating solution Biochrom 
Dimethylsulfoxide (DMSO) Hybri-Max Sigma Aldrich 
Dulbecco’s modified Eagle’s Medium (DMEM) Sigma-Aldrich 
Dulbecco’s phosphate buffered saline (PBS) Sigma-Aldrich 
Fetal Calf Serum Gibco 
Geneticin (G418) Gibco 
GolgiPlug BD Biosciences 
GolgiSTOP BD Biosciences 
Human serum, type AB, converted PAA 
Ionomycin Sigma Aldrich 
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Product Company 
L-Glutamin 200mM (100x) Gibco 
Penicillin/Streptomycin Sigma-Aldrich 
Phorbol-12-myristate-13-acetate Sigma Aldrich 
RPMI 1640 Sigma Aldrich 
Stem cell growth medium (SCGM) CellGenix 
Trypan Blue Sigma Aldrich 
Trypsin-EDTA Sigma-Aldrich 
 
5.1.3. Chemicals 
Table 5.3: Chemicals 
Chemicals Company 
51Chromium Perkin Elmer 
Batimastat Merck Millipore 
Cytofix™ Fixation Buffer BD Biosciences 
EDTA Ambion 
Ethanol Sigma-Aldrich 
Nuclease-free water Ambion 
Phosflow™ Perm Buffer III BD Biosciences 
Triton X-100 Sigma-Aldrich 
β-mercaptoethanol Sigma-Aldrich 
 
5.1.4. Solutions 
Table 5.4: Solutions 
Solution Ingredients 
FACS buffer PBS, 3% FCS, 0.05% (v/v) NaN3 
Freezing medium FCS, 10% DMSO 
MACS buffer PBS, 3% FCS, 0.5 mM EDTA 
 
5.1.5. Cytokines 
Table 5.5: Cytokines 
Cytokine Company 
IL-12 Peprotech 
IL-15 Peprotech 
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Cytokine Company 
IL-18 MBL 
IL-2 NIH 
 
5.1.6. Kits 
Table 5.6: Kits 
Product Company 
EasySep™ Human NK cell isolation kit Stemcell Technologies 
Foxp3 / Transcription Factor Staining Buffer Set eBioscience / Invitrogen 
Human IFN-γ ELISA BioLegend 
Human IL-18 ELISA R&D 
Human NK cell isolation kit Miltenyi Biotech 
LightCycler 480 SYBR Green I Master Roche 
LS Columns Miltenyi Biotech 
MACSplex human Cytokine 12 Miltenyi Biotech 
MojoSort™ Human NK cell isolation kit BioLegend 
ProtoScript M-MuLV First Strand Synthesis Kit NEB 
QIAshredder Qiagen 
RNeasy Mini Kit Qiagen 
TURBO DNA-free Kit Invitrogen 
 
5.1.7. Antibodies 
Table 5.7: Primary antibodies for flow cytometry 
Antigen Clone Company Dilution 
CD107a H4A3 Biolegend 1:100 
CD134 (OX40) 
Ber-ACT35 
(ACT35) 
Biolegend 1:40 
CD137 (4-1BB) 4B4-1 Biolegend 1:40 
CD14 HCD14 Biolegend 1:80 
CD16 3G8 Biolegend 1:50 
CD19 HIB19 Biolegend 1:80 
CD25 BC96 Biolegend 1:50 
CD3 HIT3a Biolegend 1:50 
CD56 HCD56 Biolegend 1:50 
CD57 HCD57 Biolegend 1:60 
CD69 FN50 Biolegend 1:50 
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Antigen Clone Company Dilution 
DNAM-I DX11 Biolegend 1:40 
HLA-ABC W6/32 Biolegend 1:100 
IFN-γ 4S.B3 Biolegend 1:40 - 1:50 
KIR2DL1 143211 R&D Systems 1:10 
KIR2DL1/S1/S3/S5 HP-MA4 Biolegend 1:40 - 1:50 
KIR2DL2/L3/S2 DX27 Biolegend 1:40 - 1:50 
KIR2DL2/L3/S2 GL183 Beckman Coulter 1:25 
KIR2DL3 180701 R&D Systems 1:10 
KIR3DL1 DX9 Biolegend 1:40 
NKG2A REA110 Miltenyi Biotec  1:20 
NKG2C 134591 R&D Systems 1:10 
NKG2D 1D11 Biolegend 1:40 
NKp30 P30-15 Biolegend 1:15 
NKp44 P44-8 Biolegend 1:20 
NKp46 9E2/NKp46 Biolegend 1:40 
NKp80 5D12 Biolegend 1:10 
phospho-STAT-5 47/Stat5(pY694) BD Biosciences 1:5 
TIGIT MBSA43 eBioscience 1:20 
 
Table 5.8: Isotype controls 
Antigen Clone Company 
mIgG1 MOPC-21 Biolegend 
mIgG2a MOPC-173 Biolegend 
mIgG2b MPC11 Biolegend 
 
Table 5.9: Assay antibodies 
Antigen Clone Company Concentration 
CD16 3G8 Biolegend 1 µg/ml 
IFN-α/β-R MMHAR-2 
PBL Interferon 
Source 
5 µg/ml 
IL-12 Polyclonal Goat IgG R&D Systems 5 µg/ml 
KIR2DL2/L3/S2 GL183 Beckman Coulter 25 µg/mL 
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5.1.8. Cell dyes 
Table 5.10: Cell dyes for flow cytometry 
Dye Company Dilution 
Fixable Viability Dye Zombie Aqua Biolegend 1:200 
7AAD Biolegend 1:50 
Annexin V Biolegend 1:50 
Carboxyfluorescein succinimidyl ester 
(CFSE)  
Sigma-Aldrich 1 µM 
 
5.1.9. Oligonucleotide qRT-PCR Primers 
Table 5.11: RT-qPCR Primers 
Primer Sequence 5’ - 3’ 
KIR2DL1 fwd TTGGGACCTCAGTGGTCATC 
KIR2DL1 rev GGTCCATTACCGCAGCATT 
KIR2DL3 fwd CTTCGGCTCTTTCCGTGACT 
KIR2DL3 rev AGAACATGCAGGTGTCTGGG 
β-2microglobulin fwd TCAGATCTGTCCTTCAGCAA 
β-2microglobulin rev CATGTCTCGGTCCCAGGTGA 
β-actin fwd AAACTGGAACGGTGAAGGTG 
β-actin rev AGAGAAGTGGGGTGGCTTTT 
 
5.2. Methods 
Part of this section has been published in Ewen et al. EJI 2018 710. 
5.2.1. Cell culture methods 
The 721.221 cell line and its transfectants were kindly provided by C. Watzl (Technical 
University Dortmund, Germany) and were cultured in RPMI medium supplemented with 
10 % FCS and 2 mM Glutamin. The K562 and P815 cell lines were cultured in RPMI medium 
supplemented with 10 % FCS. MRC-5 fibroblasts were cultured in DMEM medium 
supplemented with 10 % FCS. All media contained 100 U/mL penicillin and 100 mg/mL 
streptomycin and cell lines were routinely tested for mycoplasma infection by RT-PCR. All 
sera were heat-inactivated at 56°C for 30 minutes prior to usage. The transfected 
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721.221_HLA-Cw03 cell line was selected by adding in 0.5 mg/ml G418 (Geneticin) to the 
cell culture medium. 
 
5.2.2. Human NK cell isolation and culture 
PBMC isolation  
Buffy coats were provided by DRK-Blutspendedienst Mannheim, collected according to the 
principles of the Declaration of Helsinki. Written informed consent was obtained from all 
human subjects prior to blood donation and ethical approval 87/04 was granted by the 
Ethik Kommission II of the Medical Faculty Mannheim, Germany. Isolation of peripheral 
blood mononuclear cells (PBMCs) was performed by Biocoll density-gradient 
centrifugation. Peripheral blood was diluted 1:4 with pre-warmed PBS and 35 ml of diluted 
blood was carefully layered on top of 15 ml Biocoll separation solution. The tubes were 
centrifuged without brake for 30 min at 1800 rpm. The lymphocyte ring was collected, and 
cells were washed 3 times with warm PBS. PBMCs were cultured as 2x106/ml in RPMI 
supplemented with 10% FCS. 
Magnetic-activated cell sorting (MACS)  
NK cell isolation from PBMCs was performed by negative selection (human NK cell isolation 
kits) according to the manufacturer’s protocol, although only 75 % of the recommended 
reagents were used. Purity of isolated CD3- CD56+ NK cells was > 90 % as determined by 
flow cytometry. Freshly isolated NK cells are indicated as naïve throughout the manuscript 
and analyzed immediately. NK cells were cultured in SCGM medium containing 10 % 
human serum (heat-inactivated) or 20 % human serum for stimulation. NK cells were 
activated with a combination of IL-12 (10 ng/mL), IL-15 (20 ng/mL) and IL-18 
(100 ng/mL) or IL-15 alone (20 ng/mL) for 48 h or as indicated. After stimulation, NK cells 
were washed and re-cultured in the presence of 100 U/mL recombinant IL-2 and medium 
supplemented with IL-2 was exchanged every two days.  
CFSE labeling 
Freshly isolated NK cells or PBMCs were washed with PBS and adjusted to 1x107 cells/ml. 
3.3 µl/ml of 300 µM CFSE solution was added while shaking the cells to achieve a final CFSE 
concentration of 1 µM. After 10 min incubation at 37°C in the incubator, the reaction was 
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stopped by adding 5 ml of pure FCS and 5 ml of medium. Cells were washed twice with 
medium containing 10 % FCS and used in further experiments.  
HCMV Co-cultures 
One day before starting the co-cultures, 1x105/well MRC-5 fibroblasts were seeded in a 24-
well plate. The next day, fibroblasts were infected for 8 h with human cytomegalovirus 
(HCMV, subtype AD169, kindly provided by Anne Halenius, University of Freiburg) at a 
multiplicity of infection (MOI) of 10 or were left uninfected. Virus was washed away and 
fibroblasts were co-cultured together with 2x106 PMBCs per well in complete DMEM 
supplemented with 20 IU/ml IL-2. Fresh medium containing IL-2 and if applicable blocking 
antibodies was added after 5 days. After 3, 5 and 7 days, PBMCs were harvested and 
analyzed for their receptor expression by flow cytometry. For neutralization of IL-12 and 
blocking of type-I IFN receptor, PBMCs were resuspended in the appropriate amount of 
antibody (both 5 µg/ml) or isotype control and pre-incubated for 30 min. Cells were filled 
up with complete DMEM to reach the final cell and antibody concentration per well. 
Neutralizing agents were added again at day 5. 
 
5.2.3. Flow cytometry methods (FACS) 
Extracellular FACS staining  
For flow cytometry staining, cells were harvested and washed with PBS. Up to 1x106 cells 
were stained in a 96-well plate with 15 µl FACS buffer containing appropriate dilutions of 
all primary antibodies. After 30 min incubation on ice in the dark, cells were washed twice 
with FACS buffer, resuspended in FACS buffer and analyzed immediately. For co-staining 
of KIR2DL2/L3 and KIR2DL3 or KIR2DL1/S1/S3/S5 and KIR2DL1, respectively, cells were 
first incubated for 20 min with the single KIR antibody and the multiple KIR antibody was 
directly added afterwards for another 20 min. For discrimination of dead cells, 7-AAD was 
added 5 min prior to analysis. Staining of apoptotic cells was conducted by adding Annexin 
V diluted in Annexin V-binding buffer 15 min at RT before analysis according to the 
manufacturer’s protocol. 
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Intracellular FACS staining  
If cells were fixed for intracellular staining, the fixable viability dye ZombieAqua was used 
as dead cell marker instead of 7-AAD. The ZombiAqua dye was diluted 1:200 in PBS and 
25 µl were added to the washed cells prior to antibody staining. After 10 min on RT in the 
dark, 25 µl of 2x concentrated antibody mastermix was directly added and incubated for 
30 min on ice in the dark. For intracellular staining, cells were fixed and permeabilized after 
extracellular staining using the Foxp3/Transcription Factor Staining Buffer kit from 
eBioscience according to the manufacturer’s protocol. 100 µl of fixation/permeabilization 
concentrate (diluted 1:4) was added to the stained and washed cells and incubated for 
30 min on ice. Cells were washed twice with diluted permeabilization buffer and primary 
antibodies ware added in titrated concentration in 25 µl permeabilization buffer for 30 min 
on ice. Cells were washed once with diluted permeabilization buffer and once with FACS 
buffer before analysis.  
Phospho-STAT-5 staining 
NK cells were either left untreated or stimulated with IL-15 or IL-12/15/18 or for 
15 - 60 min as indicated. Cells were washed once with FACS buffer, fixed with BD Cytofix 
Fixation Buffer for 15 min at RT in the dark and washed. After permeabilization for 30 min 
on ice with BD Phosflow™ Perm Buffer III, cells were stained for phosphorylated STAT-5 
with an anti-Stat-5 (pY694) antibody for 30 min on ice. Cells were washed once with FACS 
buffer and analyzed immediately by flow cytometry.  
FACS sorting 
To keep the sorted cells in culture for several days, cells were prepared and sorted under 
sterile conditions. Freshly isolated NK cells were washed with sterile PBS and stained for 
appropriate surface markers for 30 min on ice in the dark. Cells were washed twice with 
sterile PBS, resuspended as 5x107/ml in sterile PBS supplemented with 0.1 % FCS and 
filtered through a 40 µm cell strainer. NK cells were sorted under sterile conditions through 
a 100 µm nozzle into complete medium. The 15 ml collection tubes were coated with FCS 
prior to usage and filled with 1 ml complete medium. NK cells were sorted with a FACSAria 
Fusion cell sorter (BD Bioscience) and purity of all sorted subsets was >98%. Sorted NK 
cells were analyzed immediately (naïve) or stimulated with IL-15 or IL-12/15/18 as 
described in 5.2.2. 
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FACS analysis 
Flow cytometry analyses were performed with a FACSCanto II or FACSCalibur (BD 
Bioscience) and data was analyzed using FlowJo software (Tree Star). Laser settings and 
compensation were adjusted using appropriate single stainings of each fluorophore. For 
staining of surface molecules, cell doublets and dead cells (7-AAD positive) were excluded 
and NK cells were gated on CD3–CD56+ cells. To assess fluorescence intensity staining of a 
phenotypic marker expressed on a subpopulation, the median fluorescence intensity (MFI) 
was determined only for that subpopulation. If the marker was expressed on the entire 
population, the Δ MFI was calculated by subtracting the MFI of the isotype staining from 
the MFI of the population.   
 
5.2.4. Functional in vitro assays  
CD107a degranulation assay 
Pre-activated NK cells and 721.221 target cells were harvested, washed and adjusted to 
1x106/ml in RPMI supplemented with 10 % FCS and 1 % P/S. Effector NK cells were co-
cultured with indicated target cells at an effector:target ratio of 1:1 in a 96-well plate. As a 
negative control of spontaneous degranulation, effector cells were cultured alone. PMA 
(50 ng/ml) and Ionomycin (750 ng/ml) were added to the effector cells in one condition as 
positive control. Cells were co-cultured in the presence of anti-CD107a antibody or 
respective isotype control and after 30 min 0.5 µl/well GolgiStop (monensin) was added. 
After 4 h cells were harvested and stained for CD3, CD56, KIR2DL2/L3 and 7-AAD as 
described in section 5.2.3. Degranulation was assessed by flow cytometry analysis of 
CD107a co-gated on KIR2DL2/L3 positive or negative NK cells.  
51Chromium release assay 
Cytotoxic activity of NK cells against 721.221 target cells was measured in a standard 4 h 
51Cr release assay. NK effector cells were sorted for KIR2DL2/L3 expression and activated 
with IL-15 or IL-12/15/18 for 48h. When indicated, interaction of 221_Cw03 and 
KIR2DL2/L3 was blocked by pre-incubation of NK cells with 25 µg/mL anti-KIR2DL2/L3 
mAb (GL183) or respective mIgG1 isotype control. Target cells were resuspended in 500 µl 
complete RPMI and labeled for 1 h with 100 μCi 51Cr. Target cells were washed three times 
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and 3×103 target cells were added to effector cells ± antibody at the indicated 
effector / target (E:T) ratios in triplicate in a 96-well plate. Target cells were cultured alone 
(minimum or spontaneous release) or with 10 % Triton X-100 (maximum). After 4 h 
incubation at 37°C, supernatants were collected and the release of 51Cr was measured. 
Specific lysis was calculated as [mean cpm - mean cpm (min)] / [mean cpm (max) - mean 
cpm (min)]. 
Redirected lysis assay  
Cytotoxic activity of NK cells against antibody coated P815 target cells was measured in a 
standard 4 h 51Cr release assay as described above. NK cells were sorted according to their 
KIR2DL2/L3 expression and activated for 48 h with IL-15 or IL-12/15/18 in the presence 
of 10 µM of the matrix-metalloproteinase inhibitor Batimastat or equivalent amounts of 
dimethylsulfoxide (DMSO) solvent control. For redirected lysis, FcR-bearing P815 target 
cells were pre-incubated for 30 min with 1 µg/mL anti-CD16 antibody (clone 3G8) in 
combination with either 1 µg/mL anti-KIR2DL2/L3 antibody (clone GL183) or respective 
mIgG1 isotype control. 
 
5.2.5. Cytokine measurement 
Re-stimulation 
NK cells were pre-activated with IL-15 or IL-12/15/18 for 16 h or 48 h, washed and 
subsequently re-cultured in IL-2 (100 IU/ml) or IL-15 (1 ng/ml) for additional 5 days. Cells 
were harvested, washed intensely and setup for re-stimulation in a 96-well plate in 200 µl 
fresh, cytokine-free medium. NK cells were either re-stimulated with IL-12 (10 ng/ml) and 
IL-15 (50 ng/ml) or with K562 target cells at an E:T ratio of 1:1. As positive control,  
PMA (50 ng/ml) and Ionomycin (750 ng/ml) were added in one condition. NK cells were 
cultured alone in medium as negative control. For IFN-γ detection via ELISA, supernatants 
were harvested after 24 h and the negative ‘medium’ control was subtracted from the raw 
data. For intracellular staining of IFN-γ, cells were re-stimulated for 6 h in the presence of 
1 µl/well Brefeldin A (GolgiPlug) and intracellular IFN-γ was detected by flow cytometry 
as described in 5.2.3. 
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Enzyme-linked immunosorbent assay (ELISA)  
NK cells were re-stimulated as described above. Cell-free supernatants were harvested 
after 24 h and either frozen at -20°C ore processed directly. IFN-γ and IL-18 were measured 
by ELISA according to the manufacturer’s instructions. 
MACSplex 
Cell-free supernatants of HCMV co-cultures were harvested 3 days p.i. and analyzed for 
secreted cytokines using the MACSplex Cytokine 12 Kit. The protocol was performed by 
Markus Granzin (Cerwenka lab and Miltenyi Biotech) according to the manufacturer’s 
instructions. 
 
5.2.6. Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) 
RNA isolation & cDNA synthesis 
RNA was isolated from NK cells using the RNeasy Mini Kit and QIAshredder with minor 
changes in the manufacturer’s recommended protocol. For cell lysis, min 2x105 NK cells 
were washed with PBS, lysed in RLT buffer containing 0.1 % (v/v) β-mercaptoethanol and 
stored at -80°C until further usage. Thawed cell lysates were homogenized using 
QIAshredder and RNA isolation was continued with the RNeasy Mini Kit according to the 
manufacturer’s recommendations. RNA was eluted in 30 µl nuclease-free water and was 
treated with DNase using TURBO DNA-free kit to remove possible genomic DNA 
contamination. RNA concentration (A260) and purity (A260/A280 ratio) were determined 
with a NanoPhotometer and stored at -80°C. Isolated RNA was reverse transcribed into 
cDNA using the ProtoScript First Strand cDNA Synthesis Kit and the provided random 
primer mix according to the manufacturer’s instructions. The same amount of RNA was 
employed to ensure the same cDNA concentration within all samples used for later 
comparison. Samples without reverse transcriptase (-RT control) were included to exclude 
possible genomic DNA contamination. Synthesized cDNA was stored at -20°C.  
SYBR Green qRT-PCR 
Due to low cell numbers and RNA/cDNA concentrations, cDNA was only diluted 1:2 or 1:3 
with nuclease-free water. 6 µl of diluted cDNA was added per well to LightCycler480 
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Mulitwell plates and mixed with 3 µl LightCycler 480 SYBR Green I Master Mix and 0.5 µl of 
forward and reverse primer, respectively, in a final concentration of 0.5 µM. Each reaction 
was performed in technical duplicates or triplicates. Nuclease-free water and -RT samples 
were included as negative controls. The plate was sealed with a foil, shortly centrifuged and 
the qRT-PCR reaction was performed on a Roche LightCycler 480 instrument with the 
following program: 
Preincubation:     95°C  5 min 
Amplification: Denaturation 95°C 10 s 
   Annealing  60°C 15 s 
   Extension 72°C  20 s  
   45 cycles 
Melting curves:   95°C  5 s 
     65°C 60 s 
     97°C   - 
Cooling:    40°C  10 s 
The relative expression of the gene of interest compared to a housekeeping gene (β2m or 
β-actin) was calculated as 2-ΔCp with ΔCp = Cp(target gene) - Cp(housekeeping gene). The 
efficiency of each primer pair was determined in advance using a standard curve of serial 
diluted cDNA. 
 
5.2.7. Statistical analysis 
Statistical significance was calculated by paired two-tailed student’s t-test or one- or two-
way ANOVA followed by Bonferroni’s post test using the GraphPad Prism 6 software: ns, 
not significant; *p < 0.05; **p < 0.01 and ***p < 0.001, if not assigned differently.  
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6. RESULTS 
The results reported in this study have been previously published in their original or 
modified form in Ewen et al. 2018 Eur. J. Immunol. 710 and in Rölle, Pollmann et al. 2014 J. 
Clin. Invest. 556. Text and Figures have been originally designed and written by myself. 
 
6.1. Downregulation of KIR expression on NK cells upon 
IL-12/15/18 stimulation 
6.1.1. Phenotype of IL-12/15/18–stimulated NK cells 
To dissect the improved functionality of IL-12/15/18–activated NK cells, we performed an 
in-depth phenotypical analysis of human cytokine–stimulated NK cells. Therefore, mature 
NK cells were isolated from PBMCs of healthy donors, stimulated for 60 h with IL-12/15/18 
or with IL-15 alone and analyzed for their surface receptor repertoire by flow cytometry. 
Cytokine stimulation induced changes in the expression of most NK receptors (Figure 6.1), 
either reflected by the percentage of receptor expressing cells or by receptor surface 
expression density per cell as indicated by the median fluorescence intensity (MFI). 
Expression densities of most activating NK receptors were enhanced upon cytokine 
stimulation (Figure 6.1 A), whereas expression of NKp46 was only marginally changed 
(Figure 6.1 A). NKp30, NKp44 and NKG2D expression was more potently induced by IL-15, 
whereas the intensity of DNAM-I expression was increased by IL-12/15/18 alone 
(Figure 6.1 A). Expression of NKp80 and CD16 on NK cells was substantially reduced upon 
IL-12/15/18 stimulation, which is in line with previous publications 156,711. CD25, the IL-2 
high affinity receptor α-chain, was highly upregulated on IL-12/15/18 stimulated cells 
(Figure 6.1 B) as shown previously by our group and others 271,288,289. Expression of CD69, 
which is considered to be an activation marker on NK cells, was highly induced by both 
IL-15 and IL-12/15/18, while NKG2A expression is slightly increased by both cytokine 
stimulations (Figure 6.1 B). Furthermore, the co-stimulatory TNFRSF members Ox40 and 
4-1BB were highly upregulated upon cytokine stimulation with regards to the percentage 
of positive cells as well as the expression density levels (Figure 6.1 C). Expression densities  
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Figure 6.1: Regulation of NK cell receptor 
expression upon IL-12/15/18 activation. 
Human NK cells isolated from PBMCs were 
analyzed at day 0 (naïve) and after 60 h 
stimulation with IL-15 or IL-12/15/18 for 
surface receptor expression by flow cytometry. 
(A) Expression of natural cytotoxicity receptors, 
(B) activation and maturation marker and 
(C) co-stimulatory and inhibitory receptors on 
NK cells is shown. (A - C) Bar graphs depict the 
percentage positive population gated on 7-AAD-
CD3-CD56+ NK cells (upper panels). Lower 
panels present the median fluorescence intensity 
(MFI) of the positive subpopulation or the 
isotype-corrected median fluorescence intensity 
(Δ MFI = MFI - MFI(isotype)) of the indicated 
receptors (n = 3 - 27, mean + SD). Statistical 
analysis was performed with one-way ANOVA 
followed by Bonferroni’s post test. 
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of TIGIT (Figure 6.1 C) and of the maturation marker CD57 (Figure 6.1 B) were enhanced 
by IL-15, but not by IL-12/15/18.  
 
6.1.2. Reduced expression of KIR2DL2/L3, KIR2DL1 and KIR3DL1 on 
IL-12/15/18–stimulated NK cells 
Most strikingly, activation of NK cells for 60 h with IL-12/15/18, but not with IL-15 alone, 
led to a significantly decreased surface expression of the self-HLA–binding killer cell 
immunoglobin-like receptors (KIRs) (Figure 6.2 A). The percentage of KIR positive NK cells 
(Figure 6.2  B) as well as the density of surface expression per cell (MFI; Figure 6.2  C) was 
significantly decreased upon IL-12/15/18 activation compared to IL-15 treated controls. 
Due to the high similarity in protein structure of KIR molecules, most anti-KIR antibodies 
cannot discriminate between KIRs with similar extracellular domains. Many antibodies 
hence cross-react with KIRs sharing the same extracellular Ig-like domain (2D or 3D), 
which differ only in their intracellular part. The monoclonal antibody clones DX27 and 
GL183 for example recognize the structurally similar KIR2DL2, KIR2DL3 and KIR2DS2 
molecules. In contrast, antibodies specific for either long or short cytoplasmic tails (L & S 
forms) exist only for few KIR family members, which could facilitate discrimination 
between activating (S) and inhibitory (L) receptors by flow cytometry. However, similar 
results were obtained with two different monoclonal antibody clones cross-reacting to 
KIR2DL2/L3/S2 (clones DX27, GL183) and with an antibody specific for inhibitory 
KIR2DL3 (clone 180701), indicating regulation of inhibitory KIRs with a long cytoplasmic 
tail (Figure 6.2  A - C). The antibody clone HP-MA4 cross-reacts with KIR2DL1 and the 
structurally similar activating family members 2DS1, 2DS3 and 2DS5. Reduced expression 
of KIR2DL1 was not only observed using the antibody clone HP-MA4 recognizing 
KIR2DL1/S1/S3/S5 but also by staining with an antibody specific for inhibitory KIR2DL1 
(clone 143211), implicating downregulation of inhibitory KIR receptors (Figure 6.2  A - C). 
Downregulation of KIR3DL1 could be detected with an antibody (clone DX9) specific for 
the inhibitory molecule with a long cytoplasmic tail (Figure 6.2  A - C). Expression of 
KIR2DL4, KIR2DL5 and KIR3DL2 was not detected within several healthy donors (data not 
shown) and was therefore not further investigated.  
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Figure 6.2: IL-12/15/18 stimulated NK cells display reduced levels of KIR2DL2/L3, KIR2DL1 
and KIR3DL1 expression. NK cells isolated from PBMCs were analyzed at day 0 (naïve) and after 
60 h of stimulation with IL-15 or IL-12/15/18 for the expression of killer cell immunoglobulin-like 
receptors (KIRs) by flow cytometry. (A) Histograms gated on single 7-AAD-CD3-CD56+ NK cells of 
one representative donor. (B) Summary of NK receptor expression and (C) median fluorescence 
intensity (MFI) of the KIR positive subpopulation are depicted. Results from individual donors are 
connected with a line (n = 13 - 26). Statistical analysis was performed with a paired two-tailed 
student’s t-test.  
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Kinetic studies revealed that significant changes in KIR2DL2/L3, KIR2DL1 and KIR3DL1 
expression were first detectable after 36 h of IL-12/15/18 stimulation and were most 
pronounced after 48 h and 60 h (Figure 6.3 A & B). This pattern was reflected in the 
percentage of KIR positive cells (left panel) as well as in surface expression density levels 
(MFI, right panel). Downregulation of KIR3DL1 was most evident at surface expression 
levels (Figure 6.3  C). KIR surface expression was not further decreased upon prolonged 
stimulation with IL-12/15/18 for up to 6 days (Figure 6.4 A). In contrast, differences 
Figure 6.3: KIR downregulation starts after 36 h and is most pronounced after 48 - 60 h of 
IL-12/15/18 expression. (A) KIR2DL2/L3, (B) KIR2DL1 and (C) KIR3DL1 expression levels on NK 
cells were determined by flow cytometry at the indicated time points. Bar graphs depict the 
percentage positive population (left panel) and median fluorescence intensity (MFI) (right panel) of 
KIR expressing CD3- CD56+ NK cells (n = 6 - 8, mean + SD). Statistical analysis was performed with 
a two-way ANOVA followed by Bonferroni’s multiple comparison test.  
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between IL-15 and IL-12/15/18 stimulation were most distinct after 48 h to 60 h and KIR 
expression levels converged again at later time points. Of note, prolonged stimulation 
resulted in enhanced apoptosis and reduced cell recovery (Figure 6.4 C & D). 
 
6.1.3. KIR downregulation by IL-12/15/18 is transient and NK cell 
population intrinsic  
Peripheral blood NK cells acquire KIR expression during maturation and differentiation 
from CD56bright KIR–/dim to CD56dim KIR+ subsets. Reduced KIR expression after IL-12/15/18 
stimulation could be attributed to regulation of KIR expression on CD56dim KIR+ cells or 
mediated by outgrowth of the CD56bright KIR–/dim NK subset within the whole NK cell 
population analyzed. Freshly isolated NK cells were FACS-sorted into CD56bright and  
Figure 6.4: Prolonged IL-12/15/18 stimulation results in higher apoptosis and lower cell 
numbers of NK cells. Human NK cells isolated from PBMCs were stimulated with IL-15 or 
IL-12/15/18. (A) KIR expression levels were determined by flow cytometry at the indicated time 
points after stimulation. (B) Annexin V staining for apoptotic cells and (C) absolute cell numbers at 
the indicated time points after cytokine exposure. 2x105 NK cells were seeded and absolute cell 
numbers were determined per well. Fresh medium was added to the cultures after 84 h. Statistical 
analysis was performed with a two-way ANOVA followed by Bonferroni’s multiple comparison test 
(n = 4, mean + SD). 
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CD56dim subsets (Figure 6.5 A & B) and stimulated with IL-15 or IL-12/15/18. Indeed, 
expression of inhibitory KIR2DL2/L3, KIR2DL3 and KIR2DL1 was downregulated on the 
sorted CD56dim subset after 48 h activation with IL-12/15/18, whereas naïve CD56bright NK 
cells exhibited only very low KIR expression that remained unaltered during stimulation 
(Figure 6.5  C). To determine whether KIR regulation was induced on a distinct NK cell 
subpopulation or whether it was a result of increased proliferation of the KIR negative 
Figure 6.5: KIRs are downregulated on the CD56dim NK cell subset. (A) Gating strategy of NK 
cells for FACS-sorting and for subsequent flow cytometry analyses. NK cells were distinguished by 
gating on single, living (7-AAD-), CD3- CD56+ lymphocytes. (B) NK cells isolated from PBMCs were 
further sorted into CD3- CD56dim and CD56bright subsets. Representative flow cytometry dot plots of 
naïve NK cells after sorting showing the purity of the sorted populations. Plots were gated on 7-AAD-
 lymphocytes. (C) Sorted CD56dim and CD56bright subsets were stimulated with IL-15 or IL-12/15/18 
for 48 h and analyzed by flow cytometry. Results from individual donors are connected with a line 
(n = 4 donors). Statistical analysis was performed with a paired two-tailed student’s t-test.  
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subset, freshly isolated NK cells were sorted according to their KIR expression. Since 
KIR2DL2/L3 is most frequently expressed in individuals and exhibited pronounced 
downregulation (Figure 6.5 ), NK cells were sorted into KIR2DL2/L3 positive and negative 
subsets and stimulated with IL-15 or IL-12/15/18. Figure 6.5  A and Figure 6.6 A depict the 
gating strategy for sorting of CD3– CD56+ KIR2DL2/L3+/– subsets ensuring high purity of 
sorted KIR2DL2/L3 positive and negative populations (Figure 6.6 B). KIR2DL2/L3 positive 
cells could not be isolated by negative depletion but needed to be FACS-sorted after anti-
KIR2DL2/L3 antibody staining. Due to the stochastic expression of KIR molecules on NK 
cells, the KIR2DL2/L3 positive as well as the negative subsets co-expressed other 
inhibitory self–HLA-I receptors such as NKG2A or various other inhibitory KIRs such as 
KIR2DL1 (Figure 6.6 C).  
Sorted KIR2DL2/L3 positive and negative NK cells were stimulated with IL-15 or 
IL-12/15/18 for 48 h and analyzed for their KIR expression by flow cytometry. On the 
Figure 6.6: FACS-sorting of KIR2DL2/L3 positive & KIR2DL2/L3 negative NK cells. NK cells 
isolated from PBMCs were further sorted according to their KIR2DL2/L3 expression into 
KIR2DL2/L3 positive or negative populations using the anti-KIR2DL2/L3 antibody clone DX27. 
(A - B) Representative flow cytometry dot plots of naïve NK cells (A) before and (B) after sorting 
showing the gating strategy of KIR2DL2/L3-sorting and the purity of the sorted populations as 
detected with a different anti-KIR2DL2/L3 antibody clone GL183. Dot plots were gated on 7-AAD–
CD3– CD56+ NK cells. (C) Expression of other KIRs and NKG2A on KIR2DL2/L3 positive and negative 
sorted populations shown as representative histogram overlays. 
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sorted KIR2DL2/L3 positive subset, KIR2DL2/L3 expression was significantly decreased 
after IL-12/15/18 activation compared to naïve cells and IL-15–treated controls  
(Figure 6.7 A & B). Of note, IL-15 stimulation even increased expression density of 
Figure 6.7: IL-12/15/18 drives KIR2DL2/L3 downregulation on sorted KIR2DL2/L3 positive 
NK cells. NK cells isolated from PBMCs were FACS-sorted into KIR2DL2/L3 positive and negative 
populations. Cells were analyzed before (day 0, naïve) and after 48 h of stimulation with IL-15 or 
IL-12/15/18 by flow cytometry. (A) Representative histograms showing KIR2DL2/L3 expression on 
the KIR2DL2/L3 positive sorted population. (B - D) Summary showing isotype-corrected median 
fluorescence intensity (Δ MFI) of KIR expression on the KIR2DL2/L3 positive sorted population 
(mean ± SD). KIR2DL2/L3 expression was assessed by flow cytometry using anti-KIR2DL2/L3 mAb 
clones (B) DX27 or (C) GL183 and (D) KIR2DL3 expression was detected by anti-KIR2DL3 mAb 
clone 180701 (n = 37 (B); n = 14 (C) and n = 10 (D)). Statistical analysis was determined by one-way 
ANOVA followed by Bonferroni’s post test. (E) Co-expression and regulation of KIR2DL1 on 
KIR2DL2/L3 positive and negative sorted NK cells as determined by flow cytometry. The graph 
depicts the median fluorescence intensity (MFI) of the positive subpopulation. Results from 
individual donors are connected with a line (n = 7). Statistical analysis was performed with a paired 
two-tailed student’s t-test.  
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KIR2DL2/L3 compared to expression levels on naïve NK cells. Downregulation of 
KIR2DL2/L3 was observed with different antibody clones (Figure 6.7 B - D) detecting 
KIR2DL2/L3 (DX27 & GL183) or KIR2DL3 (clone 180701), indicating regulation of 
inhibitory receptors with a long cytoplasmic tail. In addition, other inhibitory KIR 
molecules such as KIR2DL1 were downregulated on both KIR2DL2/L3 positive and 
negative subsets upon IL-12/15/18 stimulation compared to IL-15 treated controls 
(Figure 6.7 E). Of note, the sorted KIR2DL2/L3 negative population remained negative 
(data not shown). 
To address the question, whether reduced KIR expression was the result of an outgrowth 
of the KIR negative subset, proliferation of NK cells was assessed via the fluorescent cell 
division tracker dye CFSE (carboxyfluorescein succinimidyl ester). The amount of CFSE in 
the labeled cells is diluted evenly in every cell division, allowing us to track the number of 
cell divisions of each cell. After 60 h of cytokine stimulation no CFSE dilution and thus no 
proliferation of KIR2DL2/L3 positive or negative NK cells was detectable (Figure 6.8 A). 
Moreover, no significant changes in absolute cell numbers or Annexin V positive apoptotic 
cells were detectable between KIR2DL/L3 positive or negative sorted populations 
Figure 6.8: Regulation of KIR2DL2/L3 does not involve selective proliferation or apoptosis. 
(A) Freshly isolated NK cells were stained with the fluorescent cell division tracker dye CFSE and 
activated for 60 h with IL-15 or IL-12/15/18. Flow cytometry histogram overlays depict one 
representative donor out of 6 experiments gated on KIR2DL2/L3 positive or negative subsets. 
(B) Absolute cell numbers determined per well (mean ± SD; n = 26) and (C) Annexin V staining for 
apoptotic cells (mean ± SD; n = 8) of KIR2DL2/L3 positive and negative sorted subsets stimulated 
with IL-15 or IL-12/15/18 for 48 h. Statistical analysis was performed using two-way ANOVA 
followed by Bonferroni’s post test. 
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(Figure 6.8 B & C), demonstrating that decreased KIR expression did not originate from 
preferential cell death of the KIR2DL2/L3 positive population. In general, stimulation of NK 
cells with IL-12/15/18 led to elevated apoptosis levels and lower cell numbers compared 
to IL-15 activation, but both subsets were similarly affected and no differences between the 
KIR2DL2/L3 positive and negative subpopulation were observed. 
To evaluate whether KIR regulation was persistent or transient, KIR2DL2/L3-sorted NK 
cells were pre-activated for 48 h with IL-12/15/18 or IL-15 and subsequently washed and 
re-cultured in IL-2 for additional 3 to 5 days (Figure 6.9 A). As observed before, stimulation 
Figure 6.9: KIR downregulation by IL-12/15/18 on KIR2DL2/L3 sorted NK cells is transient. 
Sorted KIR2DL2/L3 positive and negative NK cells were stimulated with IL-15 or IL-12/15/18 for 
48 h, washed and re-cultured in 100 IU/ml IL-2 for additional 3 or 5 days. (A) Schematic overview 
of the experimental procedure. (B) Representative histograms of KIR2DL2/L3 positive sorted NK 
cells after 48 h stimulation and after re-culture in IL-2 for 3 or 5 days. (C) Summary of the isotype-
corrected median fluorescence intensity (Δ MFI) of KIR2DL2/L3 positive sorted NK cells. Data is 
shown as mean + SD of 9 - 14 donors. Statistical analysis was performed using one-way ANOVA 
followed by Bonferroni’s post test. Part of this figure is a reprint from Ewen et al. 2018 Eur. J. 
Immunol. 710. 
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with IL-12/15/18 decreased KIR2DL2/L3 levels after 48 h (Figure 6.9 B & C). However, 
upon re-culture in IL-2, KIR expression was restored, increasing already after 3 days on 
sorted KIR2DL2/3 positive cells, indicating that the KIR downregulation was transient 
(Figure 6.9 B & C). Moreover, expression levels of KIR2DL2/L3 as well as KIR2DL1 were 
restored when the entire NK cell culture was pre-activated with IL-12/15/18 and re-
cultured in IL-2 (Figure 6.10 A & B). Additionally, re-culture of NK cells in IL-15 
(Figure 6.10 A & C) was capable of re-inducing KIR expression.  
 
Figure 6.10: IL-12/15/18–induced downregulation of KIR2DL2/L3 and KIR2DL1 is reversible 
by re-culture in IL-2 or IL-15. Freshly isolated NK cells were stimulated with IL-15 or IL-12/15/18 
for 48 h, washed and re-cultured in 100 IU/ml IL-2 or in 1 ng/ml IL-15 for additional 5 days. 
(A) Schematic overview of the experimental procedure. (B) Summary of all NK cells re-cultured in 
100 IU/ml IL-2 for 5 days. Bar graphs depict the median fluorescence intensity (MFI) of KIR2DL2/L3 
(left) and KIR2DL1 (right) expressing NK cells (n = 11; mean + SD). (C) Summary of all NK cells after 
5 day re-culture in 1 ng/ml IL-15. Bar graphs depict the median fluorescence intensity (MFI) of 
KIR2DL2/L3 (left) and KIR2DL1 (right) expressing NK cells (n = 4; mean + SD). Statistical analysis 
was performed using two-way ANOVA followed by Bonferroni’s post test. 
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6.2. Mechanism of IL-12/15/18–induced KIR downregulation 
To investigate whether the reduction of KIR protein expression was regulated at the 
transcriptional level, we analyzed KIR mRNA levels by qRT-PCR. Indeed, IL-12/15/18 
stimulation of sorted KIR2DL2/L3 positive NK cells resulted in significantly reduced 
KIR2DL3 mRNA levels after 24 h and 48 h of cytokine exposure (Figure 6.11 B). IL-15–
activated NK cells showed enhanced KIR2DL3 mRNA levels compared to naïve cells, 
resembling the pattern of protein surface expression. After cytokine pre-activation, sorted 
KIR2DL2/L3 positive NK cells were washed and re-cultured in for 3 days in IL-2 
(Figure 6.11 A). Upon re-culture in IL-2, KIR2DL3 mRNA levels were restored after 3 days, 
demonstrating transient transcriptional KIR regulation by IL-12/15/18, mimicking our 
protein data (Figure 6.9). qRT-PCR analysis of the whole NK cell culture showed similar 
tendencies of reduced KIR2DL1 mRNA levels of IL-12/15/18–stimulated NK cells 
compared to IL-15–treated controls (Figure 6.11 C). In accordance with our results, we 
observed decreased mRNA levels of multiple inhibitory KIRs such as KIR2DL1, KIR2DL2, 
KIR2DL3, KIR3DL1, KIR3DL3, KIR2DL4 and KIR2DL5A (Figure 6.11 D) upon analysis of 
publicly available microarray data 712 comparing IL-2/12/18–stimulated with naïve NK 
cells. Taken together, we could show that IL-12/15/18–stimulation induced transient 
downregulation of KIR mRNA levels in peripheral blood NK cells.  
To dissect the essential cytokines involved in KIR regulation, we stimulated KIR2DL2/L3-
sorted NK cells with single or dual cytokine combinations of IL-12, IL-15 and IL-18 
(Figure 6.12). KIR2DL2/L3 expression levels were significantly downregulated by IL-12 
alone or in combination with IL-18 (Figure 6.12). But the combination of all three cytokines 
induced the most profound KIR regulation while ensuring survival of the cells (data not 
shown). Since we observed upregulation of KIR expression by IL-15 in contrast to 
IL-12/15/18–induced downregulation (Figure 6.7 and Figure 6.11), we tested whether the 
combination of IL-12/15/18 would diminish IL-15–mediated signaling. Therefore, we 
assessed differences in phosphorylation of the signaling adapter STAT-5, which gets 
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activated upon IL-15 signal transduction 296. KIR2DL2/L3-sorted NK cells were stimulated 
Figure 6.11: KIR mRNA levels are transiently downregulated on NK cells upon IL-12/15/18 
stimulation. Sorted KIR2DL2/L3 positive and negative NK cells were stimulated with IL-15 or 
IL-12/15/18 for 48 h, washed and re-cultured in 100 IU/ml IL-2 for additional 3 days. (A) Schematic 
overview of the experimental procedure. (B) Relative KIR2DL3 mRNA expression of KIR2DL2/L3 
positive sorted NK cells before (naïve), after 24 h and 48 h of cytokine exposure and after 3 days re-
culture in IL-2 as described in (A). KIR2DL3 surface expression on NK cells was confirmed by flow 
cytometry using the anti-KIR2DL3 antibody clone 180701. KIR2DL3 expression was determined by 
qRT-PCR and calculated relative to beta-2-microglobulin (B2M) as 2-ΔCp with ΔCp = Cp(KIR2DL3) -
 Cp(B2M). Statistical analysis was performed using two-way ANOVA followed by Bonferroni’s post 
test (n = 3 - 9, mean + SD). (C) NK cells isolated from PBMCs were treated as entire NK culture for 
24 h with IL-15 or IL-12/15/18 and analyzed for KIR2DL1 mRNA by qRT-PCR (n = 2; mean + SD). 
KIR2DL1 expression relative to beta-actin was calculated as 2-ΔCp with ΔCp = Cp(KIR2DL1) - Cp(beta 
actin). KIR2DL1 surface expression on NK cells was confirmed by flow cytometry using the anti-
KIR2DL1 antibody clone 143211. (D) Relative KIR mRNA expression levels of human NK cells in 
naïve state or treated for 24 h with IL-2/12/18 (n = 2; mean + SD). Data was extracted from the 
gene-array data set GEO GSE22919 712.  
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for 15 to 60 min with IL-15 or IL-12/15/18 and phosphorylation of intracellular STAT-5 
was detected by flow cytometry. Cytokine stimulation was sufficient to induce 
phosphorylation of STAT-5 after 15 min (Figure 6.13 A) on both KIR2DL2/L3 positive and 
negative subsets. However, no differential phosphorylation was observed between IL-15 
and IL-12/15/18 activated NK cells (Figure 6.13 B). Thus, stimulation with IL-12/15/18 
did not mediate KIR downregulation by influencing IL-15–mediated STAT-5 signaling. 
 
Figure 6.12: KIR expression on NK cells 
is regulated by different cytokine 
combinations. NK cells were sorted 
according to their KIR2DL2/L3 expression 
and stimulated for 48 h with the indicated 
cytokine combinations. KIR2DL2/L3 
expression on KIR2DL2/L3 positive sorted 
NK cells was assessed by flow cytometry 
using the antibody clone GL183. The graph 
presents the isotype-corrected median 
fluorescence intensity (Δ MFI) on the 
KIR2DL2/L3 positive sorted population 
(n = 4, mean ± SD). Each donor is 
represented by a distinct symbol. Statistical 
analysis was performed using one-way 
ANOVA followed by Bonferroni’s post test.  
 
Figure 6.13: No differential 
STAT-5 phosphorylation is 
detected after IL-15 or 
IL-12/15/18 stimulation. 
KIR2DL2/L3-sorted NK cells were 
stimulated for the indicated time 
points with IL-15 or IL-12/15/18 
and phosphorylation of 
intracellular STAT-5 was detected 
by flow cytometry. (A) Histogram 
overlays of KIR2DL2/L3 positive 
and negative sorted NK cells after 
15 min of cytokine exposure. 
(B) Median fluorescence intensity 
(MFI) of intracellular phospho–
STAT-5 after indicated time points 
of cytokine stimulation (n = 2; 
mean + SD). 
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6.3. Improved functionality of IL-12/15/18–activated NK cells 
6.3.1. IL-12/15/18–activated NK cells are less sensitive to KIR2DL2/L3-
mediated inhibition 
Down-regulation of KIR surface expression suggested that NK cells might be less sensitive 
to KIR2DL2/L3-based inhibitory signals. Hence, we assessed NK functionality in a 
redirected lysis assay with murine FcR+ P815 cells, employing NK cell activation via CD16 
crosslinking as a defined activating signal. As depicted in the scheme in Figure 6.15 A (left), 
CD16 was engaged by an anti-CD16 antibody that was cross-linked by the Fc receptor on 
P815 cells. Antibody-mediated cross-linking of activating receptors such as CD16 is capable 
of inducing activating signals within the NK cell 713–715. NK cells were sorted into 
KIR2DL2/L3 positive and negative subsets, stimulated for 48 h with IL-15 or IL-12/15/18 
and used in the redirected lysis assay. Both, IL-15 and IL-12/15/18–activated NK cells were 
capable of CD16-mediated redirected lysis (Figure 6.14 A, middle), although the latter at a 
lower extent. This correlated with lower CD16 expression on IL-12/15/18–stimulated cells 
(Figure 6.1 and Figure 6.14 B, left), which was previously shown to involve matrix-
metalloproteinase (MMP) mediated shedding 711,716. Treatment of both NK cell cultures 
with the MMP inhibitor (MMPi) Batimastat partially restored CD16 cell surface expression 
(Figure 6.14 B, right), which resulted in comparable levels of CD16-dependent killing 
between IL-12/15/18 and IL-15–cultured NK cells (Figure 6.14 A, right panel). 
Importantly, KIR2DL2/L3 expression was not influenced by the MMPi treatment 
(Figure 6.14 C). Of note, KIR2DL2/L3 positive and negative NK cells exhibited comparable 
killing capabilities upon CD16 triggering (Figure 6.14 A). Since KIR2DL2/L3 positive and 
negative sorted subsets co-expressed other inhibitory self–HLA-I receptors such as NKG2A, 
KIR2DL1 or KIR3DL1 (Figure 6.6 C), these cells were most likely educated and fully 
functional.  
To investigate whether IL-12/15/18 activation alters KIR-mediated inhibition, 
KIR2DL2/L3 was engaged with a monoclonal antibody in combination with an anti-CD16 
antibody in a redirected lysis assay (Figure 6.15 A, right). Cross-linking of inhibitory KIR 
molecules by antibody-coated P815 cells has been shown to induce inhibitory signals 
within NK cells mimicking receptor-ligand interactions 713–715. as observed before, 
engagement of CD16 alone induced comparable levels of redirected lysis by IL-15 and 
IL-12/15/18–activated NK cells (Figure 6.15 B, left). Upon inhibitory KIR co-triggering, 
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cytotoxicity of KIR2DL2/L3 positive NK cells stimulated with IL-15 was greatly reduced 
(Figure 6.15 B & C, right), indicating KIR dependent inhibition. Remarkably, the CD16-
mediated cytotoxicity of IL-12/15/18–activated NK cells was not affected by KIR2DL2/L3 
co-engagement (Figure 6.15 B & C, right). IL-12/15/18–activated NK cells possessed high 
cytotoxic potential even after co-engagement of inhibitory KIR, which was similar to lysis 
observed upon CD16 engagement by itself. Redirected lysis by KIR2DL2/L3 negative NK 
cells was not influenced by KIR cross-linking and comparable between IL-15 and  
Figure 6.14: NK cell activation with IL-12/15/18 induces MMP-mediated shedding of CD16. 
NK cells were sorted according to their KIR2DL2/L3 expression and activated for 48 h with IL-15 or 
IL-12/15/18 in the presence of solvent control (ctrl; DMSO) or treated with the matrix-
metalloproteinase inhibitor (MMPi) Batimastat. The CD16-dependent cytotoxicity of NK effector 
cells was assessed in a redirected lysis assay against antibody-coated P815 target cells, which were 
pre-incubated with mIgG1 or anti(α)-CD16 antibody (clone 3G8). (A) Representative donor showing 
different E:T ratios of CD16-mediated redirected lysis of NK cells after control (ctrl; DMSO) or 
Batimastat (MMPi) treatment. Data is presented as mean ± SD of technical replicates of one 
representative donor. (B - C) Histogram overlays depict (B) CD16 and (C) KIR2DL2/L3 surface 
expression of control (ctrl) or MMPi-treated NK cells gated on 7-AAD– CD3– CD56+ NK cells.  
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Figure 6.15: IL-12/15/18-induced KIR downregulation leads to reduced inhibition of CD16-
mediated cytotoxicity. NK cells were sorted according to their KIR2DL2/L3 expression and 
activated for 48 h with IL-15 or IL-12/15/18 in the presence of the matrix-metalloproteinase 
inhibitor (MMPi) Batimastat. Redirected lysis assays were performed against antibody-coated P815 
target cells, pre-incubated with anti(α)-CD16 mAb (clone 3G8) together with either anti-
KIR2DL2/L3 mAb (clone GL183) or with the respective mIgG1 isotype control. (A) Schematic 
overview illustrating the redirected lysis assay of CD16 triggering alone (left) and of parallel 
engagement of CD16 and KIR2DL2/L3 (right). (B) Representative data of redirected lysis against 
P815 cells pre-incubated with anti(α)-CD16 mAb together with either mIgG1 (left) or anti-
KIR2DL2/L3 mAb (right panel). Data is shown at different E:T ratios as mean ± SD of technical 
replicates. (C) Statistical summary of redirected lysis shown in (B) at E:T ratio 10:1 for 5 donors. 
Bars are drawn to mean + SD and each symbol represents one donor. (D) Percent inhibition induced 
by anti-CD16 and anti-KIR2DL2/L3 co-triggering of redirected lysis shown in (C) compared to anti-
CD16 alone. Percent inhibition by anti-KIR was calculated as [1 - [specific lysis (anti-CD16 + anti-
KIR2DL2/L3) / specific lysis (anti-CD16 + mIgG1)] x 100]. Bars are drawn to mean + SD and each 
symbol represents one donor (n = 5). Statistical analysis was determined by two-way ANOVA / 
Bonferroni’s multiple comparison test. Part of this figure is a reprint from Ewen et al. 2018 Eur. J. 
Immunol. 710. 
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IL-12/15/18 activation (Figure 6.15 B & C), indicating that in absence of KIR engagement 
both cytokine stimulations elicited the same degree of CD16-dependent cytotoxicity. Lysis 
of IL-15–treated KIR2DL2/L3 positive NK cells was reduced by approximately 50% if 
inhibitory KIR2DL2/L3 was engaged, implicating approximately 50% of inhibition by anti-
KIR. To further visualize KIR-mediated inhibition, the relative percentage of inhibition 
induced by KIR2DL2/L3 triggering was calculated for CD16-dependent lysis 
(Figure 6.15 D), demonstrating that IL-12/15/18–activated NK cells were less sensitive to 
inhibitory signals compared to IL-15 stimulated cells. Thus, our results indicate that 
reduced surface expression of KIR2DL2/L3 on IL-12/15/18–stimulated NK cells translated 
into reduced inhibition upon KIR co-engagement. 
 
6.3.2. IL-12/15/18–activated NK cells show high cytotoxicity against HLA-I–
expressing targets  
Next, we wanted to investigate whether the downregulation of KIR2DL2/L3 has an 
influence on the functionality of NK cells during their encounter of targets that express 
HLA-I. To decipher the effect of the cognate HLA-I ligand, we employed the 721.221 
lymphoma cell line, which expresses low levels of HLA-ABC as demonstrated by flow 
cytometry analysis (Figure 6.16 A). Although they showed weak but positive staining with 
a pan–HLA-ABC antibody, the 721.221 cells are described to be negative for HLA-C 717, 
bearing no ligand for KIR2D receptors. In contrast, the daughter cell line 221_Cw03 is 
transduced with the HLA-Cw03 allele, harboring the C1 epitope specifically recognized by 
KIR2DL2/L3 (Figure 6.16 A). The interaction of cytokine-stimulated NK cells with 
HLA_Cw03 positive and negative 221 cells is depicted schematically in Figure 6.16 B. The 
221 cell line is negative for cognate ligands for KIR2D receptors and thus NK activation by 
this cell line should be independent of the KIR/HLA axis. In contrast, the HLA-Cw03 cell line 
expresses the cognate ligand for KIR2DL2/L3 on NK cells, which inhibits NK activation. 
Since no ligands for other KIRs are present on both cell lines, this system allows to 
specifically study the interaction between a certain KIR and its ligand. 
Using this system, we first analyzed whether low levels of inhibitory KIR2DL2/L3 on 
IL-12/15/18–activated cells would affect NK cell degranulation against targets carrying 
cognate HLA-I molecules. Cytokine-stimulated NK cells were co-cultured for 4 h with 
HLA_Cw03 positive or negative 221 cell lines and degranulation of NK cells was assessed 
6  RESULTS 
86 
in a CD107a mobilization assay. Co-staining of KIR2DL2/L3 and CD107a allowed to 
determine specific degranulation of KIR2DL2/L3 positive and negative subsets by flow 
cytometry (Figure 6.17 A). No differences in degranulation of KIR2DL2/L3 positive and 
negative populations were detectable against 221 target cells in absence of the cognate 
ligand (Figure 6.17 B, left). Gating on KIR2DL2/L3 positive NK cells stimulated with IL-15 
revealed low levels of degranulation against 221_Cw03 targets (Figure 6.17 B, right), 
implicating inhibition of KIR2DL2/L3 positive NK cells by HLA-Cw03. In contrast, 
degranulation of IL-12/15/18–activated NK cells against 221_Cw03 cells was improved 
compared to their IL-15–treated counterparts. In parallel, both KIR2DL2/L3 negative NK 
populations exhibited comparable degranulation against 221_Cw03 cells, showing NK 
functionality independent of the KIR/HLA-I axis. Calculation of the percentage of inhibition 
Figure 6.16: HLA-I expression on 221 and 221_Cw03 lymphoma cells. (A) Parental 721.221 
lymphoma cells (221) or 721.221 cells transduced with HLA-Cw03, carrying the cognate C1 epitope 
for KIR2DL2/L3 (221_Cw03), were stained with anti-HLA-ABC mAb (clone W6/32) and analyzed by 
flow cytometry. Dead cells were excluded by gating on 7-AAD- cells. (B) Schematic overview of the 
721.221 cell lines as target cells with matched HLA-I expression. The 221 cell line is negative for 
cognate ligands for KIR2DL2/L3, which is regulated on IL-15 and IL-12/15/18–stimulated NK cells. 
The HLA-Cw03–transduced 221_Cw03 cell line expresses the cognate ligand for KIR2DL2/L3 on NK 
cells. No other ligands for other KIRs are present on both cell lines. 
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by HLA-Cw03 compared to targets expressing no HLA-C demonstrated significant less 
inhibition of IL-12/15/18–stimulated NK cells by HLA-Cw03 compared to IL-15–activated 
controls (Figure 6.17 C). Thus, our results indicate that NK cells with lower KIR expression 
levels displayed enhanced degranulation against cognate HLA-I positive targets.  
Figure 6.17: IL-12/15/18–activated NK cells exhibit enhanced degranulation towards 
cognate HLA-I positive target cells. Freshly isolated NK cells were activated for 48 h with IL-15 or 
IL-12/15/18 and co-cultured for 4 h at E:T ratio 1:1 with 221 or 221_Cw03 target cells, expressing 
the cognate HLA-I ligand for KIR2DL2/L3. Degranulation was assessed by flow cytometry analysis 
of CD107a co-gated on KIR2DL2/L3 positive or negative NK cells. (A) Gating strategy for detecting 
CD107a on KIR2DL2/L3 positive and negative NK subsets. (B) Statistical summary showing the 
percentage of CD107a positive NK cells. Bars are drawn to mean + SD and each symbol represents 
one donor (n = 4). Statistical analysis was performed using two-way ANOVA followed by 
Bonferroni’s multiple comparisons test. (C) Percent inhibition of degranulation of KIR2DL2/L3 
positive NK cells by the presence of a cognate ligand on target cells (221_Cw03) compared to no HLA 
(221 cells). Percent inhibition by HLA-Cw03 was calculated as [1 - [%CD107+ (221_Cw03) / 
%CD107+ (221)] x 100]. Statistical analysis was performed with a paired two-tailed student’s t-test 
(n = 4; mean ± SD). 
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Next, we investigated how IL-12/15/18–mediated KIR downregulation affected NK cell 
cytotoxicity towards 221 cells carrying cognate HLA-I molecules. The cytotoxicity of 
KIR2DL2/L3-sorted NK cells was determined in a standard 4 h chromium release assay 
against HLA-I low (221) and HLA-Cw03–transduced 721.221 cells (221_Cw03), bearing 
high levels of the HLA-C1 epitope specific for KIR2DL2/L3 (see Figure 6.16). No differences 
in cytotoxicity of KIR2DL2/L3 positive or negative NK cells was observed towards HLA-I 
low 221 cells regardless of IL-15 or IL-12/15/18 pre-activation (Figure 6.18 A & B, left 
panels). In absence of cognate HLA-I on target cells, NK cells stimulated with IL-15 or 
Figure 6.18: IL-12/15/18 stimulation increases NK cell cytotoxicity against cognate HLA-
Cw03–expressing lymphoma cells. Cytotoxicity assay using KIR2DL2/L3 positive and negative 
sorted NK cells activated with IL-15 or IL-12/15/18 for 48 h is shown. Sorted NK cells were 
incubated with parental 721.221 target cells (221) or with 721.221 cells transduced with HLA-Cw03 
(221_Cw3). When indicated, interaction of HLA-Cw03 and KIR2DL2/L3 was blocked by pre-
incubation of NK cells with anti-KIR2DL2/L3 mAb (GL183) or respective mouse IgG1 isotype 
control. (A) Cytotoxicity assay of one representative donor showing specific lysis of 221 or 
221_Cw03 cells at several E:T ratios (mean ± SD of technical replicates). (B) Summary of cytotoxicity 
against 221 and 221_Cw03 cells at E:T ratio 12:1. Bars are drawn to mean + SD and each symbol 
represents one donor (n = 19). (C) KIR2DL2/L3 positive NK cells were pre-incubated with anti-
KIR2DL2/L3 mAb (GL183) or respective mIgG1 isotype control. Cumulative data of specific lysis of 
221_Cw03 cells including KIR2DL2/L3 blockade at E:T ratio 12:1. Bars are drawn to mean + SD and 
each symbol represents one donor (n = 6). Statistical analysis was performed using two-way ANOVA 
followed by Bonferroni’s multiple comparisons test. Part of this figure is a reprint from Ewen et al. 
2018 Eur. J. Immunol. 710. 
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IL-12/15/18 exerted equally potent cytotoxicity at different E:T ratios. Lysis of 221_Cw03 
target cells by IL-15–stimulated KIR2DL2/L3 positive NK cells was significantly inhibited 
by the interaction of KIR2DL2/L3 with its cognate ligand (Figure 6.18 A & B, right panels). 
Importantly, KIR2DL2/L3 positive NK cells activated with IL-12/15/18 showed superior 
cytotoxicity towards cognate HLA-I–expressing 221_Cw03 targets compared to IL-15–
treated controls (Figure 6.18 A & B, right panels). In parallel, KIR2DL2/L3 negative NK cells 
exhibited comparable killing capabilities independent of KIR/HLA-I interactions. To study 
the contribution of the KIR/HLA-I axis, interaction of KIR2DL2/L3 and its ligand HLA-Cw03 
was blocked by an anti-KIR antibody (Figure 6.18 C). Indeed, KIR2DL2/L3 blockade 
increased cytotoxicity of IL-15–treated KIR2DL2/L3 positive NK cells towards 221_Cw03 
targets (Figure 6.18 C), demonstrating that cytotoxicity of IL-15–activated NK cells was 
inhibited by the interaction of KIR2DL2/L3 with its cognate ligand. The high cytotoxicity of 
IL-12/15/18–stimulated KIR2DL2/3 positive NK cells was preserved in the presence of the 
blocking anti-KIR antibody. Together, these observations indicate that IL-12/15/18 
activation led to downregulation of inhibitory KIR2DL2/L3 receptors, rendering NK cells 
proficient in killing cognate HLA-I–expressing tumor cells. 
 
6.3.3. IL-12/15/18–pre-activated cells exhibit memory-like functionality  
Previous studies reported that human and mouse NK cells can acquire potent memory-like 
functionality after 16 h pre-activation with IL-12/15/18 288,289,333,334,526. Upon re-
stimulation, these cells maintained the capacity of high anti-tumor activity and IFN-γ 
production, both after adoptive transfer in vivo and after an in vitro resting phase in the 
presence of IL-2 or IL-15, indicative of memory-like functionality. To address whether 
prolonged pre-activation for 48 h, as used in this thesis, instead of 16 h would influence the 
memory-like properties of cytokine-stimulated NK cells, we pre-activated NK cells for 48 h 
with IL-15 or IL-12/15/18 and compared them to 16 h pre-activation. Directly after 
cytokine exposure, pre-activated NK cells were re-cultured in IL-2 or IL-15 for 5 days 
(Figure 6.19 A). To assess NK functionality, cells were re-stimulated with K562 and IFN-γ 
levels were determined in the supernatant by ELISA. Of note, KIR2DL2/L3 expression was 
re-induced by IL-2 and IL-15 re-culture as observed before (Figure 6.10) and KIR 
expression levels were comparable between IL-15 and IL-12/15/18–pre-activated NK cells 
at day 5. In accordance with previous studies 288,289,334, NK cells pre-activated with 
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IL-12/15/18 produced more IFN-γ compared to IL-15–treated counterparts 
(Figure 6.19 B). IL-12/15/18 pre-activated NK cells exhibited improved IFN-γ secretion 
both after re-culture in IL-2 (Figure 6.19 B, left) as well as after re-culture in IL-15 
(Figure 6.19 B, right). Importantly, as compared to 16 h stimulation of NK cells, pre-
activation for 48 h resulted in similarly enhanced IFN-γ production of IL-12/15/18–
stimulated NK cells upon re-stimulation with K562. Thus, also longer IL-12/15/18 
stimulation could prime for generation of NK cells with memory-like properties.  
Additionally, we determined the percentage of IFN-γ producing cells upon 6 h re-
stimulation with K562 via intracellular flow cytometry staining (Figure 6.20 A). Flow 
Figure 6.19: Enhanced IFN-γ secretion by IL-12/15/18–pre-activated NK cells upon re-
stimulation with K562. Freshly isolated bulk NK cells were stimulated with IL-15 or IL-12/15/18 
for either 16 h or for 48 h, washed and re-cultured in 100 IU/ml IL-2 or in 1 ng/ml IL-15 for 
additional 5 days. For re-stimulation, NK cells were co-cultured at E:T ratio 1:1 with K562 for 24 h, 
supernatants were harvested and analyzed by ELISA. (A) Schematic overview of the experimental 
procedure. (B) IFN-γ concentration of IL-2 (left) and IL-15 (right) re-cultured NK cells upon re-
stimulation with K562. Both 16 h and 48 h pre-activated NK cells are shown (n = 4; mean + SD). 
Statistical analysis was performed using two-way ANOVA followed by Bonferroni’s multiple 
comparisons test. 
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cytometry-based quantification showed a clear tendency of enhanced IFN-γ expression 
Figure 6.20: IL-12/15/18–preactivated cells exhibit improved IFN-γ expression upon re-
stimulation with K562. Freshly isolated bulk NK cells were stimulated with IL-15 or IL-12/15/18 
for either 16 h or for 48 h, washed and re-cultured in 100 IU/ml IL-2 or in 1 ng/ml IL-15 for 
additional 5 days. For re-stimulation, NK cells were co-cultured at E:T ratio 1:1 with K562 for 6 h in 
the presence of Brefeldin A and intracellular IFN-γ was detected by flow cytometry. (A) Schematic 
overview of the experimental procedure. (B) Representative dot plots of intracellular IFN-γ staining 
detected by flow cytometry. NK cells pre-activated for 16 h (upper panel) and 48 h (lower panel) are 
shown. (C) Percentage of IFN-γ producing NK cells after re-culture in IL-2 (left) or IL-15 (right) NK 
cells. (n = 2-3; mean + SD). Statistical analysis was performed using two-way ANOVA followed by 
Bonferroni’s multiple comparisons test. 
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after IL-12/15/18 pre-activation (Figure 6.20 B & C). IFN-γ production of IL-12/15/18–
stimulated NK cells was similarly enhanced both after 16 h and 48 h pre-activation. Of note, 
since IL-12/15/18 pre-activated NK cells produced more IFN-γ at steady state without re-
stimulation, all values were corrected to baseline production. In general, re-culture of pre-
activated NK cells in IL-2 resulted in increased IFN-γ secretion upon re-culture 
(Figure 6.19 B) and in higher percentages of IFN-γ expressing cells (Figure 6.20 B & C) 
compared to NK cells re-cultured in IL-15, but also in increased background IFN-γ 
production without re-stimulation. Thus, pre-activation for 48 h with IL-12/15/18 was 
equally capable of generating memory-like NK cells with high capacity of sustained IFN-γ 
production.  
Taken together, we could show that stimulation of NK cells with IL-12/15/18 induced 
downregulation of KIR surface expression and mRNA levels, which was reversible by re-
culture in IL-2 or IL-15. Reduced expression of inhibitory KIR receptors translated into 
reduced inhibition and improved NK functionality against cognate HLA-I–expressing tumor 
cells. Furthermore, IL-12/15/18 pre-activated NK cells exhibited sustained IFN-γ 
production compared to IL-15–treated cells upon re-stimulation with K562, indicative of 
memory-like functionality.  
 
6.4. Downregulation of KIR expression on NK cells in an HCMV 
infection model 
6.4.1. KIR2DL2/L3, KIR2DL1 and KIR3DL1 are downregulated upon HCMV 
infection 
Mouse and human cytomegalovirus (MCMV and HCMV) infection have been implicated in 
the formation of memory-like NK cells with expansion of specific NK subsets 24,718. A strong 
pro-inflammatory cytokine milieu is created during these viral infections and in particular 
IL-12 has been shown to be involved in expansion of the NKG2C+ NK subset 556. Therefore, 
we wanted to investigate the impact of HCMV infection and of the cytokines produced 
during infection on KIR expression. To model HCMV infection, we employed a co-culture 
system of PBMCs together with infected fibroblasts, which was established in our 
laboratory 556. As schematically illustrated in Figure 6.21 A, MRC-5 fibroblasts were left 
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uninfected or were infected with the HCMV strain AD169 for 8 h. Virus was washed away 
and fibroblasts were cultured together with freshly isolated PMBCs for 7 days. Co-culture 
of PBMCs with HCMV-infected fibroblasts resulted in significant downregulation of 
KIR2DL2/L3, KIR2DL1 and KIR3DL1 molecules on NK cells (Figure 6.21 B) compared to 
uninfected cultures at day 3 p.i. (post infection). The percentage of NK cells expressing a 
certain KIR (Figure 6.21 B, upper panel) as well as the surface density of KIR expression  
(lower panel) was significantly decreased in HCMV-infected co-cultures, resembling the 
Figure 6.21: Downregulation of KIRs on NK cells in an HCMV infection model system. NK cells 
were analyzed in a co-culture system of PBMCs together with infected fibroblasts modelling an 
HCMV infection. (A) Schematic description of experimental procedure of HCMV co-culture system. 
MRC-5 fibroblasts were infected with human cytomegalovirus (HCMV, subtype AD169) at MOI of 10 
for 8 h or were left uninfected. Virus was washed away and fibroblasts were cultured together with 
PMBCs for 7 days. PBMCs were analyzed for their receptor expression after 3, 5 and 7 days by flow 
cytometry. NK cells were defined by gating on 7-AAD– CD3– CD19– CD14– CD56+ lymphocytes. 
(B) Expression of indicated receptors (upper panel) and median fluorescence intensity (MFI, lower 
panel) on CD56+CD3– NK cells in the HCMV co-culture system at day 3p.i. (post infection). 
(C) NKG2C expressing NK cells are shown after 7 days p.i. (B – C) Results from individual donors are 
connected with a line (n = 10 - 16). Statistical analysis was performed with a paired two-tailed 
student’s t-test.  
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IL-12/15/18–induced KIR downregulation (Figure 6.2). Of note, KIR expression was 
detected using antibody clones cross-reacting with long and short intracellular domains 
(e.g. anti-KIR2DL1/S1/S3/S5 clone HP-MA4). Thus, no clear conclusion about regulation of 
inhibitory or activating KIRs could be drawn. In addition, CD25 was highly upregulated in 
HCMV-infected co-cultures (Figure 6.21 B), similar to our observations upon IL-12/15/18 
stimulation of NK cells (Figure 6.1 B). HCMV infection was described to drive expansion of 
a NKG2C+ NK subset compared to uninfected co-cultures 556,719. However, our individual co-
cultures displayed a remarkable donor-to-donor variability after 7 days p.i. and resulted in 
heterogenous expansion or even in reduction of the NKG2C+ subsets (Figure 6.21 C). 
Kinetic studies revealed, that KIR2DL2/L3 expression is reduced 3 days after HCMV 
infection compared to uninfected cultures (Figure 6.22). However, KIR expression was 
restored and even further increased in both uninfected and infected co-cultures after 
7 days. In contrast, CD25 expression was constantly increasing upon HCMV infection and 
highly upregulated 7 days p.i. (Figure 6.22). 
Figure 6.22: Kinetics of KIR and CD25 expression in HCMV infection. PBMCs were co-cultured 
with HCMV-infected or uninfected MRC-5 fibroblasts and analyzed by flow cytometry at the 
indicated time points. (A) Percentage positive population and (B) median fluorescence intensity 
(MFI) of indicated receptor expression at day 3, 5 and 7 p.i. Statistical analysis was performed with 
a two-way ANOVA followed by Bonferroni’s multiple comparison test (n = 7 - 9, mean + SD). NK cells 
were defined by gating on 7-AAD– CD3– CD19– CD14– CD56+ lymphocytes. 
 6  RESULTS  
95 
Since stimulation of NK cells with IL-12/15/18 induced regulation of various NK receptors  
(Figure 6.1), we analyzed NK receptor expression in the HCMV co-culture system. In line 
with our observations upon IL-12/15/18 stimulation (Figure 6.1), CD16 and NKp80 
expression was significantly downregulated upon HCMV infection (Figure 6.23 A & B), 
whereas expression density of DNAM-I was increased (Figure 6.23 B). Furthermore, the co-
stimulatory TNFRSF members Ox40 and 4-1BB were highly upregulated as reflected by the 
Figure 6.23: Regulation of NK cell receptor expression in an HCMV infection system. PBMCs 
were co-cultured with HCMV-infected or uninfected MRC-5 fibroblasts and analyzed by flow 
cytometry at the indicated time points. (A) Percentage receptor positive NK cells and (B) median 
fluorescence intensity (MFI) of the positive subpopulation or the isotype-corrected median 
fluorescence intensity (Δ MFI) of the indicated receptors. Statistical analysis was performed with a 
two-way ANOVA followed by Bonferroni’s multiple comparison test (n = 2; mean + SD). NK cells 
were defined by gating on 7-AAD– CD3– CD19– CD14– CD56+ lymphocytes. 
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percentage of receptor positive cells (Figure 6.23 A), as well as by their expression density 
levels (Figure 6.23 B). 
 
6.4.2. IL-12–induced CD25 expression drives NK proliferation in HCMV 
infection 
It was previously shown by our laboratory that IL-12 is produced by monocytes in HCMV-
infected co-cultures and drives expansion of NKG2C+ NK subsets upon infection 556. IL-12 
was detected in infected co-cultures starting after 48 h and IL-12 levels were increasing up 
to 72 h 556. Indeed, MACSplex analysis of co-culture supernatants 3 days p.i. indicated 
enhanced concentrations of IL-12, IFN-α, IFN-γ and IL-10 in infected compared to 
uninfected co-cultures (Figure 6.24). Although not differentially produced, multiple 
cytokines such as IL-2, IL-6, IL-9, TNF-α and GMCSF were present in the co-culture system. 
IL-18 could not be detected in the co-culture supernatants by ELISA 3 days p.i. 
(Figure 6.24). Since we observed that IL-12 alone induced a partial KIR downregulation on 
purified NK cells (Figure 6.12), we investigated the role of IL-12 in KIR regulation upon 
HCMV infection. We neutralized IL-12 in the co-cultures by adding a blocking antibody and 
analyzed KIR expression 3 days p.i. . IL-12 neutralization had no effect on KIR2DL2/L3 or 
KIR2DL1 downregulation in HCMV-infected co-cultures, neither on KIR expression 
Figure 6.24: Cytokine profile of HCMV co-culture system. PBMCs were co-cultured with AD169-
infected or uninfected MRC-5 fibroblasts for 3 days and supernatants were analyzed for secreted 
cytokines. MACSplex analysis of co-culture supernatants harvested 3 days p.i. MACSplex analysis 
was performed by M. Granzin. IL-18 was detected by ELISA (n = 2; mean + SD; n.d. not detectable).  
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Figure 6.25: IL-12 neutralization and IFN-αR blockade in HCMV co-cultures. PBMCs were co-
cultured with AD169-infected or uninfected MRC-5 fibroblasts in the presence of indicated 
neutralizing antibodies or isotype control. (A) Percentage receptor positive NK cells and (B) median 
fluorescence intensity (MFI) of the positive subpopulation of co-cultures with IL-12 neutralizing 
antibody at day 3 p.i. (n = 6 - 7; mean ± SD). Each symbol represents one donor. (C) Representative 
histogram and (D) summary of co-cultures in the presence of IFN-α receptor blocking antibody 
(n = 2; mean ± SD). Each symbol represents one donor. Statistical analysis was performed with a 
two-way ANOVA followed by Bonferroni’s multiple comparison test. NK cells were defined by gating 
on 7-AAD– CD3– CD19– CD14– CD56+ lymphocytes. 
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Figure 6.26: Upregulation of CD25 on NK cells in HCMV-infected co-cultures is partially IL-12 
dependent. PBMCs were co-cultured with AD169-infected or uninfected MRC-5 fibroblasts in the 
presence of neutralizing antibody against IL-12 or isotype control. (A) Representative dot plots of 
CD25 expression on NK cells at day 7 p.i. Numbers indicate the percentage of CD25 positive cells 
among all CD3– CD56+ NK cells. (B) Statistical summary of percentage and (C) median fluorescence 
intensity (MFI) of CD25 positive NK cells at day 3, 5 and 7 p.i. (n = 7; mean ± SD). Each symbol 
represents one donor. Statistical analysis was performed with a two-way ANOVA followed by 
Bonferroni’s multiple comparison test. NK cells were defined by gating on 
7-AAD– CD3– CD19– CD14– CD56+ lymphocytes.  
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intensities (Figure 6.25 B) nor with regards to percentage of KIR expressing cells 
(Figure 6.25 A). Moreover, CD16 downregulation was not prevented by neutralization of 
IL-12 although it was described to involve IL-12–induced shedding of CD16 by matrix-
metalloproteinases (MMPs) shedding 711,716. This could indicate insufficient neutralization 
of IL-12 during the co-culture period or contribution of multiple cytokines. Since IFN-α was 
Figure 6.27: HCMV-induced proliferation of CD25+ NK cells is n not IL-12 dependent. PBMCs 
were labeled with the proliferation dye CFSE and co-cultured with AD169-infected or uninfected 
MRC-5 fibroblasts in the presence of IL-12 neutralizing antibody or isotype control. 
(A) Representative dot plots co-gating CFSE dilution and CD25 expression on NK cells at day 7 p.i. 
(B) Histogram overlays of CFSE dilution gated on CD3– CD56+ NK cells. (C) Summary of percentage 
and (D) median fluorescence intensity (MFI) of NK cells that showed CFSE dilution at day 7 p.i. (n = 7; 
mean ± SD). Each symbol represents one donor. Statistical analysis was performed with a two-way 
ANOVA followed by Bonferroni’s multiple comparison test. NK cells were defined by gating on 
7-AAD– CD3– CD19– CD14– CD56+ lymphocytes. 
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almost exclusively present in HCMV-infected supernatants, we blocked the IFN-α receptor 
on PBMCs in the co-culture system with a blocking antibody. Blockade of IFN-αR showed 
no effect on HCMV-induced downregulation of KIR2DL2/L3 at day 3 p.i. 
(Figure 6.25 C & D). Thus, neither IL-12 nor IFN-α alone were sufficient to drive KIR 
downregulation in the HCMV model system. In contrast, induction of CD25 on NK cells in 
HCMV-infected co-cultures was most pronounced at day 7 p.i. (Figure 6.26 A) and was 
partially dependent on IL-12 (Figure 6.26 A - C). Both, percentage of CD25 positive NK cells 
(Figure 6.26 B) as well as surface expression density (Figure 6.26 C) were reduced in 
HCMV-infected cultures when IL-12 was neutralized, whereas uninfected cultures 
remained unaffected.  
CD25 represents the IL-2 high affinity receptor α-chain and therefore contributes to IL-2–
dependent proliferation of NK cells. Since IL-2 is present in both infected and uninfected 
co-cultures (Figure 6.24 B), we investigated the impact of CD25 and IL-12 neutralization 
on NK proliferation. PBMCs were labeled with the fluorescent cell division tracker dye CFSE 
and analyzed 7 days p.i. by flow cytometry. CFSE dilution correlated with high CD25 
expression (Figure 6.27 A) at day 7 p.i. and significantly more NK cells had proliferated in 
HCMV-infected cultures compared to uninfected (Figure 6.27 A - C). Furthermore, NK cells 
in infected co-cultures exhibited stronger CFSE dilution demonstrated by lower CFSE 
intensities (MFI) (Figure 6.27 D), indicating that more cells had undergone a higher 
number of cell divisions. Neutralization of IL-12 correlated with reduced CD25 expression 
(Figure 6.27 A) but showed only a modest reduction of CFSE dilution and proliferation 
(Figure 6.27 A - D). Although IL-12 neutralization significantly reduced CD25 expression 
(Figure 6.26), the high affinity IL-2Rα was still highly present on NK cells upon infection, 
which might be sufficient to react to low IL-2 concentrations and to induce strong 
proliferation. 
Taken together, we could show downregulation of KIR expression upon HCMV infection 
3 days p.i., which was restored during longer co-culture periods and not solely dependent 
on IL-12 or IFN-α alone. CD25 upregulation was dependent on IL-12 and high CD25 
expression levels were associated with NK proliferation in HCMV infected co-cultures. 
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7. DISCUSSION 
Parts of this section have been previously published in their original or modified form in 
Ewen et al. 2018 Eur. J. Immunol. 710 and in Rölle, Pollmann et al. 2014 J. Clin. Invest. 556. 
The text has been originally written by myself. 
 
Cancer immunotherapy based on NK cells is a promising field in the treatment of 
hematological malignancies 608,614,659. In cancer patients, NK cell anti-tumor efficacy is often 
attenuated through inhibitory signals mediated by the interaction of inhibitory KIRs on NK 
cells with HLA-I molecules on autologous tumor cells. Therefore, several approaches are 
currently applied in NK cell-based immunotherapy to circumvent KIR-mediated inhibition 
and to unleash NK cell anti-tumor activity.  
For instance, adoptive transfer of haploidentical KIR/ligand-mismatched NK cells has been 
shown to greatly improve the clinical outcome of leukemia patients, since they are not 
inhibited by KIR/self–HLA-I interactions 606,658,659. However, adoptive transfer of allogeneic 
cells is limited by the selection of a matching donor, low persistence of transferred NK cells 
in the adoptive host and the risk of graft-vs-host disease (GvHD) 645,674,675,720. Therefore, it 
is of overall importance to develop new strategies to improve the anti-cancer potency of 
NK cells against HLA-I–expressing tumors in autologous transfusions.  
Here, we reveal a novel mechanism how NK cells can be transiently released from KIR-
mediated self-inhibition. Stimulation of mature peripheral blood NK cells with the 
cytokines IL-12/15/18 resulted in transient, yet robust downregulation of mRNA and 
surface expression of inhibitory KIR2DL2/L3, KIR2DL1 and KIR3DL1 molecules. 
Additionally, we observed KIR downregulation on NK cells in an HCMV infection model, 
representing a physiological setting with high concentrations of pro-inflammatory 
cytokines. IL-12/15/18–stimulated NK cells experienced less inhibition upon KIR2DL2/L3 
engagement and gained high responsiveness against HLA-I–bearing lymphomas, which 
may be translated into HLA-I matched settings of immunotherapy. Taken together, our 
study reports a novel mechanism of KIR downregulation on mature peripheral blood NK 
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cells by pro-inflammatory cytokines, generating potent effector cells for autologous NK cell 
infusions as treatment of HLA-I–expressing tumors. 
 
7.1. Phenotype of cytokine-stimulated NK cells  
Short overnight pre-activation with IL-12/15/18 has been demonstrated to induce NK cells 
with high proliferative capacity and potent effector functions 288,289,333,334,526. These cells 
exhibit sustained functionality both after adoptive transfer in vivo and after a subsequent 
re-culture period in IL-2 or IL-15, implicating the generation memory-like features. So far, 
no comprehensive phenotypical and functional characterization of IL-12/15/18–
stimulated NK cells have been performed after the initial cytokine exposure. To dissect the 
improved functionality of IL-12/15/18–activated NK cells, we conducted a systematic 
analysis of activating, co-stimulatory and inhibitory receptors on pbNK cells at different 
time points after IL-15 or IL-12/15/18 stimulation. Cytokine stimulation induced changes 
in the expression of many NK receptors (Figure 6.1), either reflected by the percentage of 
receptor expressing cells or by receptor surface expression density per cell (indicated by 
MFI).  
Expression densities of most activating NK receptors were enhanced upon IL-15 or 
IL-12/15/18 stimulation (Figure 6.1 A), whereas expression of some other receptors, such 
as NKp46, was only marginally changed. In general, exposure of NK cells to single or 
multiple combinations of IL-12, IL-15 and IL-18 has been described to enhance expression 
of activating NK receptors 271,721,722. In contrast, the activating receptors NKp80 and CD16 
(FcγRIIIA) exhibit profound downregulation upon IL-12/15/18 stimulation. Reduction of 
CD16 expression on NK cells by cytokines has been shown to involve matrix-
metalloproteinase (MMP)–mediated shedding of the receptor from the cell surface 711,716. 
NKp80 downregulation and simultaneous upregulation of the NKp80L AICL has been 
implicated in controlling overreaction of highly activated NK cells by fratricide 156. 
Expression levels of CD25 were substantially increased upon IL-12/15/18 stimulation 
compared to IL-15 (Figure 6.1). CD25 is expressed at low levels on CD56bright cells and not 
present on CD56dim NK cells 286,287, but various stimuli have been described to induce CD25 
expression on NK cells e.g. by activating receptor stimulation or by cytokine 
treatments 99,271,556,723,724. IL-12 and IL-18 have been demonstrated to increase CD25 levels 
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and the combination of IL-12/15/18 is particularly potent in promoting CD25 
expression 271,288–290. 
CD25 represents the high affinity IL-2Rα-chain that constitutes the IL-2Rαβγ, facilitating 
high responsiveness to picomolar concentrations of IL-2 284,285. Our laboratory and others 
have demonstrated that elevated CD25 expression levels on IL-12/15/18–stimulated NK 
cells were associated with high proliferative capacity and higher cell recoveries after in 
vitro culture in low dose IL-2 and in an in vivo xenograft mouse model 288,569. This is 
especially interesting in therapeutic setting of adoptive NK cell transfer, since 
administration of high concentrations of IL-2 is involved in toxic side effects and expansion 
of CD25+ regulatory T cells 302,303,643,725. 
The TNFRSF members 4-1BB (CD137) and Ox40 (CD134) are absent on naïve NK cells but 
are induced by both IL-15 and IL-12/15/18, whereas the latter even further elevates their 
surface density levels (Figure 6.1 C). Although Ox40 is intensely studied as a co-stimulatory 
receptor in T cells 216,217,221, little is known about the functionality of Ox40 in NK cells. Our 
laboratory recently described an important role for Ox40-Ox40L interaction between 
CD14+ monocyte-derived cells and NK cells, leading to NK cell activation and proliferation 
in hepatitis C virus (HCV) infection 291. There, Pollmann et al. discovered induction of Ox40 
expression on NK cells in HCV-infected co-cultures with PBMCs, which correlated with 
CD25 upregulation and enhanced proliferation of NK cells. 4-1BB expression has been 
reported to be induced on NK cells by IL-2, IL-15 and by triggering of CD16, and functions 
as a potent co-stimulatory receptor in CD16-mediated lysis 99,214,726. Thus, CD25, 4-1BB and 
Ox40 could be considered as activation markers on NK cells. 
 
7.2. IL-12/15/18–induced downregulation of inhibitory KIRs  
In addition to increased activating receptors, we observed downregulation of inhibitory 
KIR2DL2/L3, KIR2DL1 and KIR3DL1 molecules upon IL-12/15/18 activation (Figure 6.2), 
which constitute the three most important inhibitory KIRs in tumor immunity. Stimulation 
with IL-12/15/18, but not with IL-15 alone, resulted in a significant decrease in the 
percentage of KIR positive NK cells and in an even more profound reduction of surface 
expression densities (MFI). KIR downregulation was detected on the entire population of 
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mature peripheral blood (pb)NK cells (Figure 6.2) as well as on sorted CD56dim NK cells 
(Figure 6.5) and sorted KIR2DL2/L3 positive subsets (Figure 6.7).  
Previous studies that analyzed NK cells pre-activated for 16 h with IL-12/15/18, focused 
on the memory-like properties of these cells after a subsequent re-culture period in IL-2 or 
IL-15 for 4 - 7 days 288,289,334,526.  However, no differential KIR expression was detected in 
these reports after 16 h of cytokine stimulation or upon IL-2 or IL-15 re-culture. Our 
kinetics studies revealed that KIR downregulation was first observed starting 36 h after 
exposure to IL-12/15/18 with most pronounced reduction after 48 h and 60 h (Figure 6.3). 
In contrast, KIR expression on IL-12/15/18 and IL-15–activated NK cells was comparable 
after 16 h, the time point investigated in previous studies 288,289,334,526. Moreover, KIR 
downregulation was transient and could be restored upon re-culture in IL-2 and IL-15 after 
5 days (Figure 6.9 and Figure 6.10) explaining why other reports did not detect differential 
KIR expression upon 7 days of re-culture.  
 
7.3. Possible mechanism of cytokine-regulated KIR expression 
While the acquisition of KIRs during development is well understood 463,464, little is known 
about the regulation of already expressed KIR molecules on mature CD56dimKIR+ NK cells.  
In our study, downregulation of KIR2DL2/3 expression was not accompanied by reduced 
proliferation or increased apoptosis of the KIR positive subset and a concomitant 
outgrowth of CD56brightKIR– cells or the sorted KIR2DL2/L3 negative population 
(Figure 6.8 ). Rather, we demonstrated that KIR regulation occurred in the CD56dimKIR+ 
subset by sorting and separate stimulation of CD56dim and CD56bright NK cells (Figure 6.5). 
In general, surface protein expression can be modulated by multiple processes such as 
post-translational and post-transcriptional mechanisms. Post-translational mechanisms 
could involve receptor shedding, internalization or retention. However, cytokine-induced 
KIR downregulation did not involve matrix-metalloproteinase (MMP)–mediated shedding 
from the surface, as treatment with the MMP inhibitor Batimastat during cytokine exposure 
did not influence KIR expression (Figure 6.14 C). Additionally, unaltered expression of 
NKp46 and upregulation of other receptors such as CD25, DNAM-I, Ox40 and 4-1BB 
(Figure 6.1) indicated that IL-12/15/18 activation did not result in a general abrogation of 
protein expression as observed in apoptotic cells.  
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Importantly, we could demonstrate that decreased KIR expression was transiently 
regulated at mRNA level upon IL-12/15/18 stimulation (Figure 6.11), mimicking the 
modulation observed in KIR protein expression. The reduction of KIR mRNA as well as the 
protein expression was reversible upon IL-2 or IL-15 re-culture, suggesting the 
contribution of transient mechanisms. In accordance with our results, we additionally 
observed decreased mRNA levels of KIR2DL1, KIR3DL1, KIR3DL3, KIR2DL4 and KIR2DL5A 
(Figure 6.11 B) upon analysis of publicly available microarray data 712 comparing naïve 
with IL-2/12/18–stimulated NK cells. Moreover, regulation of KIR expression at a post-
transcriptional level could involve an influence of IL-12 and IL-18 on KIR mRNA stability or 
alternative splicing thus reducing the detectable mRNA concentrations.  
Overall, we could demonstrate that KIR molecules are regulated at a transcriptional or 
post-transcriptional level rather than at post-translational levels upon cytokine stimulation 
in our setting.  
 
7.3.1. KIR regulation by cytokines 
While IL-12/15/18 decreased KIR expression, we found that stimulation with IL-15 alone 
increased KIR levels compared to naïve NK cells (Figure 6.7). We observed enhanced KIR 
surface expression density, as detected by enhanced MFI values, as well as increased 
frequencies of KIR expressing cells. Additionally, re-culture in IL-2 or low-dose IL-15 after 
cytokine stimulation restored and even further increased KIR levels (Figure 6.9 and 
Figure 6.10), indicating that IL-2 and IL-15 are capable of regulating KIR expression on 
mature NK cells. IL-15 is crucial for NK cell development and homeostasis and has been 
described to drive maturation of hematopoietic progenitor cells into mature CD56+KIR+ NK 
cells in vitro 55,727. Although IL-2 and IL-15 execute similar functions in NK cell biology due 
to the shared β- and γ-chain of their receptor, IL-15 signaling is non-redundant and 
indispensable for NK cell development 294,307,311. Several studies have investigated the 
potential implication of IL-15 and IL-2 in driving KIR expression in NK cells. For mouse 
Ly49 receptors (the mouse inhibitory MHC-I binding receptor equivalent of the human KIR 
family) regulation by cytokines has been confirmed in mature NK cells 728. In vitro 
stimulation of human CD56brightKIR– pbNK cells with IL-15 or IL-2 has been shown to drive 
their maturation into CD56dim NK cells and to induce de novo KIR expression 66,729. 
Furthermore, Romagnani and colleagues demonstrated that stimulation of mature 
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CD56dimKIR– NK cells with IL-2 or IL-15 without accessory cells was sufficient to induce de 
novo KIR expression 66,510. Moreover, IL-2 and IL-15 were shown to be capable of increasing 
KIR frequencies and surface expression intensities on KIR-expressing NK cells including 
KIR2DL2/L3 and KIR2DL1 molecules 729–732. Together, these reports substantiate the role 
of cytokines, especially of IL-2 and IL-15, in driving de novo KIR acquisition and in 
increasing KIR expression in mature pbNK cells. To our knowledge, cytokine-induced 
downregulation of KIR expression has not been reported to date. Therefore, the here 
described transient downregulation of KIR expression on mature CD56dimKIR+ NK cells by 
IL-12/15/18 might represent a novel mechanism of KIR regulation.  
 
7.3.2. KIR regulation by epigenetic mechanisms 
How de novo KIR expression is initiated during development is well studied and has been 
shown to involve multiple promoters and epigenetic mechanisms. The clonally restricted 
KIR expression patterns are fixed by DNA methylation and stably maintained during cell 
division 465,467,468. As hematopoietic progenitor cells commit to the NK cell linage, histone 
acetylation and opening of chromatin is a prerequisite for promoter accessibility at the KIR 
locus 466.  
Once a KIR allele is demethylated and the promoters are active, its expression is fixed and 
passed on during multiple cell divisions. How expression levels of an already expressed KIR 
genes are regulated remains poorly defined. However, the epigenetic mechanisms 
determining KIR expression during development are not fixed events but are reversible 
and can be influenced in mature NK cells. Treatment of mature NK cells with the 
demethylation reagent 5-aza-2'-deoxycytidine (5Aza-dC, a DNA methyltransferase 
inhibitor) was capable of inducing de novo expression of previously untranscribed KIR 
alleles and in vitro methylation of a KIR promoter construct was shown to repress its 
transcriptional activity vice versa 465,467. 
To our knowledge, only upregulation of KIR expression by IL-15 and IL-2 has been 
reported 66,510,729–732. Here, we describe for the first time the transient downregulation of 
KIR mRNA and protein expression on mature CD56dimKIR+ pbNK cells by IL-12/15/18 
stimulation. Intriguingly, we observed that IL-12/15/18 stimulation not only abrogated 
IL-15–mediated upregulation but further reduced KIR frequencies and surface expression 
intensities on KIR positive NK cells. Treatment of CD56dim or complete pbNK cells with IL-2 
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or IL-15 increased the frequencies of KIR2DL2/L3 and KIR2DL1 expressing cells 
(Figure 6.9 and Figure 6.10), implicating de novo KIR gene transcription in NK cell clones 
that previously exhibited silencing of this particular KIR allele. Vice versa, activation with 
IL-12/15/18 resulted in decreased frequencies of KIR expressing cells indicating silencing 
of KIR2DL2/L3 and KIR2DL1 loci in individual NK cell clones. Additionally, the intensity of 
KIR surface expression levels (as measured by elevated MFI levels) on sorted KIR2DL2/L3 
positive NK cells was enhanced by IL-15 and reduced by IL-12/15/18, respectively 
(Figure 6.7), suggesting that the transcriptional activity of KIR promoters might have been 
altered.  
Activation with IL-12/15/18 might modulate KIR gene regulation via direct or indirect 
mechanisms by interfering with the effects mediated by IL-15 or IL-2. IL-15 responsiveness 
in CD56bright cells is associated with transcription from the distal promoter and initiation of 
proximal promoter activity leading to DNA demethylation and chromatin opening 464,471,472. 
Moreover, epigenetic remodeling and DNA demethylation of the KIR3DL1 promoter has 
been described upon IL-2 stimulation of CD56dim NK cells, resulting in de novo acquisition 
of KIR3DL1 surface expression 510. IL-12/18 signaling might impede the recruitment of 
DNA demethylating enzymes, modulate their functional activity or might interfere with 
interaction partners necessary for complex formation. Moreover, IL-12 and IL-18 might be 
directly involved in in epigenetic remodeling of the KIR locus through recruitment of DNA 
methyltransferases or other repressors such as histone modifying enzymes leading to re-
silencing of the KIR promoter region.  
Epigenetic remodeling by pro-inflammatory cytokines has been reported for other genes 
in different models. Pre-activation of NK cell with IL-12/15/18 and subsequent transfer 
into mice has been demonstrated to induce demethylation of the IFN-γ locus 569. 
Furthermore, a recent publication indicated a general role of IL-12 and STAT-4 signaling in 
epigenetic remodeling of the IRF8 locus during MCMV infection 540. These data provide 
proof of principle that pro-inflammatory cytokines can induce epigenetic modifications 
that drive NK cell adaptation.  
However, whether alterations of histone modifications would be involved in KIR 
downregulation in mature NK cells is open to question, because active as well as repressed 
KIR alleles exhibit the same high degree of histone acetylation and deacetylase inhibitors 
were unable to induce expression of silenced KIR genes 465,466. Preliminary data from our 
laboratory indicated that IL-12/15/18 stimulation of NK cells in combination with 
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methyltransferase inhibitor treatment (e.g. 5Aza-dC) did not affect KIR downregulation. 
Analysis of a publicly available microarray data set 712, which compared naïve with 
IL-2/12/18–stimulated NK cells, did not reveal targets involved in epigenetic regulation. 
However, IL-12 and IL-18 might indirectly affect epigenetic enzymes and a complex 
interplay of individual epigenetic mechanisms might contribute to cytokine-mediated KIR 
downregulation. 
 
7.3.3. Transcription factors and promoter elements involved in KIR 
regulation 
Three kinds of general KIR promoter types have been described corresponding to their KIR 
expression characteristics: One unique for KIR3DL3 which is undetectable in pbNK cells, 
one for KIR2DL4 which is transcribed early in all NK cells and one promoter type common 
for all clonally distributed KIR genes such as KIR2DL2/L3, KIR2DL1 and KIR3DL1 462,733. 
These three types all contain a distal promoter (Pro-D), a bidirectional proximal promoter 
switch (Pro-S), intergenic elements and an intermediate promoter element (Pro-1), but 
their characteristics of regulation and transcription factor binding might be different for 
KIR2DL4, KIR3DL3 and the other clonally restricted KIRs according to their expression 
patterns 462,464,469,733. In this study, we observed cytokine-induced changes of inhibitory 
KIR2DL2/L3, KIR2DL1 and KIR3DL1 expression, which belong to the third group of 
clonally distributed KIR genes and share the same promoter type. A gradual model 
describes how these different promoters orchestrate KIR expression during different 
developmental stages (see Figure 3.5) 464,469.  
The probabilistic and bidirectional activity of the proximal promoter switch (Pro-S) 
accounts for the stochastic KIR expression during the transition of CD56bright to CD56dim NK 
cells. It is active in both the forward and reverse direction and only high ratios of sense vs. 
antisense transcripts result in functional KIR gene and protein expression 473–475. The Pro-S 
element harbors multiple transcription factor binding sites and polymorphisms and the 
balance of transcription factor affinities determine whether either the forward or reverse 
activity is predominantly active 449,473. Several transcription factor binding sites have been 
described to be present in the proximal promoter region such as CREB, AML/Runx, YY-1, 
STAT-5, AP-1/4, Sp-1 and Ets-1 462,473,733–735. A high functional redundancy exists between 
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these transcription factor binding sites and mutation of several sites was necessary to 
inactivate the KIR promoter 734.  
The described STAT-5 binding site within the proximal promoter might account for the 
IL-15–mediated increase in KIR expression observed in our study. However, a direct 
correlation between STAT-5 binding and enhanced KIR expression has yet to be 
experimentally verified. A recent publication reported that another STAT family member, 
STAT-4 involved in IL-12 signaling, was capable of inducing epigenetic remodeling of the 
IRF8 gene in MCMV infection 540. They further suggested a cooperative function of IL-12 
and STAT-4 together with IL-2 or IL-15 signaling in inducing epigenetic modifications. 
However, a STAT-4 binding site has not been detected in one of the KIR promoter elements. 
AML/Runx binding sites have been described for all promoter types but controversial 
reports indicate activating as well as inhibitory regulatory functions of AML/Runx proteins 
in KIR transcription 462,734,736–738. AML/Runx was shown to be involved in demethylation 
and establishment of an open chromatin confirmation of the proximal promoter (Pro-S) 
and to additionally possess either activating or repressive functionality depending on the 
association with different cofactors 462,736,739. AML/Runx proteins might represent possible 
candidates for mediating KIR downregulation observed in our study. Future investigations 
could explore whether expression or functions of AML/Runx proteins are influenced by 
IL-12/15/18 stimulation.  
A recently described intermediate promoter element (Pro-1) adds further complexity to 
KIR gene regulation and Pro-1 regions have been detected in all KIR loci 477,478. It has been 
proposed that Pro-1 represents the main regulatory element controlling KIR transcription 
in mature CD56dimKIR+ NK cells while the bidirectional switch (Pro-S) primary functions in 
establishing the stochastic and clonal KIR expression during development. Li et al. 
identified several transcription factor binding sites located in the Pro-1 element, such as 
YY-1, Oct-1, Ets-1, AP-1 and C/EBP, which might be involved in controlling and maintaining 
KIR gene expression in mature NK cells 478. Binding of the transcription factors YY-1, ETs-1 
and AP-1 has also been described for the proximal promoter 462,473,733–735. It would be highly 
relevant to analyze the Pro-1 element for binding sites of potentially repressive 
transcription factors downstream of IL-12 or IL-18 signaling. Future investigations of the 
Pro-1 element in cytokine-stimulated NK cells could help to uncover the molecular 
mechanisms involved in IL-12/15/18–mediated KIR downregulation.  
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Until now, only upregulation of KIR expression by IL-15 and IL-2 has been 
reported 66,510,729–732. In our study, we observed that IL-12/15/18 stimulation not only 
abrogated IL-15–mediated upregulation but further decreased KIR frequencies and surface 
expression intensity on mature CD56dimKIR+ NK cells. However, to our knowledge no 
negative influence of IL-12 or IL-18 signaling on binding of the above-mentioned 
transcription factors has been described that would indicate for the observed KIR 
downregulation. Due to the high functional redundancy of the transcription factor binding 
sites in the KIR Pro-S and Pro1 region, candidates may be hard to identify and IL-12/18 
signaling would need to interfere with several transcription factors simultaneously to 
reduce KIR expression. The mechanism of KIR downregulation upon IL-12/15/18 
stimulation might be complex and involve multiple layers and interaction partners. 
IL-12/18 might interfere with IL-15 signaling, impeding the recruitment of activating 
transcription factors to the KIR promoter region. IL-12/18 signaling components might 
modulate the functional activity of transcription factors by inducing posttranslational 
changes within the protein structure or through inhibition of protein complex formation 
by segregating necessary interaction partners. Additionally, IL-12/18 might directly act on 
the KIR promoter through recruitment of inhibitory transcription factors, repressors or 
epigenetic complexes leading to silencing of KIR gene expression. Moreover, increasing the 
antisense-to-sense ratio of proximal transcripts through preferential reverse promoter 
activity might represent a potential mechanism how IL-12/18 stimulation reduces KIR 
expression. It would be intriguing to analyze whether IL-12/18 stimulation selectively 
promotes the reverse transcriptional activity of the bidirectional proximal promoter 
(Pro-S), since increased antisense transcripts have been shown to result in reduction of KIR 
expression 449,475. 
In addition to the Pro-S and Pro-1 element, also other promoter elements, such as the distal 
promoter, may be affected by cytokine stimulation. Manipulation of the Pro-D might 
negatively influence the accessibility of the Pro-S or Pro-1 region or result in re-
methylation of the entire KIR loci. The different layers of complexity of KIR gene regulation 
and the high redundancy of transcription factor binding sites might also account for our 
observation of only partial downregulation and not complete abrogation of KIR expression. 
Additional hypotheses of cytokine-mediated KIR regulation involve more indirect 
mechanisms and crosstalk to other pathways as for instance the Notch signaling pathway. 
A recent publication by Felices and colleagues reported a contribution of the Notch 
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pathway not only for early stages of NK cell development but also for functional maturation 
and terminal differentiation of pbNK cells 740. Notch signaling partially contributed to de 
novo acquisition of KIR expression in KIR negative CD56dim and CD56bright NK cells and was 
enhanced upon IL-15 stimulation. IL-15–induced KIR expression is facilitated through 
functional Notch signaling by releasing Notch from its inhibitor cis-DLL1, which was also 
shown to restrict KIR expression in CD56bright NK cells. In addition, IL-15 and Notch potently 
enhanced expression of the transcription factor c-Myc, which was demonstrated in a 
previous publication to be involved in the initiation of de novo KIR transcription in 
CD56+KIR– pbNK cells 472. Direct binding of c-Myc to the KIR distal promoter was able to 
drive full transcriptional activity resulting in opening of the proximal promoter element, 
which subsequently allowed KIR gene expression 464,472. Together these studies present a 
mechanism of IL-15–induced KIR expression in CD56+ NK cells through releasing Notch 
from DLL1-mediated inhibition leading to downstream c-Myc activation, which in turn 
binds to the distal KIR promoter resulting in initiation of KIR transcription.  
IL-15 mediated activation of the distal promoter is in line with our observations that IL-15 
stimulation enhanced the frequency of KIR expressing cells, indicating de novo KIR 
expression on formerly KIR negative clones. Stimulation with a combination of IL-15 
together with IL-12 and IL-18 abrogated IL-15–mediated KIR expression and resulted in 
decreased frequencies of KIR expressing cells. Our data indicate that pro-inflammatory 
cytokines, such as IL-12 and IL-18, might impede the functions of IL-15 involved in KIR 
expression. The mechanism of IL-12/18–mediated KIR downregulation might involve 
interference with Notch signaling or c-Myc binding. C-Myc is a helix-loop-helix leucine 
zipper transcription factor that needs to form a dimer with Max proteins to be able to bind 
to regulatory DNA elements 741. IL-12 and IL-18 might diminish c-Myc activity by 
interfering with c-Myc interaction partners or with IL-15–mediated induction of c-Myc 
expression, resulting in reduced distal promoter activity and lower KIR expression. 
Moreover, IL-12/18 signaling might interfere with the Notch pathway by inhibiting Notch 
inducers such as miRNA-181, or by promoting negative Notch regulators such as cis-DLL1 
or another notch inhibitor NLK (nemo-like kinase) 740,742,743. Stimulation with IL-12/15/18 
might also directly target Notch pathway components or impair the formation of the 
ternary protein complex necessary for Notch-mediated gene expression 743. Future studies 
could investigate possible interaction partners of IL-12 and IL-18 signaling with the Notch 
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and c-Myc pathway to unravel the complex mechanism of KIR downregulation by 
IL-12/15/18. 
 
7.4. Improved functionality of IL-12/15/18–activated NK cells 
Reduced KIR2DL2/L3 expression on IL-12/15/18–activated NK cells suggested that the 
sensitivity of NK cells to KIR2DL2/L3-based inhibitory signals might be affected. Indeed, 
IL-12/15/18–stimulated NK cells experienced less KIR-mediated inhibition upon 
KIR2DL2/L3 engagement in redirected lysis assays resulting in increased cytotoxicity 
(Figure 6.15). Moreover, downregulation of KIR2DL2/L3 expression on IL-12/15/18-
activated NK cells translated into enhanced killing of lymphoma cells bearing the cognate 
HLA-Cw03 ligand (Figure 6.18). Blocking the interaction of KIR2DL2/L3 and HLA-Cw03 
with an anti-KIR2DL2/L3 antibody confirmed the contribution of the KIR/HLA-I axis on the 
superior functionality of IL-12/15/18–stimulated NK cells against 221_Cw03 cells.  
Importantly, in absence of KIR engagement both cytokine stimulations elicited the same 
degree of CD16-dependent cytotoxicity as illustrated in comparable levels of specific lysis 
for KIR negative subsets (Figure 6.15 B - C) and when only CD16 alone was triggered 
(Figure 6.14 A). Furthermore, in absence of cognate HLA-I on target cells, NK cells 
stimulated with IL-15 or IL-12/15/18 possessed the same cytotoxic potential against 221 
cells (Figure 6.18 A – B, left). In parallel, KIR2DL2/L3 negative subsets exhibited 
comparable killing capabilities independent of KIR–HLA-I interactions against 221 and 
221Cw03 cells (Figure 6.18). These observations indicate that regulation of KIR expression 
and its interaction with the cognate HLA-Cw03 ligand account for the superior functionality 
of IL-12/15/18 stimulated cells, which is not mediated via upregulation of activating 
pathways. Of note, KIR2DL2/L3 negative subsets exerted equally potent cytotoxicity and 
showed full functional capacity. Both KIR2DL2/L3 positive and negative sorted 
populations co-expressed additional self–HLA-I receptors such as NKG2A, KIR2DL1 or 
KIR3DL1 (Figure 6.6 C) and were most likely educated and functional. Together, these 
observations indicate that IL-12/15/18–mediated downregulation of inhibitory KIR 
receptors endowed NK cells with high responsiveness against HLA-I–expressing tumor 
cells, which may be translated into autologous settings of immunotherapy.  
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Autologous NK cell infusions against HLA-I positive malignancies are limited through 
impaired anti-tumor efficacy of autologous NK cells receiving inhibitory signals via KIR 
receptors recognizing self–HLA-I on cancer cells. To restore and improve NK cell activity, 
several studies attempted daily IL-2 administration, albeit with limited success due to toxic 
adverse effects and recruitment of CD25+ regulatory T cells 641,643–645. Moreover, autologous 
infusion of ex vivo IL-2–expanded NK cells showed only limited clinical efficacy 640. Hence, 
novel approaches are needed to preserve NK cells activation and to improve their anti-
cancer efficacy for treatments using autologous cell transfer.  
KIR-mediated inhibition can be bypassed by selection of a haploidentical donor with KIR-
ligand mismatch, lacking one or more cognate HLA-I ligands for donor inhibitory KIRs. This 
KIR ligand incompatibility model results in potent donor NK cells not inhibited by HLA-I on 
tumor cells 658,659. This principle of NK cell alloreactivity in the GvH direction according to 
the ‘missing self’ hypothesis has been identified as the basis of successful allogeneic 
hematopoietic stem cell transplantations (HSCT) in leukemia therapy 606. However, the 
adoptive transfer of allogenic NK cells alone or as HSCT requires the availability of a 
matching donor and might be hampered by short persistence of the transferred NK cells in 
the patient 645. Moreover, it might bear the risk of promoting severe GvHD, probably 
exerted by contaminating alloreactive T cells as reported in recent studies 666,674–678. 
Here, we present an alternative strategy of transiently and safely releasing autologous NK 
cells from KIR-mediated inhibition to harness their full anti-tumor potential of future 
immunotherapy protocols. Our data describes robust KIR downregulation on mature NK 
effector cells upon pre-activation with IL-12/15/18, resulting in less KIR-mediated 
inhibition and increased lysis of cognate HLA-I–expressing targets (Figure 6.18). 
Accordingly, reduced KIR expression may render autologous NK cells less sensitive to 
inhibition by self–HLA-I on tumor cells, exploiting the concept of ‘missing-self’ recognition 
in HLA-I matched settings. Short ex vivo stimulation of NK cells with IL-12/15/18 and 
subsequent infusion into the patient might translate into superior effector functions 
against HLA-I–expressing tumors and substantially improve autologous NK cells transfer. 
Our results imply that the transient resistance to self-inhibition might contribute to 
superior anti-cancer efficacy of NK cells even in autologous settings.  
Furthermore, ex vivo activation with the combination of IL-12, IL-15 and IL-18 before 
adoptive transfer might be of particular interest as it has been demonstrated to prime for 
the generation of NK cells with memory-like properties 673. IL-12/15/18 pre-activated NK 
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cells exhibited high proliferative capacity and pronounced anti-cancer responsiveness in 
vivo and in vitro 288,334,526,568,569. The safety and feasibility of adoptive transfer of 
IL-12/15/18–activated NK cells has been recently reported in a phase-I clinical trial with 
AML patients 526. In this trial, allogeneic NK cells were stimulated for 16 h with IL-12/15/18 
and infused into the patient. Haploidentical donor NK cells exhibited substantial 
proliferation and long persistence in the recipient. Importantly, upon ex vivo re-stimulation 
7 days post-infusion, IL-12/15/18–pre-activated NK cells showed potent anti-leukemia 
responses, correlating with improved survival. Mouse models employing allo-HCT of 
IL-12/15/18–pre-activated NK cells even suggested a protective role against GvHD while 
their GvL effect was preserved 744,745. Accordingly, adoptive transfer of IL-12/15/18–
activated cells has been demonstrated to be safe, feasible and to improve survival in AML 
patients.  
The long persistence and sustained effector functions of IL-12/15/18–stimulated NK cells 
have been assigned to their memory-like features 288,289,334,526. We and others have shown, 
that activation of NK cells with IL-12/15/18 induced profound expression of the high 
affinity IL-2R α-chain (CD25) (Figure 6.1)and  288,289, facilitating strong expansion and 
persistence in response to low-dose IL-2 after adoptive transfer in mice 288,569. For adoptive 
transfer of memory-like NK cells, picomolar concentrations of IL-2 might be sufficient or 
exogeneous cytokine support might no longer be necessary at all to preserve NK cell 
activity and persistence in vivo. Our group could show that sustained proliferation of NK 
cells was assisted by IL-2 produced by autologous CD4+ T cells upon adoptive transfer of 
IL-12/15/18 pre-activated NK cells in mice 288,569. In contrast to allogeneic infusions, 
adoptive transfer of autologous memory-like NK cells might further increase their 
persistence in the host through intensive homeostatic proliferation assisted by autologous 
CD4+ T cells in an MHC-I compatible setting. 
The design of the clinical study employing adoptive transfer of cytokine-induced NK cell 
comprised overnight activation of allogeneic NK cells for 16 h and direct infusion into the 
patient. To address the question whether prolonged pre-activation for 48 h, as used here, 
instead of 16 h would influence memory-like NK cell differentiation, we pre-activated NK 
cells for 16 h or 48 h and re-cultured them subsequently in IL-2 or IL-15 for 5 days. As 
compared to 16 h stimulation of NK cells, pre-activation for 48 h resulted in similarly 
enhanced IFN-γ production of IL-12/15/18–stimulated NK cells upon re-stimulation with 
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K562 (Figure 6.19 and Figure 6.20). Thus, also longer IL-12/15/18 stimulation of NK cells 
was capable of inducing memory formation.  
In addition to the generation of NK cells with sustained functionality and memory-like 
properties, we observed pronounced downregulation of inhibitory KIRs 48 h after 
stimulation with IL-12/15/18. Reduced KIR levels correlated with enhanced cytotoxicity 
against tumor cells expressing cognate HLA-I ligands. Therefore, we hypothesize that 
prolonged pre-activation of NK cells for two days could additionally enhance their early 
effector functions towards self–HLA-I–expressing tumors and could be exploited in 
autologous settings of NK cell immunotherapy. The transient release of KIR-mediated 
inhibition could combine high cytotoxicity against autologous tumor cells at early time 
points directly after adoptive transfer into the patient with high IFN-γ secretion, long 
persistence and sustained anti-tumor activity late after infusion. Thereby, besides the 
memory-like functionality of cytokine-induced NK cells, the here uncovered transient 
resistance to self-inhibition due to KIR downregulation could improve the benefits of 
autologous NK cell transfer.  
 
7.5. KIR downregulation on NK cells in HCMV infection  
Mouse and human cytomegalovirus (MCMV and HCMV) infection have been implicated in 
the formation of adaptive NK cells with memory-like properties 24,718. A strong pro-
inflammatory cytokine milieu is created during these viral infections and in particular IL-12 
has been shown to be involved in NK cell subset expansion 556. Therefore, we employed an 
in vitro model of HCMV-infected fibroblasts co-cultured with PBMCs to investigate the 
impact of the produced cytokines on KIR expression.  
In addition to IL-12/15/18 stimulation of purified NK cells, we observed downregulation 
of KIR expression on NK cells in HCMV infection (Figure 6.21). In accordance with our 
observations of KIR downregulation after 48 h to 60 h of cytokine treatment, the 
percentage of KIR expressing cells and the surface densities were reduced 3 days p.i. 
compared to uninfected co-cultures. Decreased KIR expression did not originate from 
increased proliferation and preferential outgrowth of the KIR negative population as no 
proliferation of NK cells was detectable 3 days p.i. (data not shown). Furthermore, KIR 
downregulation was transient and KIR expression levels were restored and even further 
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increased in both uninfected and infected co-cultures after 7 days (Figure 6.22). Increased 
KIR expression at later times in HCMV infection might be attributed to IL-2 produced by T 
cells in the co-cultures 556, since IL-2 was reported to induce KIR expression 66,510,729–732.  
A strong pro-inflammatory cytokine milieu (e.g. IL-12, IFN-α, IFN-γ) is created in HCMV 
infected co-cultures mimicking viral infections in vivo (Figure 6.24). However, IL-18 was 
not detected in infected or uninfected co-cultures 3 days p.i. . Individual blocking of IL-12 
and the IFN-αR was not sufficient to prevent KIR downregulation (Figure 6.25), revealing 
that neither IL-12 nor IFN-α alone were responsible for driving KIR downregulation in 
HCMV infection. Possibly, the combination of several pro-inflammatory cytokines is needed 
to reduce KIR expression as observed in our in vitro stimulation with IL-12/15/18 
(Figure 6.12). Potential mechanisms could also involve additional cellular factors and 
interaction with other activated immune cells present in the PBMC co-cultures. Taken 
together, downregulation of inhibitory KIR receptors in HCMV infection suggests a general 
and physiological mechanism of reducing inhibition of NK cells and improving their 
functionality in pro-inflammatory settings as viral infections or cancer.  
In addition to KIR regulation, we observed substantial upregulation of CD25 on NK cells in 
HCMV-infected co-cultures (Figure 6.21 B) resembling CD25 induction by IL-12/15/18 
(Figure 6.1 B). Indeed, increased expression of CD25 was partially IL-12 dependent with 
highest expression detectable 7 days p.i. (Figure 6.26). CD25 represents the high affinity 
IL-2Rα-chain that constitutes the IL-2Rαβγ, facilitating high responsiveness to picomolar 
concentrations of IL-2 and therefore contributes to IL-2–dependent proliferation of NK 
cells. Although IL-12 neutralization significantly decreased CD25 expression, proliferation 
was only moderately affected (Figure 6.27), since also reduced CD25 surface expression 
might be sufficient for increased sensitivity to IL-2 and induction of strong proliferation. 
Rölle and colleagues from our group recently demonstrated that the NKG2C/HLA-E axis 
and IL-12 produced by inflammatory monocytes are critical for the expansion of NKG2C+ 
NK cells in response to HCMV infection 556. We therefore envision a scenario in which IL-12 
induces high CD25 expression on NK cells, thereby permitting strong proliferation and 
contributing to expansion of the NKG2C+ subset. Moreover, upregulation of CD25 on NK 
cells has been recently reported by our group to play an important role in in hepatitis C 
virus (HCV) infection 291. CD25 expression and enhanced proliferation correlated with 
Ox40 induction and enhanced IFN-γ production, marking a NK cell subset with superior 
functionality. Interestingly, we could also detect high levels of Ox40 and 4-1BB (another 
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TNFRSF member) in HCMV infected co-cultures (Figure 6.23). Thus, high CD25 expression 
induced upon viral infection might serve as a marker of activated and highly functional NK 
cells.  
 
7.6. Therapeutic implications 
NK cell-based immunotherapy is a promising treatment approach for different types of 
hematological malignancies. However, one major obstacle in effective autologous NK cell 
therapy represents the impaired NK cell activation through interaction of self–HLA-I on 
tumor cells with inhibitory KIR receptors. The success of haploidentical NK cell transfer 
provided evidence that KIR/ligand-mismatched donor NK cells can elicit potent anti-
leukemia effector functions if they are not inhibited by self–HLA-I 606,658,659. However, not 
all patients are eligible for HSCT and adoptive allogeneic NK cell transfer still bears the risk 
of GvHD 645,674,675. Therefore, new treatment strategies are needed to unleash NK cell anti-
tumor efficacy in HLA-I matched settings.  
An alternative approach could involve transfer of autologous NK cells in combination with 
modulation of inhibitory KIR molecules to reduce the threshold of NK cell activation. 
Indeed, checkpoint blockade of inhibitory pan-KIR2D receptors with the antagonistic 
antibody Lirilumab (1-7F9/IPH2101/IPH2102) is currently explored in clinical trials to 
increase NK cell responsiveness across self–HLA-I barriers 693,694.The safety and efficacy of 
KIR blockade has been reported for the treatment of patients with AML or multiple 
myeloma 700–705. Additionally, clinical investigations of KIR checkpoint blockade have been 
recently extended for various other hematological malignancies and for solid tumors 706. 
However, a recent study indicated contraction and functional detuning of KIR2D positive 
NK cells upon single therapy with Lirilumab in smoldering multiple myeloma patients 707. 
In addition, constant KIR engagement bears the risk of inducing hyporesponsiveness and 
anergy in NK cells, similar to processes observed in NK cell education 479,480. Therefore, 
combination of anti-KIR therapy with other approaches are currently considered, for 
instance together with anti–CTLA-4 or anti–PD-1 blockade 682,708 or with ADCC inducing 
therapeutic antibodies 697,698,709. 
We here present a novel strategy of transiently and safely releasing NK cells from KIR-
mediated self-inhibition to improve autologous NK cells transfer. Transient modulation of 
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inhibitory KIR receptors may be well suited to improve the anti-tumor efficacy of 
autologous NK cells in adoptive transfer. Our data describes robust KIR downregulation by 
IL-12/15/18 on mature NK effector cells, resulting in less KIR-mediated inhibition and 
increased lysis of cognate HLA-I–expressing targets (Figure 6.15 and Figure 6.18). 
Accordingly, reduced KIR expression may render autologous NK cells less sensitive to 
inhibition by self–HLA-I on tumor cells, exploiting the concept of ‘missing-self’ recognition 
in HLA-I matched settings. Moreover, the transient nature of KIR regulation on NK cells 
might provide safe application regarding autoimmunity against healthy tissue, since 
inhibitory KIR expression is most likely restored after the initial NK cell effector phase in 
patients. Transient KIR modulation and the recovery of KIR expression might also be 
beneficial in preventing functional detuning and anergic hyporesponsiveness of 
transferred NK cells. We envisage that the transient release from KIR-mediated inhibition 
could combine advantages of safety and alloreactivity in autologous NK cell transfer 
together with the sustained anti-leukemia effectiveness and memory-like properties that 
have been recently demonstrated for IL-12/15/18–activated NK cells in a clinical trial 526. 
Our study implies that transient modulation of the KIR/HLA-I axis by pro-inflammatory 
cytokines could be of high functional importance for immunotherapy protocols especially 
for autologous NK cell infusions.  
In general, harnessing the adaptive features of memory-like NK cells is currently 
considered for application in immunotherapy 23,673,746,747. Adoptive transfer of allogeneic 
NK cells pre-activated with IL-12/15/18 has been recently employed in a clinical trial of 
AML patients and could induce remission in a subset of patients 526. Moreover, clinical 
studies have suggested anti-leukemia properties for HCMV-induced adaptive NKG2C+ NK 
cells 545–547. Compared to conventional NK cells, FcεRIγ-deficient adaptive NK cells elicited 
superior ADCC in response to antibody-coated target cells 564. Furthermore, adaptive NK 
cells have been shown to exhibit lower TIGIT expression and to be therefore less 
susceptible to MDSC-mediated inhibition in the tumor bed 748. Recently, a protocol for 
successful ex vivo expansion of these adaptive NKG2C+ NK cells has been reported, resulting 
in effector cells with high anti-tumor potential for the application in cancer 
immunotherapy 549.  
We hypothesize that the advantages of their memory-like properties together with the here 
uncovered reduced self-inhibition of IL-12/15/18–activated NK cells make them suitable 
targets for adaptive autologous cell transfer. In addition, IL-12/15/18–stimulated NK cells 
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could be employed in combinatorial strategies of cancer immunotherapy. Thereby, 
autologous NK cells with memory-like properties and high effector functions against 
HLA-I–expressing tumors could be harnessed to improve other therapies currently tested 
in the clinics. Adoptive transfer allows the combination of ex vivo activation of NK cells with 
other treatment options that have been shown to enhance NK cell ani-tumor efficacy, for 
instance with therapeutic antibodies or immunomodulatory drugs. The concept of 
combining NK cells released from self-inhibition together with the immunomodulatory 
drug lenalidomide is currently explored in clinical trials with the pan-KIR2D blocking 
antibody Lirilumab 698,701,704. 
Therapeutic antibodies and antibody-derived constructs can specifically redirect immune 
cells to tumor-restricted antigens expressed on cancer cells and can elicit potent NK cells 
effector function through the induction of ADCC 100,101. The anti-tumor efficacy of 
therapeutic antibodies or BiKEs (bispecific killer engagers) can be enhanced by 
administration of cytokines that stimulate and expand NK cells in vivo 109,673,684. However, 
in vivo administration of cytokines might involve toxic adverse effects and expansion of 
regulatory T cells 641,643–645. Ex vivo cytokine-induced memory-like NK cells have been 
shown to potently exert ADCC in response to therapeutic antibodies such as rituximab 512. 
line with this, we observed high capacity of CD16-mediated cytotoxicity of NK cells 
stimulated with IL-12/15/18 in redirected lysis assays (Figure 6.15). Of note, cytokine 
stimulation resulted in shedding of CD16 by matrix metalloproteinases (MMP) 711 but 
MMPi treatment restored CD16 surface expression (Figure 6.14). Sustaining the expression 
of CD16 and preventing MMP-mediated shedding is currently explored for ADCC protocols 
in the clinics by administration of broad MMPi or more selective ADAM17 inhibitors 749,750. 
Additionally, the reduced KIR expression on IL-12/15/18–activated NK cells observed in 
our study translated in reduced KIR-mediated inhibition upon KIR co-triggering and upon 
engagement with cognate HLA-I ligands (Figure 6.15 and Figure 6.18). We therefore 
envisage that KIR downregulation by IL-12/15/18 might greatly improve ADCC against 
HLA-I–expressing tumor targets by unleashing NK cells from self-inhibition. Indeed, the 
combination of therapeutic antibodies together with the anti-KIR blocking antibody 
Lirilumab have been reported to enhance NK cell-mediated ADCC in vitro against multiple 
myeloma and lymphoma cells 697,698,709. Autologous transfer of NK cells that are transiently 
and safely released from KIR-mediated self-inhibition might therefore improve the clinical 
efficacy of therapeutic or bispecific antibodies in the treatment of HLA-I positive cancers.  
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Furthermore, adoptive transfer of memory-like NK cells together with antibody therapy 
could exploit the sustained functionality of long lived effector cells with potent CD16-
dependent activation and specific redirection towards tumor cells. Recently, our group has 
described the implication of CD16 engagement with therapeutic antibodies in priming NK 
cells with sustained effector functions, resembling memory-like NK cells with adaptive 
features 99. Upon a re-culture period in IL-2, CD16-primed NK cells showed extensive 
proliferation due to high CD25 expression and exhibited enhanced IFN-γ production and 
cytotoxicity against various tumor targets. CD16-priming might further sustain the anti-
tumor functionality of IL-12/15/18–stimulated NK cells, which might result in superior 
anti-cancer efficacy against HLA-I–expressing tumors. Therefore, adoptive transfer of 
cytokine-induced NK cells together with the application of therapeutic antibodies or 
bispecific constructs targeting CD16 might represent a promising strategy for HLA-I 
matched settings in tumor therapy. 
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221  721.221 EBV transformed lymphoblastoid cell line 
7-AAD  7-aminoactinomycin D 
ADCC 
Antibody-dependent cellular cytotoxicity 
or antibody-dependent cell-mediated cytotoxicity 
AICL  Activation-induced C-type lectin 
AML Acute myeloid leukemia 
APC Antigen presenting cell 
Bat-3 Human leukocyte antigen-b-associated transcript 3 
Bcl-2 B-cell lymphoma 2 
BCR B cell receptor 
BCR  B cell receptor 
BiKEs bispecific killer engagers 
BM Bone marrow 
BSA  Bovine serum albumin 
CD Cluster of differentiation 
CFSE Carboxyfluorescein succinimidyl ester 
CLP Common lymphoid progenitor 
CTLA-4 Cytotoxic t-lymphocyte-associated protein 4 
DAMPs Damage-associated molecular patterns 
DC Dendritic cell 
DD Death domain 
DISC Death-inducing signaling complex  
DKFZ 
Deutsches Krebsforschungszentrum / German Cancer Research 
Center 
DLL1 Delta-like protein 1 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DNAM-I Dnax accessory molecule-1 
dsRNA Double-stranded RNA 
E:T  Effector-to-target 
ELISA  Enzyme-linked immunosorbent assay 
FACS  Fluorescence-activated cell sorting 
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FcR  Fragment, crystalizable-receptor 
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FcγR  Fragment, crystallizable γ-receptor 
FoxP3 Forkhead box protein P3 
GM-CSF  Granulocyte macrophage colony-stimulating factor 
Grb-2 Growth factor receptor-bound protein 2 
GvHD Graft-vs-host disease 
GvL Graft-vs-leukemia 
H-60 Histocompatibility antigen 60 
HCMV Human cytomegalovirus 
hESC Human embryonic stem cell 
HLA Human leukocyte antigen 
HMGB1 Chromatin-associated protein high-mobility group box 1 
HSC Hematopoietic stem cells 
HSCT Hematopoietic stem cell transplantation 
IFN-α/γ Interferon-alpha/gamma 
Ig Immunoglobulin 
IL Interleukin 
IL-2R Interleukin-2 receptor 
ILC Innate lymphoid cell 
iNK Immature NK cells 
iPSC Induced pluripotent stem cell 
IRAK Interleukin-1 receptor-associated kinase 
ITAM Immune tyrosine-based activating motif 
ITIM Immunoreceptor tyrosine-based inhibitory motif 
ITT Immunoglobulin tail tyrosine-like motif 
JAK Janus tyrosine-kinase  
KIR Killer immunoglobulin-like receptor 
KIR Killer cell immunoglobulin-like  
LAK  Lymphokine-activated killer  
LFA1  Leukocyte functional antigen 1 
lncRNA Long non-coding RNA 
LPS Lipopolysaccharides 
LRC Leukocyte receptor complex 
LTi Lymphoid tissue inducer cell 
mAb Monoclonal antibody 
MACS  Magnetic activated cell sorting 
MAPK Mitogen-activated protein kinase  
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MCMV  murine cytomegalovirus 
MDSC Myeloid-derived suppressor cell 
MFI  Median fluorescence intensity 
MHC Major histocompatibility complex 
MIC-A/B MHC class I chain-related gene A/B 
mIgG Mouse immunoglobulin G 
min Minute 
miRNA  Micro RNA 
MM Multiple myeloma 
MMP Matrix-metalloproteinase 
MMPi Matrix-metalloproteinase inhibitor 
mNK Mature NK cell 
MULT-1 Murine UL16-binding-like transcript-1 
MyD88 Myeloid differentiation primary response gene 88 
n.d.  Not detectable 
NCAM Neural cell adhesion molecule 
NCR Natural cytotoxicity receptor 
NF-κB Nuclear factor-κB 
NK cell Natural killer cell 
NKG2A/C/D Natural killer group 2 A/C/D 
NKP NK cell precursor 
NLK Nemo-like kinase 
p.i. Post infection 
PAMPs Pathogen-associated molecular patterns 
PB Peripheral blood 
pbNK Peripheral blood NK cells 
PCR  Polymerase chain reaction 
PD-1 Programmed cell death protein 1 
PD-L1 Programmed cell death 1 ligand 1 
PI3K Phosphatidylinositol-3 kinase 
PKC Protein kinase C 
PRR Pattern recognition receptor 
Rae-1 Retinoic acid early transcript-1 molecules 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
Rpm Revolutions per minute 
RT Room temperature 
SHIP SH2 domain-containing inositol-5-phosphatase  
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SHP  Src homology region 2 domain-containing phosphatases 
STAT Signal transducer and activator of transcription 
TAM Tumor-associated macrophage 
TCR T cell receptor 
TGF-β Transforming growth factor β 
TIGIT T cell immunoreceptor with Ig and ITIM domains 
TILs Tumor-infiltrating lymphocytes 
TLR Toll-like receptor 
TNFRSF Tumor necrosis factor receptor superfamily 
TNF-α Tumor necrosis factor alpha 
TRAF TNF receptor associated factor 
TRAIL  Tumor necrosis factor related apoptosis inducing ligand 
Tregs Regulatory T cell 
TYK2 Tyrosine kinase 2 
UCB Umbilical cord blood 
ULBP UL16 binding protein 
VEGF-A Vascular endothelial growth factor-A 
w/o  Without 
α-a Anti- 
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